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NUCLEAR PYRUVATE KINASE M2 FUNCTIONAL STUDY IN CANCER CELLS

by

XUELIANG GAO

Under the Direction of Zhi-Ren Liu

ABSTRACT

Cancer cells take more glucose to provide energy and phosphoryl intermediates for cancer
progression. Meanwhile, energy-provider function of mitochondria in cancer cells is disrupted.
This phenomenon is so-called Warburg effect, which is discovered over eighty years ago. The
detail mechanisms for Warburg effect are not well defined. How glycolytic enzymes contribute to
cancer progression is not well known. PKM2 is a glycolytic enzyme dominantly localized in the
cytosol, catalyzing the production of ATP from PEP. In this study, we discovered that there were
more nuclear PKM2 expressed in highly proliferative cancer cells. The nuclear PKM2 levels are
correlated with cell proliferation rates. According to our microarry analyses, MEK5 gene was
upregulated in PKM2 overexpression cells. Our studies showed that PKM2 regulated MEK5 gene
transcription to promote cell proliferation. Moreover, nuclear PKM2 phosphorylated Stat3 at Y705
site using PEP as a phosphoryl group donor to regulate MEK5 gene transcription. Our study also

showed that double phosphorylated p68 RNA helicase at Y593/595 interacted with PKM2 at its
FBP binding site. Under the stimulation of growth factors, p68 interacted with PKM2 to promote
the conversion from tetrameraic to dimeric form so as to regulate its protein kinase activity.
Overexpression PKM2 in less aggressive cancer cells induced the formation of multinuclei by
regulating Cdc14A gene transcription. Overall, this study presents a step forward in
understanding the Warburg effect.

INDEX WORDS: PKM2, P68 RNA helicase, MEK5, Stat3, Cdc14A, Tyrosine phosphorylation,
Gene transcription, Cell cycle, Glycolysis.
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CHAPTER I
GENERAL INTRODUCTION
Cancer is a serious human disease and the detail mechanism is not well
understoond. Cancer cells uptake more glucose to provide energy and phosphoryl
intermediates for macromolecule systhesis, and their oxidative phosphorylation activity is
decreased, so-called Warburg effect. Warburg effect has been known for decades and the
detail mechanisms are not well defined. In this project, we studied how a glycolytic
protein played a role to regulate gene transcription in cells. Moreover, we investigated
how phosphorylated proteins affect the glycolytic process by regulating the quaternary
structure of a glycolytic enzyme, which provided part explanations for Warburg effect.

1.1 Cancer Metabolism
1.1.1 Tumors and Cancer
In general, tumors are the outcome of abnormal growth of normal cells. There are
three continuous stages normal cells go through to completely develop into tumor cells.
The first stage is hyperplasia, and at this stage the cells grow out of control but still
behave like normally physiological cells. At this stage, tumors can be removed by
surgery; also at this point they are called benign tumors. The second stage is dysplasia,
which is also called the early form of cancerous lesions. At this stage, cells change their
behavior and the differentiation and mature processes of cells are delayed. However, cells
are not invasive to the basement membrane of the soft tissues. Dysplasic cells can be
further graded into different levels even though cells at the highest level of this stage are
still considered very low level cancers. The third stage is anaplasia, which is a reversion
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process of cell differentiation. At this stage, cells lose their functional and structural
differentiations at physiological conditions. The nuclei of anaplasic cells become
astoundingly hyper-chromatic and large. The nuclear-cytoplasmic ratio increases to 1:1
instead of 1:4~1:6 for normal cells. At this stage, cells gain the ability to invade the blood
system as well as neighboring tissues, which are called malignant tumors; these are also
defined as cancers.
According to their original tissue location, cancers are further divided into five
groups: Carcinoma is originally generated from epithelial cells covering the surface of
internal organs. Sarcoma is a cancer initially from muscle, bone or connective tissues.
Leukemia is generated from white blood cells. Lymphoma is originally from lymphatic
cells. Myeloma is from mature B lymphocyte.
Cancer cells are characteristically different from normal cells. For example, the
disruption of cytoskeletons in cancer cells, such as microfilaments and microtubules,
changes their interactions with neighboring cells as well as their appearances. The change
in cell to cell adhesion helps cancer cells to lose the restrictions of contact inhibition so
that cancer cells can grow unlimitedly even surrounded by other cells. The secretion of
enzymes from cancer cells facilitates them in degrading the basement membrane to
invade into deep tissues. Therefore, these changes create six functional characteristics for
cancer cells with the presence of variously genetic alterations, such as avoidance of
apoptosis, constant reaction to growth signals or stimuli, unrestricted replicative
capability, angiogenesis capacity, invasion ability and metastasis potential.
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1.1.2 Cancer Metabolism and Warburg Effect
The metabolism in cancer cells is, to a certain extent, different from normal cells
(Merida and Avila-Flores 2006). One important characteristic of cancer cell metabolism
is the consistent switch of the energy production pathway from oxidative phosphorylation
to glycolysis (Kondoh, Lleonart et al. 2007). In most normal mammalian cells, glycolysis
flux is tightly regulated, and the glycolysis process is inhibited by the presence of
oxygen, which was first discovered by Louis Pasteur. For decades, it has been known that
cancer cells utilize more glucose and display a higher glycolysis rate than normal cells. In
the 1920s, Otto Warburg found that even in the presence of sufficient oxygen, cancer
cells consume glucose for ATP production instead of using the oxidative phosphorylation
pathway (Warburg 1956; Warburg 1956).
In general, through the glycolysis process, one molecule of glucose generates two
molecules of pyruvate and produces two molecules of ATP. In mammals, the product of
the glycolysis process, pyruvate, has diverse fates. In an environment with limited
oxygen, pyruvate is catalyzed into lactate by lactate dehydrogenase, a process which is
called anaerobic glycolysis. In the presence of efficient oxygen, pyruvate is catalyzed
into acetyl coenzyme A by the pyruvate dehydrogenase complex. Acetyl coenzyme A is
consumed in the citric acid cycle to generate electrons in the mitochondria. The electrons
create an electron gradient which generates a pH gradient across the mitochondrial
membrane. The force motive produced by the pH gradient generates ATP by ATP
synthases. This process is called aerobic oxidative phosphorylation. Overall, one acetyl
CoA molecule through citric acid cycle produces two molecules of NADH, one molecule
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of FADH2, and eight molecules of electrons. Compared to the aerobic oxidative
phosphorylation pathway, anaerobic glycolysis only produces a small fraction of the total
energy of glucose. One molecule of glucose can be completed degraded into H2O and
CO2 in the oxidative phosphorylation process to produce 38 molecules of ATP. Overall,
the oxidative phosphorylation process is more efficient in producing ATP than
glycolysis.
However, cancer cells desire the glycolysis process to produce ATP instead of the
oxidative phosphorylation pathway. The reason why cancer cells prefer consuming
glucose to produce ATP is not well defined yet. One fact is that the glycolysis process
provides a lot of phosphointermediates besides ATP for cells to synthesize
macromolecules such as lipids, proteins, and nucleic acids.

1.2 Possible Causes of Metabolic Changes in Cancer Cells
1.2.1 Tumor Microenvironment Affects Tumor Metabolism
The metabolism in cancer cells is regulated by many effectors at diverse levels.
Firstly, tumor microenvironment is, to a certain extent, different from normal cells,
characterized by being surrounded with disorganized microvasculature (Allinen,
Beroukhim et al. 2004; Joyce 2005; Anderson, Weaver et al. 2006; Fukumura and Jain
2007; Mohla 2007). Tissues of human bodies need nutrients and oxygen to keep their
normal functions, which is provided through surrounding capillary vessels. Even though
the growth and proliferation of cancer cells is not totally controlled by the same
mechanisms as normal cells, cancer cells still need nutrients as well as oxygen provided
by blood vessels. In most conditions, cancer cells proliferate and grow so fast that the
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surrounding blood vessels can not provide enough oxygen or other nutrients to them.
Under these conditions, the solid tumor grows in a hypoxic environment (normally below
3%–5% O2). Without enough oxygen provided to the cancer cells they begin to rely on
glycolysis to produce ATP as the major energy providing source. Meanwhile, the
hypoxic environment surrounding cancer cells induces continuous expression and
activation of hypoxia-inducible transcription factor (HIF-1) to regulate the expression of
glycolytic enzymes as well as glucose transporters. Under anoxic conditions, HIF-1 is
degraded by proteasomes due to the recognition by the von Hippel-Lindau (VHL) tumor
suppressor (Mahon, Hirota et al. 2001). Under hypoxic conditions, HIF-1 is activated and
translocates into the nucleus and binds to β-subunit of aryl hydrocarbon receptor nuclear
translocator (ARNT) to regulate O2-induced gene transcriptions (Wiesener and Maxwell
2003). Nearly all the expression of the glycolysis enzymes, such as hexokinase,
phosphofructokinase,

aldolase,

glyceraldehyde

3-phosphate

dehydrogenase,

phosphoglycerate kinase, enolase, pyruvate kinase, lactate dehydrogenase is regulated by
HIF-1 activity (Semenza 2007). The overexpression of these glycolysis enzymes
enhances the glycolysis process to provide more energy to cancer cells. On the other
hand, under hypoxic conditions, HIF-1 induces VEGF expression from cancer cells
which facilitates the growth of blood vessels to provide more oxygen. However, the
blood vessels surrounding tumor cells are so disorganized that they can not provide
enough oxygen and nutrients as in normal physiological conditions. Under these
conditions, the blood vessels surrounding tumor cells still can not alleviate the hypoxic
levels of cancer cells. Therefore, aerobic glycolysis is still dominant in these tumor cells.
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1.2.2 Oncogenes and Tumor Suppressor Genes Regulate Cancer Cell Metabolism
Some oncogenes and tumor suppressor genes regulate the glycolysis process in
cancer cells, such as c-Myc, AKT, AMPK, Ras and p53.
Akt, a Serine/Theronine kinase, was initially discovered as a cellular homolog of a
viral oncoprotein; this protein is amplified in diverse cancers, such as ovarian, breast
carcinomas, and gastric adenocarcinoma (Vivanco and Sawyers 2002). Akt is the
downstream target of phosphatidylinositide-3-kinase (PI-3 kinase) in growth factor
induced signal pathways. Under the stimulation of diverse survival signals such as IL-6
and IGF-1, PI-3K is activated by phosphorylation to generate phosphoinositides. Akt is
then recruited by phosphoinositides to the cellular membrane to be phosphorylated at
Serine 473 and Threonine 308 residues (Kitamura, Kitamura et al. 1999). Akt can be
dephophorylated by protein phosphatase 2A (PP2A). The PI3K-Akt pathway is an
important signal transduction pathway, playing crucial roles in regulating the cell cycle,
apoptosis, cell survival and cell proliferation (Thompson and Thompson 2004). Cellular
Akt is also activated by the deletion of phosphatase and tensin homolog on chromosome
10 (PTEN), an antagonist of PI-3, in many cancers, such as brain, breast, and prostate
cancers (Li, Yen et al. 1997). In addition, Akt is activated by a number of oncoproteins,
such as Bcr-Abl in chronic myelogenous leukemia, Her2 in breast cancer, as well as Ras.
Activated Akt has many downstream targets, such as nuclear factor-kappa B (NF- B),
GSK-3, and Bad. Activated Akt is pluripotent in contributing to tumorigenisis, such as
avoiding apoptosis and promoting cell proliferation. In leukemia cells, the overexpression
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of Akt promotes its survival capability by inceasing glycolysis levels. Akt regulates
glycolysis though many aspects. Firstly, the activated Akt pathway in respiration
deficient cancer cells increases glucose consumption by regulating the transcription and
translation of glucose transporter1 (GLUT1) to support their survival and growth (Plas,
Talapatra et al. 2001; Rathmell, Fox et al. 2003). Second, activated Akt stimulates
hexokinase activity to convert glucose to glucose-6-phosphate, a modified form of
glucose which can not diffuse freely out of the cell, so as to increase the cellular amount
of glucose (Gottlob, Majewski et al. 2001) (Rathmell, Fox et al. 2003). Third, Akt
regulates phosphofructokinase (PFK-1) activity, a key enzyme in controlling the
glycolysis rate, through phosphorylating and activating PFK-2. PFK-2 catalyze the
production of fructose 2,6-bisphosphate, which is an allosteric regulator of PFK-1 to
overcome the inhibition effect of high ATP levels on PFK-1 (Deprez, Vertommen et al.
1997). In addition, it is reported that the overexpression of Akt is sufficient to promote
transformed cells’ aerobic glycolysis without affecting their oxidative phosphorylation
level (Elstrom, 2004 #5019). Furthermore, the inactivation of mitochondrial respiration
in human leukemia and lymphoma cell activates PI-3K-Akt pathway by oxidating the
tumor suppressor PTEN. The activated PI-3K-Akt pathway benefits cell survival
(Pelicano, Xu et al. 2006). The direct effect of Akt on glycolysis may contribute to the
Warburg effect

(Coloff and Rathmell 2006).

c-Myc is a nuclear oncoprotein, which is constantly active in many malignant
tumor cells independent of growth factor stimulations (Elliott, Ge et al. 2000). It is
reported that c-Myc regulates many glycolysis-related gene transcriptions to control
energy production, such as glucose transporters, hexokinase, phosphoglucose isomerase,
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phosphofructokinase, aldolase, enolase and pyruvate kinase (Gordan, Bertout et al.
2007). Interestingly, c-Myc not only upregulates glycolysis-related genes transcriptions
for energy production, but also promotes mitochondrial biosynthesis through targeting
the mitochondrial transcription factor A (TFAM) (Li, Wang et al. 2005). The products
from mitochondrial biosynthesis provide intermediates for macromolecular synthesis,
such as fatty acid, nucleotide, polyamine as well as amino acids (Coller et al., 2000;
O’Connell et al., 2003).
AMP-activated protein kinase (AMPK), is a master regulator controlling energy
metabolism, which was first identified in 1994 as an inhibitor of acetyl-CoA carboxylase
and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) (Kemp, Stapleton et al. 2003).
AMPK activity is stimulated by its upstream effetor, AMPK kinases (AMPKKs), with
the phosphorylation at Threonine172 residue. AMPK is also directly activated by AMP.
AMPK is reported to regulate glucose consumption by controlling the transcription of
GLUT1 and the translocation of GLUT1 to cellular surface (Russell, Bergeron et al.
1999). AMPK activates 6-phosphofructo-2-kinase (PFK-2), the enzyme that synthesizes
fructose 2,6-bisphosphate in cardiac muscle cells under ischaemic conditions (Marsin,
Bertrand et al. 2000).
p53, an important tumor suppressor, plays important roles in regulating apoptosis,
cell cycle arrest, and DNA replication. p53 is inactive in more than half of cancers
(Hainaut and Hollstein 2000). It is reported that the activation of p53 causes the
downregulation of several glycolytic enzymes’ transcription, such as phosphoglycerate
mutase (PGM), and GLUT (Schwartzenberg-Bar-Yoseph, Armoni et al. 2004). In the
glycolysis process, PGM converts 3-phosphoglycerate to 2-phosphoglycerate to decrease
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the glycolysis flux. Interestingly, the activation of p53 increases the oxidative
phosphorylation rate by upregulation of the synthesis of cytochrome oxidase 2 (SCO2).
SOC2 is crucial for regulating cytochrome c oxidase (COX) complex activity to use
oxygen in oxidative phosphorylation pathway. Therefore, the loss of p53 activity benefits
cell proliferation by increasing the glycolysis rate and decreasing mitochondrial oxidative
phosphorylation activity, which is another possible explanation for the Warburg effect
(Matoba, Kang et al. 2006). p53 is a nuclecytoplasmic shuttling protein which depends
on its leucine-rich nuclear export signal (Stommel, Marchenko et al. 1999). It is reported
that p53 also translocates to mitochondria under stimuli to induce apoptosis by directly
interacting with a Bcl-2 family protein (Erster, Mihara et al. 2004). Moreover, p53 plays
important functions in maintaining mtDNA integrity in response to mtDNA damage by
interacting with mtDNA and DNA polymerase γ to enhance poly γ transcriptional
activity (Achanta, Sasaki et al. 2005).

1.2.3 Mitochondrial Malfunction in Cancer Cells
Mitochondrion is an important cellular organelle which takes part in regulating cell
metabolism, producing reactive oxygen species (ROS) as well as inducing apoptosis (Lu,
Sharma et al. 2009). Mitochondria have their own DNA as well as DNA transcription,
replication and repair system to encode 13 polypeptides as the components of oxidative
phosphorylation chain (Anderson, Bankier et al. 1981). In cancer cells the energy
producer function of mitochondria is decreased for many reasons. First, in cancer cells,
the transcription rate of the mitochondrial genome is reduced to a certain level compared
to normal cells (Gogvadze, Orrenius et al. 2008; Bellance, Lestienne et al. 2009). Second,
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mtDNA lacks histone protection from damages. Third, mitochondrial DNA is circular,
supercoiled, and is easily damaged due to diverse exogenous or endogenous effects, such
as radiation and ROS. Fourth, there are few DNA repair mechanisms in mitochondria
compared to the nuclear genome (Achanta, Sasaki et al. 2005). All these properties make
mitochondrial DNA to be easily affected by mutations, which disrupts the electron
transport chain to decrease mitochondrial respiration rate. In addition, the malfunction of
the electron transport chain in cancer cells produces superoxide, which forms ROS with
other radicals. The accumulation of ROS damage mtDNA and nuclear DNA causes
genetic instability as well as cancer progression (Pelicano, Carney et al. 2004). Usually,
there are two characteristics of mtichondrial DNA mutations in cancer cells. First, the
mutations are base transitions from T to C or G to A. Second, the mutations in the
mitochondrial genome frequently occur in the 1.1 kb displacement-loop region (Ding, Ji
et al. 2009).
The malfunction of mitochondrial genome decreases oxidative phosphorylation
efficiency for ATP production. On the other hand ATP produced in the oxidative
phosphorylation process is an inhibitor for phosphofructokinase 1 (PFK1) in glycolysis.
PFK1 is the major pace-keeping enzyme in glycolysis, and activated PFK1 increases
glycolysis flux, which makes a transition for energy production from oxidative
phosphorylation to glycolysis in cancer cells. Moreover, studies show that the disruption
of mitochondrial respiration function in cancer cells induces tumorigenesis. For example,
the

interruption

of

mitochondrial

respiration

with

genetic,

chemical

and

microenvironmental methods, activates the PI3K-Akt pathway (Robey and Hay 2009). It
is well known that the PI3K-Akt pathway in cancer cells plays important functional roles
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in cell survival, proliferation and migrations (Robey and Hay 2009). In mitochondriadeficient human leukemia and lymphoma cells, glycogen synthase kinase-3 (GSK-3), the
substrate of Akt, is activated by Akt phoshphorylation. Therefore, the malfunctions of
mitochondrial respiration in cancer cells may present part of the full explanation for the
Warburg effect.

1.2.4 Metabolic Malfunction is a Potential Cancer Therapy Method.
Even though the mechanisms of the Warburg effect are not fully understood, thus
far, the theory of the Warburg effect has been applied clinically in cancer diagnosis and
therapy. For example, the Warburg effect has been used in cancer imaging for tumor
detection by a glucose analogue, fluorodeoxyglucose, Positron Emission Tomography
(FdG-PET) (Weber, Schwaiger et al. 2000). The fact that cancer cells require more
glucose for energy production leads to FdG-PET, a powerful method in cancer diagnosis
and prognosis (Kelloff, Hoffman et al. 2005). In addition, the increase of protein
expression in glycolysis in cancer cells, such as HK2, and the decrease of the expression
of components in the oxidative phosphorylation pathway, such as β-F1-ATPase,

are

also applied as biomarkers for cancer diagnosis (Cuezva, Ortega et al. 2009).
On the other hand, Akt/mTOR/HIF-1, a major regulatory signal pathway for the
Warburg effect, has been targeted as a cancer therapy method to switch the energy
production sources, that is, to decrease glycolysis efficiency and increase oxaditive
phosphorylation competence (Jiang and Liu 2008). The activation of HIF-1 induced by
Akt under hypoxia environment promotes cancer cell survival. By these methods, the
survival advantages of cancer cells in hypoxic environments will be removed so that the
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cancer cells cannot survive in the abnormal physiological conditions. For this purpose,
some inhibitors for mTOR, such as RAD001, AP-23573 and CCI-779, and HIF-1a
inhibitors, such as NSC644221, PX-478 and YC-1 are applied to impact cancer cell
metabolism (Yeo, Chun et al. 2004; Smolewski 2006; MacKenzie and von Mehren 2007;
Sun, Liu et al. 2007; Wan and Helman 2007; Gridelli, Maione et al. 2008; Jiang and Liu
2008).
Moreover, the fact that cancer cells depend on increased glycolysis as an ATP
provider in hypoxic environments, brings a basis for disruption glycolysis as a potent
cancer therapy. The disruption of the glycolytic pathway in order to limit the energy
production has been studied as a promising cancer therapeutic method (Pelicano, Martin
et al. 2006). For example, 3-BrPa, a hexokinase inhibitor, shows effective anti-cancer
properties in colon cancer cells and lymphoma cells (Chen, Hewel et al. 2007). 2deoxyglucose, a glucose analogue, which cannot be metabolized to produce ATP, is in
clinical trails as an interruptor of the glycolytic pathway which induces tumor cell death
(Mohanti, Rath et al. 1996). A hexokinase inhibitor, lonidamine, releases hexokinase
bound to mitochondria, and inhibits oxygen consumption and glycolysis effectively in
cancer cells (Brawer 2005). Glufosfamide, an alkylating agent from D-glucose, which
damages DNA and activates PARP, is also in phase II clinical trials in patients with
advanced non-small cell lung cancer (Giaccone, Smit et al. 2004). Evasion from
apoptosis is one of the characteristics of cancer cells. Tumor cells that are defective in
cell apoptosis can be diverted into another cell death pathway, necrosis (Zong and
Thompson 2006) (Nelson and White 2004). Necrosis is happening in tumor cells when
the cell cannot provide itself enough energy for consumption. The dismantling of the
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glycolysis pathway may induce tumor cell necrosis. Even though chronic necrosis may
trigger chronic inflammation, it still is a potent method for tumor therapy.

1.3 The Introduction of Glycolysis---Functional and Regulational Mechanisms of
Glycolysis in Cancer Cells
Glucose is a very important energy source for the human body, and the body can
use many sources for producing glucose. Glucose is a monosaccharide which can be
generated from the hydrolysis of polysaccharides and disaccharides, such as starch and
lactose. In some tissues, such as brain cells, glucose is the only available energy source,
under non-starvation conditions. Glucose can also be synthesized from non-carbohydrate
precursors, such as lactate, amino acids and glycerol. The formation of glucose from
other non-cabohydrate carbon substrates, such as glycerol, lactate and glucogenic amino
acides is called gluconeogenesis. The gluconeogenic pathway occuring in mitochondrial
and cytosol, converts pyruvate into glucose. Gluconeogenesis is not simply the reverse
process of glycolysis, as it takes two steps to convert pyruvate into PEP. The first step is
the carboxylation of pyruvate to generate oxaloacetate catalyzed by pyruvate carboxylase
at an expense of one molecule of ATP. The second step is under the function of
phosphoenolpyruvate carboxykinase to generate PEP from oxaloacetat at the expense of
one molecule of GTP.
Glycolysis is the metabolic process for cells to catalyze one molecule of glucose to
produce two molecules of pyruvate, with a net energy production of two molecules of
ATP. There are 10 reaction steps in this process carried out by 10 distinct enzymes. In
mammals, glucose is first taken into cells with a family of glucose transporters (GLUT).
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The sequence of glucose transporters is 500 amino acids long and consists of 12
transmembrane α helices. There are five members of GLUT family presented in specific
tissues. GLUT1 and GLUT3 are responsible for controlling basal glucose uptake. GLUT2
exists in liver and pancreatic β cells to control glucose uptake from the blood with a very
high Km value. GLUT4 is present in muscle and fat cells. GLUT5 exists in the small
intestine. Once glucose is transported into the cells through GLUT, hexokinase, the first
enzyme in the glycolysis process, phosphorylates glucose to form glucose 6-phosphate.
Once phosphorylated, glucose 6-phosphate can not diffuse through the cell membrane
and is trapped in the cytosol. Glucose 6-phosphate is further converted into fructose-6phosphate through the function of phosphoglucose isomerase. In the next stage, the sixcarbon fructose is cleaved by aldolase to generate two molecules of three-carbon
fructose, glyceraldehyde 3-phosphate (GAP) and dihydroxyacerone phosphate (DHAP).
GAP is the only form of the two, three-carbon molecules that can be used in the
glycolysis process. Triose phosphate isomerase converts one molecule of DHAP into one
molecule of GAP. Next, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyzes
the formation of 1,3-bisphosphoglycerate (1,3-BPG) from GAP with the production of
NADH. In this step, phosphorylation is coupled to the oxidation of three-carbon
molecules. 1,3-BPG is an acyl phosphate, which has a high phosphoryl-transfer potential.
The phosphate is transferred to ADP in the next step under the catalytic function of
phsophglycerate kinase with the production of ATP. In the next step, the phosphoryl
group is shifted with the conversion of 3-phosphoglycerate to 2-phosphoglycerate by
phosphoglycerate mutase. Enolase catalyzes the conversion from 2-phosphoglycerate to
phosphoenolpyruvate (PEP) with the formation of an enol in PEP and the production of a
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molecule of H2O. The enol phosphate in PEP has a high potential to transfer phosphate.
In the final step, pyruvate kinase catalyzes this reaction and a phosphate is transferred to
ADP with the production of a molecule of ATP committed with the formation of
pyruvate.
The fates of pyruvate are diverse in different living organisms. In yeast and some
other microorganisms, pyruvate is converted into ethanol catalyzed by pyruvate
decarboxylase. In mammalian cells pyruvate is catalyzed into lactate by lactate
dehydrogenase when oxygen is lacking. Most pyruvate produced in the glycolysis
process enters into the citric acid cycle and the electron-transport chain in mitochondria
to generate energy needed for higher organisms.
The pace of glycolysis is tightly regulated by the catalytic enzymes. Three
glycolytic enzymes, which catalyze these irreversible glycolytic reactions, are involved
in the regulatory process; they are hexokinase, phosphofructokinase and pyruvate kinase
(Weber, Convery et al. 1966). Among these three enzymes, phosphofructokinase is the
predominant regulator in the glycolytic pathway whose enzymatic activity is tightly
controlled by the ATP/AMP ratio in mammalian cells. Phosphofrucokinase catalyzes the
third step in the glycolysis process, which is the conversion from fuctose 6-phosphate to
fructose-1,6-bisphosphate (FBP). During this process, fructose 2,6-bisphosphate formed
from the phosphorylation of fructose 6-phosphate by phosphofuctokinase 2, regulates the
activity

of

phosphofuctokinase.

Fructose

2,6-bisphosphate

activates

phosphofructoskinase by increasing the affinity for fructose 6-phosphate as well as
decreasing the ATP inhibitory effect to phosphofructokinase. Meanwhile, as an important
regulator in the glycolytic pathway, the concentration of fructose 2,6-bisphosphate is
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tightly controlled by its phosphorylation status. Fructose 2,6-bisphosphate can be
dephosphorylated by fructose bisphosphatase 2 (FBPase 2). Phosphofuctokinase 2 and
FBPase 2 are in a single peptide chain as a bi-functional enzyme. This bi-functional
enzyme has five isoforms presenting as tissue specific. Overexpression of fructose 2,6bisphosphatase decreases glycolysis flux and delays cell cycle progression (Perez, Roig
et al. 2000).
Hexokinase is the second control element for the glycolytic pathway and it
phosphorylates glucose to phospholate-6-glucose in the first step of the glycolysis
process. Hexokinase activity is inhibited by its catalytic product, phospholate-6-glucose.
Under these circumstances in which cells have enough energy production or high sources
for macromolecule biosynthesis, phospholate-6-glucose will pass these signals to
decrease the glycolysis process. In livers hexokinase has another isozyme, glycokinase,
whose affinity to glucose is 50 folds lower than that of hexokinase. The function of
glycokinase in liver is to provide phospholate-6-glucose for glycogen synthesis as well as
fatty acid synthesis.

1.4 Pyruvate Kinase Type M2
Pyruvate kinase (PK) is the third rate-limiting enzyme in glycolysis process.
Pyruvate kinase catalyzes the transfer of phosphoryl group from phosphoenolpyruvate
(PEP) to ADP to produce pyruvate and ATP (ΔG°’PEP=58 kJ/mol, ΔG°’ATP=29
kJ/mol). This reaction is chemically irreversible. In mammalian cells, there are four types
of pyruvate kinases in different tissues. L type is expressed exclusively in liver and R
type is found in erythrocytes. M1 type is dominant in adult muscles tissues. M2 type is
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expressed in fetal tissues and some proliferating tissues, such as tumor cells. During
tumorigenesis, the tissue specific forms of PK, such as L and M1 types, lose their
expression and M2 type is expressed (van Berkel, de Jonge et al. 1974; Miwa,
Nakashima et al. 1975; Etiemble and Boivin 1976; Marie, Kahn et al. 1976). The L and R
types are generated from one gene with different transcriptional start sites. M1 and M2
types are isoforms derived from the same gene but are different due to alternative
splicing (Saheki, Saheki et al. 1982; Noguchi, Inoue et al. 1986). The M gene consists of
12 exons and 11 introns. In M2 type, exon 10 is spliced out, and in M1 type, exon 9 is
spliced out. The splicing generates 23 different amino acids in a 56 stretch between M1
and M2 types at the carboxyl terminal from 378-434. During tumorigenesis, M1 type
expression is replaced by M2 type. The replacement of M1 type by M2 type changes the
glycolysis rate to produce more phosphoryl intermediates for cell proliferation.
The PKM2 protein consists of 531 amino acids and each monomer has four
designated domains, such as A, B, C and N domains. Two monomers contact each other
through the A domain interface to form a dimeric structure. Two dimers form a tetramer
through the A and C domain interface (Dombrauckas, Santarsiero et al. 2005). The Ndomain consists of residues 1-43. The A domain, consisting of residues 44-116 and 219389, and is the core structure of the monomer. The B domain comprises residues 117218. The C-domain is made of residues 390-531. The active site of PKM2 is located in
the cleft constructed by A and B domains. The FBP binding site for PKM2 is positioned
at the C-domain. Lysine 433, Serine 434, Serine 437, and Glycine 520 residues are
backbone amides that bond to the 6’-phosphate oxygens of FBP. Among these residues,
Lysine 433 is important for the binding of FBP to PKM2 as well as for PKM2 binding to
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Tyrosine phosphorylated peptides (Christofk, Vander Heiden et al. 2008; Christofk,
Vander Heiden et al. 2008; Spoden, Morandell et al. 2009). Lysine 270 is a conserved
site for all four types of pyruvate kinases and is crucial for its kinase activity
(Dombrauckas, Santarsiero et al. 2005).
In mammalian cells PKM2 has two known quaternary structures, dimeric and
tetrameric forms. Tetrameric PKM2 has a higher affinity to its glycolysis substrate, PEP,
compared to its dimeric form. In tumorigenesis, there is more dimeric PKM2 expressed
with low affinity to PEP, which is called human tumor PKM2. The presence of dimeric
PKM2 in patients feces, blood is utilized as a biomarker for the diagnosis of many
cancers, such as colorectal cancer, prostate cancer and pancreatic cancer (Hardt,
Ngoumou et al. 2000; Ahmed, Dew et al. 2007; Chung-Faye, Hayee et al. 2007; Dube,
Grigull et al. 2007; Ewald, Schaller et al. 2007; Goonetilleke, Mason et al. 2007; Haug,
Rothenbacher et al. 2007).
The low affinity of tumor PKM2 (dimeric PKM2) to PEP decreases the glycolysis
rate so as to produce more phosphor intermediates, which are used to synthesize lipids,
amino acids and some other macromolecules for cell growth and proliferation. The
quaternary structure of PKM2 is regulated by many factors, such as fructose 1, 6bisphosphorylate (FBP), Serine and some oncoproteins (Mazurek, Grimm et al. 2002).
Fructose 1, 6-bisphosphate (FBP), a proceeding molecule in the glycolysis process, binds
to PKM2 to induce its conformational change to the exposed active sites binding to PEP.
The allosteric activity of PK is also regulated both by ATP and alanine, an important
amino acid used in the building blocks for macromolecular synthesis. The activities of
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PK are also controlled by reversible phosphorylation. Phosphorylated PK is less active
than non-phosphorylated form.
Tetrameric PKM2, not dimeric PKM2, is associated with many other glycolytic
enzymes to perform its glycolytic function, such as hexokinase (HK), glyceraldehyde 3-P
dehydrogenase (GAPDH), phosphoglycerate kinase, phoglyceromutatse (PGM), enolase
and lactate dehydrogenase (LDH) (Mazurek, Hugo et al. 1996). However, the interaction
of PKM2 with some other proteins in the cytosol may change its glycolytic activity.
Some oncoproteins, such as pp60V-src kinase and HPV-16E7 proteins directly interact
with PKM2, individually to help the conversion of dimeric forms from tetrameric form,
which results in a decreased ATP/ADP ratio and upregulated FBP level in the cytosol
(Zwerschke, Mazurek et al. 1999). On the other hand, some tumor suppressor proteins,
such as promyelocytic leukemia (PML), also interact with tetrameric PKM2 to suppress
its glycolytic activity (Shimada, Shinagawa et al. 2008). Interestingly, PKM2 is a
phosphoTyrosine binding protein, and the binding of Tyrosine phosphorylated peptides
to PKM2 decreases its enzymatic activity (Christofk, Vander Heiden et al. 2008).
Moreover, it is reported that the cytosolic monomer of PKM2 binds to cytoplasmic
thyroid hormone 3,3',5-triiodo-L-thyronine (T3) to regulate transcription activity of
thyroid hormone receptors (Ashizawa and Cheng 1992).
Besides its well-known glycolytic function in the cytosol, it is not known whether
PKM2 have any other biological functions. Under the stimulation of interleukin 3 (IL-3),
more PKM2 localizes to the nucleus to regulate cell proliferation in an IL-3-dependent
hematopoietic cell line, Ba/F3 (Hoshino, Hirst et al. 2007). There are many reported
nuclear partners of PKM2, such as Oct-4 and PIAS3. PKM2 interacts with Oct-4, an
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important transcription factor for regulating the pluripotent state of embryonic stem cells,
to positively modulate gene transcription (Lee, Kim et al. 2008). Interestingly, the Nterminal (a.a.1–348) of PKM2, interacts with the SUMO-E3 ligase protein PIAS3
(inhibitor of activated STAT3) in the nucleus of many cell lines, such as NIH3T3 and U2 OS (Spoden, Morandell et al. 2009). SUMO, the small ubiquiting modification, is a
post-translational modification occurring at lysine residues in many proteins (Miller,
Levy et al. 2005). Sumoylation modification changes protein properties including
transcriptional activity, nuclear-cytosolic translocation as well as protein stability. For
example, sumoylation of interferon regulatory factor-1 (IRF-1) induced by PIAS3,
represses its transcriptional activity (Nakagawa and Yokosawa 2002). The transcriptional
activity of microphthalmia transcription factor (MITF) is suppressed due to sumoylation,
it is dependent on the targeting sequence in the promoter of TRPM1 (Miller, Levy et al.
2005). PIAS, the protein inhibitor of activated STAT family, was originally identified as
a cytokine-induced inhibitor of Stat3 and appears to have SUMO-E3 ligase activity
(Chung, Liao et al. 1997; Nishida and Yasuda 2002). PIAS has several family members
(PIAS1, PIAS2, PIAS3 PIAS3b, PIASxa, PIASxb, PIASy, and PIASyE6) sharing similar
protein structures, such as the RING finger-like structure (Shuai and Liu 2005). PKM2 is
sumoylated in U-2 OS cells affected by PIAS3, a human bone osteosarcoma. The
overexpression of PIAS3 increases the sumoylation level of PKM2, which leads to the
accumulation of nuclear PKM2 (Spoden, Morandell et al. 2009). According a SUMO
prediction program and PKM2 X-ray structure analyses, there are eight lysine sites in
PKM2 exposed on the protein surface possibly modified by PIAS3 (Spoden, Morandell et
al. 2009).
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On the other hand, somatosatin, a neuropeptide hormone and its anti-cancer
analogues, TT-232, interact with pyruvate kinase in COS-7 cells. The interaction induces
nuclear accumulation of PKM2 from cytosol to trigger caspase-independent apoptosis
(Stetak, Veress et al. 2007). Moreover, UV and H2O2 also cause PKM2 nuclear
accumulation independent of its kinase activity to induce apoptosis (Stetak, Veress et al.
2007). PKM2 also has its function in regulating viral replication abilities. For example,
PKM2 interacts with NS5B, the Hepatitis C virus (HCV) RNA-dependent RNA
polymerase, in HCV replicon 9B cells (Wu, Zhou et al. 2008). The downregulation of
PKM2 by shRNA in n HCV replicon 9B cells reduces the replication of HCV (Wu, Zhou
et al. 2008).
Besides its transcriptional regulatory activity, nuclear PKM2 also shows a kinase
activity. It is reported that nuclear PKM2 isolated from Morris hepatoma 7777 tumor cell
nuclei has kinase activity to phosphorylate histone H1 and it is speculated that PKM2
transfers phosphate from PEP to the ε-amino group of L-lysine (Ignacak and Stachurska
2003).

1.5 p68 RNA Helicase
p68 RNA helicase is a member of the DEAD box family proteins which share a
conserved an Aspartic acid–Glutamic acid–Alanine–Aspartic acid (D-E-A-D) sequence
motif (Hirling, Scheffner et al. 1989). There are many members in the DEAD family,
such as p68, p72 and eIF-4a. All the members of the DEAD box family have a conserved
amino acid motif, which includes the conserved DEAD box (Petry, Johnson et al. 1995;
Shin, Rossow et al. 2007; Wilson and Giguere 2007). The conserved regions can be
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found in many species, such as mouse, human, Escherichia coli, Drosophila and
Saccharomyces cerevisiae (Jost, Schwarz et al. 1999). The DEAD box family proteins
show RNA binding and unwinding activities through the conserved DEAD box amino
acids sequence (Iggo and Lane 1989). DEAD box proteins have been shown to be
involved in a wide range of biological processes involving interaction with specific RNA
substrates; examples include pre-mRNA splicing, ribosome biogenesis, translation and
embryogenesis (Stevenson, Hamilton et al. 1998).
Many homologs of p68 RNA helicase have been discovered in chickens, yeast,
frogs, human and mice. In humans, p68 RNA helicase is encoded by a single gene locus.
The transcribed part of human p68 gene is ~6.7 kb long and is split into 13 exons. Human
p68 RNA helicase was first identified as an antigen cross reacting with a monoclonal
antibody to SV40 large-T antigen, which is a DNA dependent ATPase (Huang and Liu
2002).
P68 RNA helicase plays important roles in pre-mRNA splicing process (Huang and
Liu 2002; Liu 2002). Pre-mRNA splicing is an accurate process, which requires four
small nuclear ribonucleoprotein particles (snRNPs): U1, U2, U4/U6 and U5 as well as
some other non-snRNPs proteins. U1 snRNP binds to the 5’ splicing site of pre-mRNA
and U2 snRNP binds to the branch point. The spliceosome is formed when the U4/U6/U5
triRNPs joins the intermediate spliceosome complex. The 5’ splice site is cleaved and the
exposed 5’ end of the intron links to the branching site. Next, the 3’-OH end of the first
exon adds to the 5’ end beginning site of the second exon. The whole intron between the
two exons is cut off and released as a lariat and the two exons are jointed together to form
a mature mRNA. p68 RNA helicase unwinds the transient U1-5’ splice site duplex during
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the spliceosome assembly process. The ATPase and helicase activities of p68 are
required for the dissociation of U1 snRNA from the 5’ slice site, which indicates that p68
RNA helicase might play roles in unwinding U1 snRNA and 5’ splicing site complex.
p68 RNA helicase might have functions in the formation of the spliceosome with the
adding of U4/U6 and U5 snRNPs, which does not require the ATPase and helicase
activities of p68 (Lin, Yang et al. 2005). As an RNA helicase, p68 is required for
microRNA duplex unwinding, which is required for the unwinding of the transient RNA
duplex to single stranded RNA, to take into the Argonaute protein to perform its
silencing activity (Salzman, Shubert-Coleman et al. 2007). p68 RNA helicase plays
important roles in early organ development and maturation. In mouse embryonic
fibroblasts, the lack of p68 is related to the depression of many microRNAs (Salzman,
Shubert-Coleman et al. 2007).
In the nucleus, p68 RNA helicase interacts with many other proteins to regulate its
gene transcription as a co-activator (Warner, Bhattacherjee et al. 2004; Fuller-Pace,
Jacobs et al. 2007). p68 interacts with p53 through the C-terminal region of p53 to
regulate p53 downstream targeting genes, such as p21, Fas, PIG3 and mdm2 (Bates,
Nicol et al. 2005). p68 RNA helicase is reported to

be recruited to pS2 gene promoter, a

downstream target of estrogen receptor alpha (ERα), to regulate its transcription
(Watanabe, Yanagisawa et al. 2001). In these studies, neither the ATPase activity nor the
RNA helicase activity of p68 is required for its co-activator function. p68 also interacts
with CBP through the C-terminal of CBP to enhance CBP-mediated transcription
(Rossow and Janknecht 2003). p68 RNA helicase interacts with Smad3, specifically the
MH2 domains of Smad3, to form an active transcription regulator complex (Warner,
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Bhattacherjee et al. 2004). Recently it is reported that p68 RNA helicase interacts with
the androgen receptor (AR) in the nucleus and regulate gene transcription as a coactivator for androgen-dependent and androgen-independent prostatic malignancy (Clark,
Coulson et al. 2008).
There are many post-translational modifications of p68 RNA helicase in
mammalian cells, such as sumoylation, polyubiquitylation and phosphorylation. p68 was
first reported to be polyubiquitylated in colorectal cells (Causevic, Hislop et al. 2001).
Sumoylation is found at a single site of p68, Lysine 53, which is enhanced by PIAS1
(protein inhibitor of activated STAT1) (Jacobs, Nicol et al. 2007). The sumoylated p68
co-represses gene transcription through interacting with HDAC1 for p300 and Elk1 (Etslike kinase 1) (Jacobs, Nicol et al. 2007). Recombinant p68 RNA helicase purified from
E.Coli, is phosphorylated at Serine, threonine and Tyrosine residues (Yang and Liu
2004). In many cancer cells, p68 is phosphorylated at Tyrosine residues but not in their
corresponding normal cell lines (Yang, Lin et al. 2005). p68 is phosphorylated at the
Tyrosine 593 residue under the stimulation of PDGF-β in colorectal cells. The Tyrosine
phosphorylated p68 blocks the phosphorylation of β-catenin by GSK-3β and displaces
Axin from β-catenin distruction complex. The released β-catenine is shuttled into the
nucleus by p68 RNA helicase which interacts with the LEF/TCF site to regulate gene
expressions, which are required for EMT process (Yang, Lin et al. 2006). p68 is also
double phosphorylated at Tyrosine 593 and Tyrosine 595 residues in T98G glioblastoma
cells as well as

HeLa cells. The double phosphorylation of p68 facilitates its apoptosis

resistance to some TRAIL-induced apoptosis. The double phosphorylation of p68 RNA
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helicase protects T98G cells from caspase-8 activation to trigger apoptosis (Yang, Lin et
al. 2007).
Immunohistochemical examination shows p68 RNA helicase is dominantly
localized in the nucleus in mammalian cells. p68 is detected in the cytosol depending on
the cell cycle (Yang, Lin et al. 2007). Under the stimulation of growth factors, such as
EGF, PDGF, some p68 comes out of the nucleus into the cytosol. According to the
sequence analysis, there are many putative NES and NLS signals in p68. Two NES and
two NLS functional signals are discovered in p68 RNA helicase sequence. Interestingly,
the shuttling capability of p68 RNA helicase is not dependent on its ATPase activity. The
nucleocytoplasmic shuttling function of p68 is CRM-1 dependent.

1.6 MEK5 and MAP Kinase Pathway
1.6.1 MAPK Family Members and Their Biological Functions
The mitogen-activated protein kinase (MAPK) family is an important kinase
family in mammalian cells, consisting of four subfamilies: extracellular-regulated protein
kinase1 and 2 (ERK1/2), ERK5, c-jun NH2-terminal protein kinases (JNK), and p38
MAPKs (Graves, Campbell et al. 1995; Seger and Krebs 1995; Attar, Atten et al. 1996;
Hu and Plaxton 1996). The biological functions of MAPK pathways are diverse, playing
roles in many cellular processes. In general, ERK subfamilies are related to cell growth,
proliferation and survival, induced by growth factor stimulations. JNK and p38 MAPKs
are associated with inflammation, apoptosis, cell growth and differentiation induced by
cytokine stimulation, as well as extracellular stresses (Obata, Brown et al. 2000;
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Hardwick, van den Brink et al. 2001; Papatsoris and Papavassiliou 2001; Saldeen, Lee et
al. 2001).
All the MAPK family members are activated by phosphorylation at Threonine and
Tyrosine residues within the activation loop TxY of kinase subdomain VIII by diverse
activators: mitogen-activated protein kinase kinase

(MEK1) and MEK2 for ERK1/2,

MEK5 for ERK5, MKK4 and MKK7 for JNKs, MKK3 and MKK6 for p38 MAPKs
(Graves, Campbell et al. 1995). The x in the TxY motif of the kinase subdomain VIII is
diverse in MAPKs. For example, x is proline in JNK, glutamate in ERK, glycine in p38
MAP kinases. MEKs are activated by an upstream activator, MEK kinase. There are
many MEK kinases that activate MEKs: Raf-1, A-Raf, B-Raf, c-Raf, Mos, Tpl2 are for
MEK1 and MEK2; MEKK1, MEKK2, MEKK3, Tpl2 are for MEK5; PAK is for MKK3
and MKK6; MEKK4 and DLK are for MKK4 and MKK7. Cross-talk is always occurring
among these MAPK signaling pathways. In addition, some activators are involved in
more than one MAPK pathway. For example: the activators for MEK5 can also activate
MEK1 and MEK2. In general, MAPK cascade members use docking interactions to
regulate the efficiency and specificity between upstream activators and downstream
substrates (Hu, Shen et al. 2007). In MAP2ks, such as MKK6, the docking domains are
located at the N-terminal or C-terminal to bind its activator, MAP3Ks. The docking
domain of MEK5, consisting of amino acids sequence, EYEDEDGD, is located in its Nterminus which interacts with its upstream regulator, MEKK2 or its downstream
substrate, ERK5 (Seyfried, Wang et al. 2005). For MAPKs, such as ERK2, the docking
domain is located in both the N- and C-terminals. ERK2 has a CD domain (common
domain) consisting of a group of negatively charged amino acids, which is located in the
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C-terminal region just after its kinase domain. ERK2 also has a docking domain named
the ED site, which is located at its N-terminal region in front of its kinase domain.
MAPK substrates have docking domains for their regulation by MAPK. C-Jun has a D
domain to interact with its activator, JNK. c-Fos has DEF (docking site for ERK or FX)
domain in its C-terminal region to interact with ERK. Some ERK substrates have both D
domain and DEF domain to interact with their activators, such as JNK and ERK. In
addition, some MAPK cascades use scaffold proteins to assemble functional MAPK
modules to increase the interaction specificity. For example, JIP-1, a scaffold protein in
the JNK pathway, contains a D domain to bind JNK (Dickens, Rogers et al. 1997)
On the other hand, the activation of MAPK is negatively controlled by MAPK
phosphatase activity. Any dephosphorylation at either Threonine or Tyrosine residues in
TxY motif inactivates MAPK. The dephosphorylation and inactivation process in the
activation loop in MAPK last from minutes to hours depending on cell type and stimuli.
Serine/Threonine protein phosphotases, such as PP2A, a member from the PPP family,
inactivates ERKs. Members of Tyrosine protein phosphotase, such as PTP-SL, STEP,
and HePTP, also dephosphorylate and inactivate ERKs. MAPK phosphatase plays
important roles in diverse biological functions. For example, the JNK phosphatase
family, the puckered mutation leads to cytoskeletal defects resulting in dorsal closure
during Drosophola embryogensis. Interestingly, a subclass of the tyrosine phosphotase
family called dual specificity phosphatase (DSP) dephosphorylate both tyrosine and
threonine residues to inactivate MAPKs (Camps, Nichols et al. 2000). There are nine
members identified in DSP family, such as CL100/MKP-1, PAC1, hVH-2/MKP-2,
hVH3/B23, hVH-5, MKP-3/PYST1, B59, and MKP-5. PAC1, hVH-2/MKP-2,
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hVH3/B23, hVH-5 are expressed exclusively in the nucleus and MKP-3/PYST1 is
expressed in the cytosol. MKP-4 is expressed in both the cytosol and the nucleus.

1.6.2 ERK5-MEK5 Signal Pathway
Extracellular signal-regulated kinase 5 (ERK5), which is also named big-MAPK or
BMK1, is one of the important MAPK family members, and it is activated through a
cascade of signal transduction by MAP3Ks (MEKK2/3 and Cot), MEK5 and ERK5.
ERK5 activation is exclusively activated by MEK5. The MEK5 signal pathway was first
discovered in 1995 by Dixon and co-workers with a yeast two-hybrid screen experiment.
ERK5 was used as the bait to interact with MEK5. ERK5-MEK5 signal pathway plays
important roles in cell growth, cell differentiation, neuronal survival and embryonic
angiogenesis (Sohn, Sarvis et al. 2002; Wang, Merritt et al. 2005). There are many
transcription factors that can be phosphorylated by ERK5, such as c-Myc, MEF2 family
members and c-Fos (Kamakura, Moriguchi et al. 1999) (Yang, Ornatsky et al. 1998).
ERK5 has two splicing variants, ERK5 and ERK5b. ERK5b is shorter in the N-terminal
compared with ERK5. ERK5b is a naturally dominant negative mutant which regulates
ERK5 kinase activity. Overexpression of ERK5b inhibits ERK5b kinase function on
nuclear substrate, such as MEF2C.
The MEK5 gene codes a 444 amino acids protein, which has two splicing variants,
MEK5a and MEK5b (English, Vanderbilt et al. 1995; Chao, Hayashi et al. 1999).
MEK5a is a protein with 89 amino acids longer than MEK5b at the N-terminal.
Both of MEK5a and MEK5b can individually interact with ERK5. Double
phosphorylated MEK5a at Serine 311 and Threonine 315 activates ERK5 as well as its
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nuclear translocation, but not MEK5b (Kato et al., 1997). MEK5a directly interacts and
stimulates ERK5 kinase activity by phosphorylating threonine and Tyrosine residues in
the TxY motif. On the other hand the overexpression of MEK5b disrupts the interaction
of MEK5a with ERK5, which indicates MEK5b is a putative dominant negative mutant
which regulates MEK5a kinase function to activate ERK5.
The expression and cellular localization of MEK5a and MEK5b are tissue specific
(English, Vanderbilt et al. 1995). MEK5a is localized dominantly in the cytosol and
MEK5b is distributed evenly in the whole cell. MEK5a expression is abundant in actively
mitotic tissues, such as liver and brain (English, Vanderbilt et al. 1995). MEK5b has
more expression than MEK5a in differentiated tissues, such as muscle, lung, kidney et al.
Many studies showed the expression of MEK5 is closely related with
tumorigenesis. MEK5 is overexpressed in human prostate cancer cells as detected by
antibodies that recognize the specific N-terminal of MEK5a (Mehta, Jenkins et al. 2003).
Immunohistostaining results also show that MEK5 is overexpressed in human prostate
cancer but not in benign prostate tissues (Mehta, Jenkins et al. 2003). Moreover, the
expression level of MEK5 in malignant prostate cancer is correlated with its bone
metastases (Mehta, Jenkins et al. 2003). Patients with higher expression of MEK5 had a
shorter disease-specific survival time (52 months) compared to those with weaker MEK5
expression which survived in 58 months. The activation of MEK5 induces prostate
cancer cell proliferation. The overexpression of a constitutively active MEK5 mutant
(MEK5D) in LNCaP cells, a metastatic prostatic adenocarcinoma cell line derived from
the lymph node, induces a 3.7 fold higher cell proliferation compared to control vectors.
In our experiments the expression of MEK5 is upregulated by PKM2 overexpression,
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which results in cell proliferation, especially in more metastatic cancer cell lines
compared to the less aggressive cell lines. Moreover, MEK5D overexpression in LNCaP
cells increases cell migration by 1.8 fold and invasion ability by 2.1 fold compared to
control vectors, which indicates that MEK5 plays a role in tumor metastasis as well as
invasion. MEK5 is a putative modulator in regulating gene expression involved in tumor
metastasis and migration processes. Matrix metalloproteinases 9 (MMP9), a zincdependent enzyme involved in the metastasis process, is transcriptionally upregulated by
MEK5 overexpression (Mehta, Jenkins et al. 2003).

1.7 Stat Family and the Biological Function of Stat3
Signal transducer and activator of transcriptions (Stat) is an important transcription
factor family playing crucial roles in cell differentiation, proliferation, cell survival as
well as other cellular activities (Johnston, Bacon et al. 1995; Ripperger, Fritz et al. 1995;
DaSilva, Rui et al. 1996). Stat family proteins were first identified as a molecule required
for interferon (IFN)-triggered gene expression around 15 years ago (Yang, Shi et al.
1996). Stat is highly expressed in a large number of human malignant tumor cells, such
as breast cancer, lung cancer, colorectal cancer and hematological malignancies. The Stat
family consists of seven members, such as Stat1, Stat2, Stat3, Stat4, Stat5 (Stat5a, Stat5b)
and Stat6. Stat1 and Stat2 were first identified as transcriptional factors binding to a
consensus sequence TT(C/A)YNR(G/T)AA (Schindler, Shuai et al. 1992). Stat family
members share a number of well conserved domains. The N-terminal domain is a binding
region for some other transcription co-activators, such as CBP/p300, c-Jun, and Nmi
(Giraud, Bienvenu et al. 2002; Cvijic, Bauer et al. 2009). In the middle of the sequence is
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a DNA binding domain, which binds to cognate targeting DNA sequences. A flexible
linker connects DNA binding domain with SH2 domain, which is required for the
dimerization of Stat proteins as well as for Tyrosine phosphorylation binding. The Cterminal region of Stat protein is a transactivation domain and the phosphorylation of
Tyrosine/Serine residues at this domain is required for Stat protein activation.
In general, Stat is a transcription factor family activated by phosphorylation
through a cascade of signal transductions induced by interleukins or growth factors
(Wen, Zhong et al. 1995). The Stat family of proteins is latent and inactive within the
cytosol under normal conditions. Once ligands bind to the receptors on cellular
membrane, autophosphorylation of the receptors is triggered, which induces the
dimerization of these receptors. The dimerization of growth factor receptors activates
their intrinsic Tyrosine phosphorylation activity. The phosphroylated receptors at
Tyrosine residues subsequently create docking sites at their cytoplasmic tails for Stat
proteins via their Src-homology (SH2) domain. Stat proteins binding to the
phosphorylated receptors are phosphorylated by the receptors and form an activated
form. In some cases the engagement of cytokines to their receptors results in the
activation of these receptor-associated Tyrosine kinases, such as Janus kinase (JAK).
Subsequently, JAK kinase phosphorylates Stat proteins at their C-terminals. The
phosphorylated Stat proteins are released from the binding sites on the membrane and
form homodimers or heterodimers. The dimerized Stat proteins then translocate into the
nucleus and bind to promoter regions bearing conserved DNA sequences. Once bound,
Stat proteins recruit other transcription elements at the promoter site to trigger gene
transcription.
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Stat family members can be activated by many cell-surface binding ligands
involved in diverse signal pathways. Stat1 activation is induced by interferon signaling
exclusively (Qing and Stark 2004; Ho and Ivashkiv 2006). Stat3 activation can be
inducible by many cytokinses, such as interleukin-6 (IL-6) and growth factors, such as
EGF, PDGF, VEGFR, FGFR and IGFR. In transformed cells, some oncoproteins, such as
Src and Abl, can also activate Stat3 (Yu, Meyer et al. 1995). The activation of the Stat
family requires Tyrosine phosphorylation at the C-terminal region, which is adjacent to
its transcriptional activation domain. For example, Y705 in Stat3, Y694 in Stat5a and
Y699 in Stat5b are the activation sites for these Stat family members. A phenylalanine
substitution of the Tyrosine residue position at 705 of Stat3 results in a reduction in
Tyrosine phosphorylation of wild type Stat3 and inhibits its endogeous activity (Kaptein,
Paillard et al. 1996). Serine phosphorylation at the C-terminal of the Stat family is also
important for regulating their transcriptional activity. For example, phosphorylation at
Serine 727 in Stat3 and Stat1 upregulates their transcriptional activity mediated by
several kinases, such as p38，JNK and protein kinase C (Nagy, Wang et al. 2002)
(Wierenga, Vogelzang et al. 2003) (Pircher, Petersen et al. 1999). On the contrary, Serine
phosphorylation at residue 725 in Stat5 down-regulates the transcriptional activity of
Stat5 (Yamashita, Nevalainen et al. 2001)

(Yamashita, Xu et al. 1998) .

An important Stat family member is Stat3, whose activity is tightly controlled
under diverse physiological conditions. Stat3 is activated/phosphorylated in a low level
in normal cells, which is negatively regulated by many inhibitory proteins including
Suppressor of Cytokine Signalling (SOCS) and Protein Inhibitor of Activated Stat (PIAS)
(Flowers, Subramaniam et al. 2005; Tokumaru, Sayama et al. 2005; Diao, Wang et al.

32

2009). It is reported that PIAS3 specificly interacts with Stat3, not other members of Stat
family. The interaction blocks Stat3 DNA binding activity to inhibit its gene
transcriptional regulatory activity in many cell lines, such as HepG2 cells, IL-6-treated
M1 and MCF7 cells (Chung, Liao et al. 1997). Some protein Tyrosine phosphatases, such
as PTP1B, SHP1, SHP2, CD45 are reported to inhibit the Stat3 pathway as well (Ohtani,
Ishihara et al. 2000; Zhang, Chan et al. 2009). In cancer cells, such as breast cancer, head
and neck cancer, prostate cancer, Stat3 is detected with high levels of expression and
activation (Bromberg, Wrzeszczynska et al. 1999) (Yu and Jove 2004). Activated Stat3 is
sufficient to mediate tumor formation in nude mice (Bromberg, Wrzeszczynska et al.
1999). A constitutively active Stat3 mutant transfected in melanoma cells, enhances its
brain metastasis (Xie, Huang et al. 2006). Phosphorylated Stat3 activates many genes
related to cell proliferation and differentiation as well as anti-apoptosis, such as c-Myc,
Cyclin D1, BCL2 family gene Bcl-XL (Nielsen, Kaestel et al. 1999) (Bienvenu, Gascan
et al. 2001), (Song, Ethier et al. 2004). Stat3 also induces the gene expression of HIF-1,
MMP-2 and VEGF to promote tumor metastasis and angiogenesis (Niu, Wright et al.
2002).
Moreover, Stat3 plays important roles as a cross-talker in regulating the activities
between tumor cells and tumor immune microenvironments by suppressing immune
responses from both tumor cells and immune cells (Cheng, Wang et al. 2003;
Kortylewski and Yu 2008). In tumor cells, the overexpression of Stat3 inhibits the release
of immuno-stimulating molecules so that the tumor cells can prevent the infiltration of
immune cells. For example, the overexpression of a Stat3 dominant negative mutant in
B16 melanoma, greatly enhances the release of pro-inflammatory mediators to promote
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the infiltration of immune cells to B16 melanoma (Wang, Niu et al. 2004). Moreover, the
releasing of pro-inflammatory mediators blocked by phosphorylated Stat3 stimulates the
activation of innate immune response cells, such as neutrophils and macrophages (Wang,
Niu et al. 2004). Activated Stat3 not only inhibits the release of pro-inflammatory
mediators from tumor cells, but also prohibits the expression of pro-inflammatory
mediators in normal immune cells. For example, the inhibition of Stat3 expression in
macrophages results in a high level release of pro-inflammatory mediators found in
Stat3-inactiated tumor cells (Takeda, Clausen et al. 1999).
Stat3 is a important mediator playing roles in multiple oncogenic signaling
pathways to regulate tumorigenesis as well as immunosuppressive pathways (Yu,
Kortylewski et al. 2007). Stat3 has been identified as a potential target for cancer
immuno-therapy (Zhang, Zhang et al. 2007; Zhou, Wulfkuhle et al. 2007; Al Zaid
Siddiquee and Turkson 2008). The suppression of Stat3 activities in tumor cells induces
cell apoptosis, decreases tumor cell proliferation, and inhibits tumor cell migration
(Grandis, Drenning et al. 2000; Epling-Burnette, Liu et al. 2001; Wang, Ouyang et al.
2008; Baral, Bose et al. 2009; Xin, Zhang et al. 2009; Yagil, Kay et al. 2009). Disruption
of Stat3 activity blocks VEGF expression, a key mediator for solid tumor angiogenesis
(Wei, Kuo et al. 2003). The interruption of the Stat3 signaling pathway activates the
expression of IP-10 and IFN-β, both of which are inhibitors of solid tumor angiogenesis
during malignant process (Niu, Heller et al. 1999; Niu, Bowman et al. 2002). Some Stat3
inhibitors, such as phosphopeptide and platinum (IV) complexes, have been proven to
inhibit Stat3 signaling so as to deregulate Stat3-dependent malignant transformation and
cell proliferation, and induce apoptosis of cancer cells (Turkson, Ryan et al. 2001;
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Turkson, Zhang et al. 2005). The suppression of Stat3 activities in many immune cells
decreases the release of negative immune regulators such as immature dendritic cells.
The suppression of Stat3 activities also increases the activity of CD8+ T cells, natural
killer cells as well as neutrophils.
Stat3 is located in diverse cellular compartments dependent on its phosphorylation
status, such as the cytosol and the nucleus. Non-phosphorylated Stat3 shuttles between
the nucleus and the cytosol depending on its own NLS and NES. Stat3 binds to α/β
importin to translocate into the nucleus, and binds to CRM1 to export from the nucleus
(Sato, Tsuruma et al. 2005). Once phosphorylated by its upstream activators, Stat3 is
retained in the nucleus, binding to its target DNA sequence to start regulating gene
transcription by recruiting other transcriptional factors. Recently, it is reported that Stat3
exists in mitochondria where it interacts with GRIM-19 in complex 1 and 2 to regulate
cell respiration (Wegrzyn, Potla et al. 2009). The functional role of Stat3 in regulating
energy production in the oxidative phosphorylation pathway is independent of its
transcriptional function. Moreover, unlike its transcription role in the nucleus, DNA
binding domain, the dimerization motif or Tyrosine phosphorylation at 705, are not
required for its mitochondrial function. Interestingly, phosphorylation at Serine 727 is
crucial for Stat3 oxidative phosphorylation regulatory function, which indicates the
possible involvement of either growth factor triggered phosphorylation signal pathways
or non-receptor protein kinase induced phosphorylation pathways (Wegrzyn, Potla et al.
2009).

1.8 Cdc14 Regulates Mitosis Exit in Eukaryotic Cells
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Cyclin Dependent Kinases (CDKs) play important roles in regulating the entry
from interphase to mitosis. For cells to exit from mitosis, CDKs must be degraded or be
dephosphorylated to inhibit their functions. How cells exit from mitosis has been well
characterized in the budding yeast, Saccharomyces cerevisiae (Jensen and Johnston
2002). In Saccharomyces cerevisiae, cells exit from mitosis is regulated by a cascade of
reactions named Cdc Fourteen Early Anaphase Release (FEAR) and Mitosis exit network
(MEN). MEN are a group of proteins that can inactivate mitotic cyclin-dependent kinases
including Tem1p, Lte1p, Cdc5p, Cdc15p, Dbf2p, and Dbf20p, and Mob1p (McCollum
and Gould 2001). In anaphase, MEN activated by a small G protein, Tem1, induces the
export of Cdc14, which is located in the nucleolus held by inhibitors Cfi1/Net1 during
interphase, from the nucleolus into cytoplasm. Cdc14 is a Serine/Threonin phoshpatase.
In Saccharomyces cerevisiae, Cdc14 antagonize the effect of Cdc28/Clb, a key regulatory
kinase for cell cycle in yeast, to regulate cell cycle. Cdc14 dephosphorylates several
downstream targets of Cdc28/Clb, such as Hct1, Sic1 and Swi5, to regulate cell cycle.
(Toyn, Johnson et al. 1997). The dephosphorylation of Hct1 results in cyclin B
degradation. The dephosphorylation of Swi5, a transcription factor, by Cdc14 results in
the nuclear accumulation of Swi5. Cdc14 also mediates dephosphorylation of Sic1, an
inhibitor of Cdc28/clb, results in the accumulation of Cdc28/clb (Verma, Feldman et al.
1997)
In fission yeast, Saccharomyces pombe, Cdc14 has a homologous, Flp1/Clp1,
which has a distinct functions in cell cycle regulation from Cdc14 in Saccharomyces
cerevisiae. Flp1/Clp1 is not an essential gene in fission yeast and regulates G2 phase of
the cell cycle.
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In higher eukaryotes, two types of anaphase promoting complexes (APC), a large
ubiquitin ligase, must be activated for cells to exit from anaphase. APC and their coeffectors, such as Cdc20 and Cdh1, form a complex, such as APCCdc20 and APCCdh1.
During G2/M phase, APCcdc20 is activated to ubiquitnate securin so that separase was
released into the cytosol to promote sister-chromatid separation. APCcdh1 is activated
during M/G1 phase and APCCdh1 ubiqutinates mitotic cyclins to allow cells to exit from
mitosis. The activity of APC relies on the phosphorylation status of their co-effectors,
Cdc20 and Cdh1. Cdh1 is phosphorylated by cyclin B-cdc2 and dephosphorylated by
Cdc14A. In addition, Cdc14A is the major phosphatase for Cdh1 (Bembenek and Yu
2001).
In mammalian cells, Cdc14 has two orthologs Cdc14A and Cdc14B, encoding by
two distinct genes. Cdc14A and Cdc14B share a conserved amino acid sequences over
80% in their N-terminal and phosphatase domain. Cdc14A and Cdc14B have distinct
dynamic cellular localizations spatiotemporally. Cdc14A resides in centrosome in
interphase and Cdc14B locates in nucleolus. During mitosis Cdc14A is released into the
cytoplasm. Cdc14A was interacted with MTOC in the cytosol.
In human, Cdc14A gene is located on chromosome 1 on the band 1p21 and
consists of 16 exons. The expression of Cdc14A is tightly controlled during cell cycle.
The expression of Cdc14B is even during whole cell cycle. Cdc14A is highly expressed
in brain, heart, small intestine and skeletal muscle. And has a low expression level in
kidney, liver, lung, testis and pancreas (Paulsen, Starks et al. 2006). The expression of
Cdc14A is quite differentially in cancer cells, even within the same specific tumor type.
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In mammalian cells, Cdc14A has several putative downstream targets. Cdc14A
interacts with tumor suppressor p53 both in vitro and in vivo. The interaction is
dependent on the N-terminal of Cdc14A and the C-terminal of p53. The phosphorylation
site of p53, Ser315, is specifically dephosphorylated by Cdc14A. The other
phosphorylation site in p53, such as Ser392, is not dephosphorylated by Cdc14A. The
phosphorylaion of p53 protein at Ser315 is related to its DNA binding activity (Li,
Ljungman et al. 2000).
As two isoforms, Cdc14A and Cdc14B have distinct functions in regulation
centrosome duplication. Studies show that Cdc14A overexpression induce multinucleus
in mammalian cells. The depletion of Cdc14A results in centrosome separation and
cytokinesis failure (Mailand, Lukas et al. 2002). On the other hand, the depletion of
Cdc14B results in amplification of centriole (Wu, Cho et al. 2008).
As an important physiological regulator, the expression of either Cdc14A or
Cdc14B affects genomic stability (Mailand, Lukas et al. 2002). So far, the mechanism of
Cdc14A gene transcription regulation is not well defined.

1.9 Aims of Dissertation
Aerobic glycolysis is been established as a hallmark for cancer progression, which
is well known as Warburg effect. In 1924 Otto Warburg hypothesized that cancer is
caused by the metabolism switch from oxidative phosphorylation to glycolysis (Warburg
1956; Warburg 1956). With the development of modern oncology and the discovery of
many oncogenes and tumor suppressor genes, cancer is gradually recognized as a genetic
disease and the metabolism change in cancer cells is a company phenomenon of
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tumorigenesis. Many oncogenes as well as tumor suppressor genes results in the
metabolism switch from oxdative phosphorylation to glycolysis by regulating metabolic
enzymes activities, such as Ras, Akt and Myc (Gordan, Thompson et al. 2007). However,
how glycolysis enzymes directly regulate tumorigenesis is not well studied. In this
project, we found that a glycolytic enzyme, pyruvate kinase M2 (PKM2), plays an
important role as a transcriptional co-activitor in regulating cell proliferation in the
nucleus of cancer cells. PKM2 phosphorylates its downstream target, Stat3, using PEP as
a substrate. Morover, phosphorylated p68 RNA helicase Y593/595 interacts with PKM2
to shuttle cytosolic PKM2 into the nucleus. In addition, the interaction between
phosphorylated p68 RNA heliase and PKM2 transforms a tetrameric PKM2 into a
dimeric form under the stimulation of EGF. Nuclear PKM2 and p68 RNA helicase coregulates Cdc14A gene transcription to induce multinucleus in less aggressive cancer
cells. Overall, this study provides evidences about how glycolytic enzymes affect
tumorigenesis, which brings centain levels of explanations about why cancer cells prefer
to glycolysis for Warburg effect.
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CHAPTER 2
PYRUVATE KINASE M2 PROMOTES CELL PROLIFERATION BY
REGULATING GENE TRANSCRIPTION

2.1 Abstract
Alterations in metabolism may play a critical role in the transformation to
malignancy during tumor progression. However, the ways by which the metabolism
alterations affect tumor progression are not well understood. Here, we show that PKM2,
a glycolysis enzyme, localizes to the cell nucleus. The nuclear PKM2 levels correlate
with cell proliferation rates. Expression of PKM2 promotes cell proliferation. Nuclear
PKM2 promotes cell proliferation by upregulating transcription of MEK5, a MAP kinase
associated with cell proliferation. PKM2 regulates the MEK5 transcription by promoting
stat3 phosphorylation at Y705 and facilitating stat3 binding to MEK5 promoter. Our
studies reveal an important molecular link that connects metabolic alterations with gene
expressions during tumor progression.

2.2 Introduction
Most cancer cells utilize aerobic pathways for glucose metabolism. Upon tumor
progression, the oxidative phosphorylation in mitochondria is usually dramatically
reduced even in the presence of oxygen (Warburg effects) (Warburg, 1956). Although it
is still debatable whether the metabolic alteration is just a symptom of cell transformation
or a causative factor in tumorigenesis, the evidence suggests that metabolic adjustments
by tumor cells are necessary processes for tumorigenesis and tumor progression
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(Deberardinis et al., 2008; Garber, 2006). It is generally believed that oncogenic products
regulate the metabolic pathways (Matoba et al., 2006). Expression of oncogenes can
result in substantial changes in composition of metabolism isoenzymes that regulate the
flows of metabolites (Dang & Lewis, 1997; Elstrom et al., 2004; Semenza, 2007).
However, it is not well understood whether, and how, metabolic changes during tumor
progression will produce a feedback effect on cell proliferation. An important molecular
signature of tumor development and progression is a shift in expression of pyruvate
kinase isoenzymes. The tissue specific isoform (L, R, or M1) disappears and is replaced
by pyruvate kinase isoenzyme type M2 (PKM2) in cancer cells (Elbers et al., 1991;
Hacker et al., 1998). The glycolysis catalytically active PKM2 exists as a tetramer and
associates with a glycolytic enzyme complex in normal cells (Altenberg & Greulich,
2004; Dombrauckas et al., 2005; Zwerschke et al., 1999). In tumor cells, it is believed
that PKM2 dominantly forms a dimer, and appears to be catalytically inactive for
conversion of PEP to pyruvate (Ashizawa et al., 1991; Mazurek et al., 2005). The
inactive PKM2 actually provides an advantage for metabolism as it helps to channel the
carbon source from glycolytic intermediates to biosynthesis, especially syntheses of
nucleic acids, lipids, and proteins, to meet the demands for tumor cell proliferation.
Recent studies have suggested that PKM2 changes its catalytic activity, consequently
facilitating cell proliferation by binding to tyrosine phosphor-proteins (Christofk et al.,
2008a; Christofk et al., 2008b). The observations suggest that growth signals regulate the
flow of carbon sources from glucose.
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2.3 Results
2.3.1 Nuclear PKM2 Levels Correlate with Tumor Progression and Expression of
PKM2 Promotes Cell Proliferation
PKM2 is an enzyme that catalyzes the last step of glycolysis converting PEP to
pyruvate. Several independent studies have revealed that the protein may localize to the
cell nucleus (Hoshino et al., 2007; Schneider et al., 2002; Stetak et al., 2007). We further
verified the nuclear localization of PKM2 in different cancer cells by immunostaining
using antibody raised against a peptide spanning aa 399 – 412 of PKM2 (PabPKM2) (Fig.
S1A). To understand the functional significance of nuclear localization of PKM2, we
examined nuclear PKM2 levels in ten different cancer cell lines by immunoblot of
nuclear extracts and whole cell lysates using the antibody PabPKM2. These ten different
cell lines represented different cancer progression stages and are derived from cancers of
different organs/tissue types. SW480 and SW620 are colon cancer cell lines derived from
the same cancer patient. LN686 is a head-neck squamous cell carcinoma cell line while
the M4C1 is derived from LN686 by selecting high metastatic and high proliferation sublines in nude mice (Zhang et al., 2002). WM115 and WM266 are melanoma cell lines
from the same patient. T98G and U87MG are cell lines of glioblastoma. H146 and H460
are cell lines derived from lung cancer patients. Cell proliferation analyses demonstrated
that M4C1, SW620, WM266, and H460 are more proliferated than their corresponding
lines in the matched pairs (Fig. 2.1A). Immunoblot analyses indicated much higher
nuclear levels of PKM2 in the more proliferated cancer cells than those in the
corresponding less proliferated cells (Fig. 2.1B), The higher nuclear PKM2 levels were
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not attributed to differences in PKM2 expression levels in different cells, as shown in
figure 1B whereas no significant differences were observed in total PKM2 in cell lysates
in all test cells. The detection of PKM2 in the nuclear extracts was not due to
contamination of cytoplasmic proteins as demonstrated by lack of GAPDH in the
immunoblot analyses of the nuclear extracts.
We next investigated the effects of expression of PKM2 on cell proliferation with these
ten different cell lines. HA-PKM2 was exogenously expressed in the cells using a
commercially available Adeno-viral expression system. Quantization of PKM2 before
and after exogenous expression revealed an approximately ~30% increase in cellular
levels of PKM2 (Fig. 2.7 B). No significant differences in expression of HA-PKM2 were
observed among the different cells (Fig. 2.1C). The expressed HA-PKM2 was distributed
similarly to the endogenous PKM2 between the nucleus and the cytoplasm, as shown by
immunoblot analyses using anti-HA antibody (Fig. 2.7C). It was evident that all cells that
exogenously expressed HA-PKM2 experienced some degree of cell proliferation, with
more proliferated cancer cells experiencing a higher proliferation rate increase than those
of corresponding less proliferated cancer cells (Fig. 2.1D). The results suggested that
expression of PKM2 promoted cell proliferation. To further test the role of PKM2 in
promoting cell proliferation, we used a smartpool RNAi to knock down PKM2 in SW620
and SW480 cells (Fig. 2.1E). The cell growth rate of the more proliferated SW620 was
dramatically reduced by PKM2 knockdown, while the growth rate of the less proliferated
SW480 cells was moderately reduced by PKM2 knockdown (Fig. 2.1E). Similar results
were also observed with the pair of melanoma cell lines (WM115/WM266, Fig 2.1E).
Thus, both PKM2 expression and knockdown experiments indicated that PKM2 plays a
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role in promoting cell proliferation with stronger effects on the more proliferated cancer
cells. The effects of expression of PKM2 in different cancer cells on cell proliferation
correlated very well with nuclear levels of PKM2 in different cancer cells.

2.3.2 PKM2 Activates Transcription of MEK5
The observations that the nuclear PKM2 levels completely correlated with the cell
proliferation and that the expression of HA-PKM2 promoted cell proliferation led us to
believe that nuclear PKM2 plays an important role in promoting cell proliferation by
action other than that in the glycolysis. One possibility is that nuclear PKM2 is involved
in regulation of gene expressions. To explore this possibility, we carried out gene
expression array analyses with SW620 cells that exogenously expressed HA-PKM2.
Expressions of 350 genes were upregulated, and expressions of 359 genes were
downregulated, by at least two fold under the expression of HA-PKM2 (Table S1).
Among those affected genes, expression of MEK5 (also named MAP2K5), a MAP kinase
closely associated with cell proliferation, was affected by over seven fold. The expression
array analyses indicated that nuclear PKM2 may function as a regulator for gene
transcription. Expression and activation of MEK5 plays a very important role in cell
proliferation (Diaz-Meco & Moscat, 2001). Expression and activation of MEK5 have
also been shown to closely associate with cancer progression, including prostate cancer
and breast cancer (McCracken et al., 2008; Mehta et al., 2003; Song et al., 2004). Thus,
we reasoned that upregulation of MEK5 may mediate, at least partially, the effects of
nuclear PKM2 on promoting cell proliferation. To test this conjecture, we first verified
the effects of expression of PKM2 on the expression of MEK5 by RT-PCR. Consistent
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with the gene expression array analyses, RTPCR demonstrated a marginal increase in
MEK5 expression in SW480 cells following the expression of PKM2. However, the
changes in the MEK5 expression in SW620 cells were much more dramatic (Fig. 2.2A).
Similar patterns were also observed with another pair of cell lines, WM115 and WM266.
The effects on the expressions of MEK5 by the expression of PKM2 were further
confirmed by immunoblot analyses of cellular MEK5. It was clear that the cellular
MEK5 levels increased subsequent to expression of PKM2. The more aggressive cancer
cells experienced more dramatic increases in MEK5 levels upon expression of PKM2
(Fig. 2.2B). Interestingly, immunoblot of MEK5 using antibody against the
phosphorylated MEK5 revealed a strong increase in the cellular levels of phosphorylated
MEK5 (activated MEK5) in aggressive cancer cells compared to the less aggressive
cancer cells upon exogenous expression of PKM2 (Fig. 2.2B). To further verify the role
of PKM2 in transcriptional regulation of MEK5 gene, PKM2 was knocked down in
SW620 and SW480 cells. Immunoblot analyses showed an approximately 80% PKM2
knockdown efficiency (Fig. 2.2C). It was evident that MEK5 expression was slightly
reduced in SW480. However, the reduction in cellular levels of MEK5 in SW620 cells
was dramatic upon knockdown of PKM2 (Fig. 2.2C). Again, the phosphorylated MEK5
experienced a sharp reduction in SW620 upon PKM2 knockdown, which was not
observed in SW480 cells (Fig. 2.2C). We also analyzed the MEK5 mRNA levels in
SW620 and WM266 cells upon PKM2 knockdown. Quantitative RT-PCR analyses
demonstrated a strong reduction in cellular MEK5 mRNA in both PKM2 knockdown
SW620 and WM266 cells (Fig. 2.2D). Thus, it is clear that PKM2 regulates the
expression of MEK5. Expression of PKM2 appeared to also regulate MEK5 activation in
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the more aggressive cancer cells. We further probed whether PKM2 regulates the
transcription of the MEK5 gene directly, or if the regulatory effects were mediated
through other cellular factor(s). To this end, we examined whether PKM2 interacted with
the MEK5 promoter by chromatin immunoprecipitation (ChIP). We carried out the ChIP
experiments with SW620 cells using the PCR primer pair that spanned the region of nt –
1,621 – -1,366 of MEK5 promoter. Our ChIP assays clearly demonstrated that PKM2
indeed interacted with the MEK5 promoter (Fig. 2.2E), indicating that PKM2 most likely
regulates the transcription of the MEK5 gene directly. The preceding experiments
suggested that PKM2 plays an active role in regulating the transcription of the MEK5
gene. We next sought to test whether up-regulation of MEK5 by PKM2 contributed to
cell proliferation. We first knocked down MEK5 by RNAi in SW620 and WM266 cells.
As a result, the cell proliferation rate was dramatically reduced (Fig. 2.3A). The
proliferation rate increases stimulated by expression of HA-PKM2 in MEK5 knockdown
SW620 and WM266 cells were also largely reduced (Fig. 2.3A), suggesting that upregulation of MEK5, at least partially, mediated the effects of HA-PKM2 overexpression
on cell proliferation. Moreover, we analyzed the MEK5 expression levels and
phosphorylation status in these ten different cancer cell lines. MEK5 was expressed in all
ten cell lines, but there were substantially higher levels of MEK5 in the more proliferated
cancer cells than in the less proliferated cancer cells. Strikingly, the levels of
phosphorylated MEK5 were also consistently higher in more proliferated cancer cells
than in less proliferated cancer cells (Fig. 2.3B). Clearly, there is a close correlation
between cellular MEK5 expression levels, the MEK5 phosphorylation levels and nuclear
PKM2 levels, and all were correlated closely with the cell proliferation status of the cells
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(comparing Fig. 2.3B with Fig. 2.1B). We concluded from these studies that upregulation and activation of MEK5 by nuclear PKM2 contributed to cell proliferation.

2.3.3 PKM2 Upregulates MEK5 Transcription by Activation of Stat3
In searching for the proteins (possibly transcription factor) that may interact with
nuclear PKM2, we noted that stat3 regulates transcription of MEK5 gene and the protein
interacts with MEK5 promoter at -1776 nt – -1520 nt region by the ChIP assay (Song et
al., 2004). Interestingly, PKM2 also interacts with MEK5 promoter at the same region by
ChIP assay (Fig. 2.2E). Thus, we wondered whether PKM2 would interact with stat3 in
the cell nucleus. To probe the interaction between PKM2 and stat3, we carried out coimmunoprecipitation with nuclear extracts made from SW620 and SW480 cells. Clearly,
stat3 co-precipitated with PKM2. As a control, stat3 was not precipitated using rabbit
IgG as IP antibody (Fig. 2.3C). Consistent with our previous observations, there were
substantially less PKM2 and stat3 co-immunoprecipitation in the nuclear extracts
prepared from SW480 than in the extracts made from SW620 cells. The
coimmunoprecipitation was also carried out using reversed IP and IB antibodies, and
with exogenously expressed HA-PKM2 (Fig. 2.8 A&B). These co-immunoprecipitation
experiments indicated that PKM2 indeed interacted with stat3 in the nuclear extracts. We
next tested whether the activation of stat3 was required for the effects of PKM2 on
upregulation of MEK5 transcription. To this end, we first knocked down stat3 using
RNAi in SW620/SW480 and WM266/WM115 cells and subsequently HA-PKM2 was
expressed in the stat3 knockdown cells. It was clear that expression of HA-PKM2 could
no longer upregulate MEK5 gene transcription as measured by cellular levels of both
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mRNA and protein of MEK5 (Fig. 2.4 A&B, C&D). To further test the role of stat3 in
mediating the effects of PKM2 on upregulation of MEK5 transcription, we used a
dominate-negative mutant stat3 (Y705F) (Xie et al., 2006). The wild-type or dominate
negative

mutant

was

co-expressed

with

HA-PKM2

in

SW620/SW480

and

WM266/WM115 cells. Expression of MEK5 in both mRNA and protein levels was
examined. It was evident that expression of dominate-negative stat3 mutant largely
diminished the effects of PKM2 on upregulating MEK5 transcription (Fig. 2.8 C&D,
E&F). It is well documented that the activity of the active stat3 can be inhibited by
specific inhibitor (Xu et al., 2008). We therefore tested the effects of a stat3 inhibitor on
the upregulation of MEK5 by expression of HA-PKM2 in SW620 and WM266 cells.
Treatment of the HA-PKM2 expressing cells with the inhibitor resulted in a decrease in
MEK5 transcription (Fig. 2.8 G&H). Thus, we concluded that activation of stat3
mediated the regulatory effects of PKM2 on MEK5 transcription.
We further investigated whether expression of PKM2 affected the stat3 binding to
its target DNA at the MEK5 promoter. We first carried out ChIP analyses with SW620
cells using the PCR primer pair span the region -1621 nt - -1366 nt. Our ChIP assays
showed that interaction of stat3 with the MEK5 promoter can be detected by this PCR
primer pair (Fig. 2.9A). To probe whether knockdown or expression of PKM2 affected
the interaction of stat3 with the MEK5 promoter, we performed ChIP experiments in
SW620 cells in which the endogenous PKM2 was knocked down or HA-PKM2 was
expressed. Clearly, the stat3 and MEK5 promoter interaction was strengthened by HAPKM2 expression and was weakened by PKM2 knockdown (Fig. 2.5A). To further
analyze the effects of PKM2 on the interaction between stat3 and its target DNA, we
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carried out gel mobility shift assays using a 32P-labled oligonucleotide duplex containing
a stat3 binding sequence (Xie et al., 2006). The gel-shift experiments were carried out
with nuclear extracts made from SW620 cells with/without PKM2 knockdown or
with/without HA-PKM2 expression. Autoradiography indicated that a slow migration
complex was assembled with the labeled oligonucleotide and addition of the antibody
against stat3 or PKM2 resulted in a supershift complex (Fig. 2.5B). The supershift
complexes clearly indicated the coexistence of both PKM2 and stat3 in the assembled
oligo-protein complex. Interestingly, knockdown of PKM2 substantially decreased the
assembly of the oligo-protein complex and assembly of stat3 in the complex (the weak
supershift) (Fig. 2.5D), while expression of HA-PKM2 dramatically increased assembled
complex and assembly of both stat3 and PKM2 in the complex (Fig. 2.5C). The gelshift
and supershift experiments suggested that PKM2 and stat3 might participate in
transcription complex at the same stat3 DNA binding site, and PKM2 facilitated stat3
binding to its target DNA sequence. To further test this notion, we carried out ChIP/ReChIP experiments with the MEK5 promoter using antibody against stat3 and the antibody
PabPKM2. The ChIP/Re-ChIP experiment clearly indicated that both PKM2 and stat3
interacted simultaneously with MEK5 promoter at the region of -1621 – -1366 nt (Fig.
2.5E). Stat3 is a transcription activator that is activated by phosphorylation at Y705
mainly by JAK or Src kinase. The phosphorylation increased the stat3 and DNA binding
affinity (Sehgal, 2008). We observed the interaction between stat3 and PKM2 in the cell
nucleus and PKM2 increased the stat3 binding to its target sequence both in vitro and in
vivo. We suspected that PKM2 may play a role in stat3 phosphorylation at Y705. To test
this conjecture, we analyzed the stat3 phosphorylation in SW620 cells in which the HA-
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PKM2 was exogenously expressed. The phosphorylation of stat3 at Y705 in the nuclear
extracts was examined by immunoblot using antibody against the Y705 phosphorylated
stat3. Clearly, a significant increase in Y705 phosphorylation of stat3 in the nuclear
extracts was evident by the immunoblot, upon expression of HA-PKM2 in the cells.
Examination of the cellular levels of stat3 by immunoblot indicated that the expression
levels of stat3 were not affected by the PKM2 expression (Fig. 2.6A). We further
examined the effects of knockdown of PKM2 on the phosphorylation of stat3.
Immunoblot analyses demonstrated that the phosphorylation levels of stat3 were
significantly reduced upon PKM2 knockdown. The cellular levels of stat3 were not
affected by PKM2 knockdown (Fig. 2.6B). It is known that JAK2 and c-Src are the most
common protein tyrosine kinases that phosphorylate stat3. We therefore probed whether
JAK2 and c-Src were activated by the HA-PKM2 expression. We examined
JAK2/activated JAK2 and c-Src/activated c-Src by immunoblot using antibodies against
JAK2, the phosphorylated (Y1007/1008) JAK2 (activated), c-Src, and the phosphorylated
c-Src (Y530) with the cell lysate made from SW620 cells with/without HA-PKM2
expression. Clearly, JAK2 and c-Src were not activated upon the HAPKM2 expression
(Fig. 2.6 C&D). The experiments suggested that expression of PKM2 promoted stat3
phosphorylation (activation), and the phosphorylation was not due to activation of JAK2
and c-Src.

2.3.4 Expression of PKM2 did not Alter Production of Pyruvate and Lactate
PKM2 is an enzyme that acts in the glycolysis pathway. We therefore analyzed
production of lactate and pyruvate in two pairs of cells, SW620/SW480 and
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WM266/WM115, in which the HA-PKM2 was exogenously expressed. Upon exogenous
expression of HA-PKM2, there were no significant changes in cellular lactate and
pyruvate for either WM266 or SW620 cells (the more proliferated cell lines). Cellular
pyruvate and lactate increased slightly in SW480 and WM115 cells (the less proliferated
cell lines), indicating a slight increase in glycolytic pyruvate kinase activity upon
exogenous expression of HA-PKM2 in the less aggressive cancer cells, while expression
of PKM2 did not lead to any changes in glycolytic pyruvate kinase activity in the more
proliferated cancer cells. Overall, no substantial changes in cellular pyruvate and lactate
were observed (Fig. 2.9 B-E), suggesting that the differences in stimulating cell
proliferation by expression of HA-PKM2 in more proliferated and less proliferated
cancer cells were not simply due to the effects on the carbohydrate metabolism.

2.4 Discussion
During tumor progression, growth signals stimulate the conversion of
glycolytically active PKM2 to an inactive form of the enzyme, consequently regulating
the glycolysis pathway to channel the carbon source from glucose for biosynthesis
(Christofk et al., 2008a; Deberardinis et al., 2008; Garber, 2006; Mazurek & Eigenbrodt,
2003). It is conceivable that tumor cells need to coordinate the metabolism alterations
with expression of genes that are related to cell proliferation during tumor progression.
PKM2 has long been recognized as a so-called ‘moonlight’ enzyme that plays a very
important role in tumor progression (Sriram et al., 2005). Clearly, the activity of PKM2
in transcription regulation is an important ‘moonlight’ activity of the protein. The
functions of PKM2 in regulating expression of genes fulfill the role of feedback
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signaling from metabolic alterations to gene regulation during tumor malignancy
transformation (see model in Fig. 2.6E). It is intriguing that a glycolytic enzyme can
translocate to the nucleus and act in gene transcription. Our co-immunoprecipitation
experiments demonstrated that nuclear PKM2 coimmunoprecipitated with stat3, a
transcription activator whose activations response to various growth factor and cytokines
stimulations. PKM2 activates stat3 and increases the capability of the transcription
activator binding to its target DNA, thus consequently activates transcription. This is a
new pathway that leads to activation of stat3. Stat3 is a transcription activator that is
activated in response to inflammatory cytokines, such as IL-6 (Gao et al., 2007; Watson
& Neoh, 2008). Strikingly, activation of stat3 represents probably one of the most
important molecular signatures involved in promoting cancer progression. It has been
observed that activation of stat3 is detected in almost all cancer types (Frank, 2007;
Groner et al., 2008; Huang, 2007; Kim et al., 2007). However, it is generally believed
that activations of stat3 in response to growth factor and cytokines are usually transient.
A long standing question is “How do the malignant cancer cells maintain constitutive
activation of stat3?” Currently, mutation(s) that lead to constitutive activation of stat3
have not been identified. Thus, activation of stat3 by PKM2 in malignant cancer cells
potentially provides a very attractive explanation for this long-standing question. The
increase in nuclear stat3 phosphorylation at Y705 by expression of PKM2 implies a
possibility that PKM2 may function as a protein kinase in the cell nucleus. Consistent
with this conjecture, it was observed that PKM2 purified from extracts of hepatoma cells
could phosphorylate histone H1 in vitro (Ignacak & Stachurska, 2003). We attempted to
test possible kinase activity of the recombinant PKM2 expressed in E. coli with a
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commercial recombinant GST-stat3 in the presence of ATP. No phosphorylation of stat3
was observed (data not shown). However, it is possible that PKM2 expressed in bacteria
did not adapter the same structural or conformational properties. Alternatively, PKM2
may interact with tyrosine phosphorylated stat3 and the interaction helps redistribution of
the phosphorylated stat3 to the cell nucleus. PKM2 is demonstrated to interact with
tyrosine-phosphor-peptide. It is believed that interaction of PKM2 with tyrosine
phosphor-protein confers the functional role of PKM2 in promoting cell proliferation
(Christofk et al., 2008a; Christofk et al., 2008b). However, the interaction of PKM2 with
a particular tyrosine phosphorylated protein has not been identified. Here, we
demonstrated an example that PKM2 targeted a cellular tyrosine phosphor-protein stat3.
PKM2 interacts with the phosphorylated stat3 and aids the activity of the phosphorylated
protein in gene transcription, which consequently confers the functional role of PKM2 in
promoting cell proliferation.

2.5 Materials and Methods
2.5.1 Reagents, Cell lines, and Antibodies
The KLH conjugated peptide spans aa 399 – 412 of PKM2 was synthesized by
Global Peptide Services. PKM2 polycolonal antibody and anti-HA antibody was raised in
the animal facility of Georgia State University. Antibodies against Lamin A/C, Histone
2A, MEK5, MEK5(pSer311/Thr315), stat3, stat3(pY705), JAK2, JAK2(p-1007/1008), cSrc, p-c-Src(pY530), and _-actin were purchased from Cell Signaling, Abnova,
Invitrogen, SantaCruz, Abcam, and AnaSpec respectively. Recombinant GST-stat3 was
purchased from Abcam. Cell lines LN686 and M4C1 were gifts from Dr. Georgia Chen,
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Emory University. Cell lines SW480, SW620, WM115, WM266, T98G, U87MG, H146
and H460 were purchased from ATCC and cultured by following the vendor’s
instructions. The vector for expression of dominate negative stat3 (Y705F) was a kind
gift from Dr. Suyan Huang, The University of Texas, M.D. Anderson Cancer Center (Xie
et al., 2006). Stat3 inhibitor, Ethyl-1-(4-cyno-2,3,5,6-tetrafluorophenyl)-6,7,8-trifluoro-4oxo-1,4-dihydroquinoline-3-carboxylate (Xu et al., 2008) was purchased from
Calbiochem and used without further purification.

2.5.2 RNA Interference, Subcellular Extracts Preparation, Co-immunoprecipitation,
immunoblot, Cell Proliferation Assays, and Chromatin immunoprecipitation (ChIP)
The siRNA duplexes for PKM2, stat3, and MEK5, siGENOME ON-TARGETplus
SMARTpool duplex, were purchased from Dharmacon RNA technologies. The
experimental procedures for preparation of subcellular extracts, co-immunoprecipitation,
RNA interference knockdown, immunoblot, cell proliferation assays, and chromatin
immunoprecipitation (ChIP) were similar to that of our previous reports (Yang et al.,
2006; Yang et al., 2007b). Cell proliferations were measured using the commercial cell
proliferation kit (Calbiochem) that monitors incorporation of BrdU (Yang et al., 2006;
Yang et al., 2007a).

2.5.3 Expression of PKM2 by Adenovirus Using Commercial AdEasy System
The cDNA encoding PKM2 was purchased from OriGene Technologies. PKM2
cDNA was cloned into a shuttle vector pAdEasy-1 with EcoRI and NotI restriction
endonuclease sites. The resultant plasmid was digested with Pme1 and transformed into
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competent AdEasier cells containing the adenovirail backbone plasmid pAdEasy-1 by
electroporation (BJ5183-AD-1, Stratagene). Recombinants were selected for kanamycin
resistance and further confirmed by restriction endonuclease analyses and DNA
autosequencing. The confirmed plasmid with PKM2 cDNA was digested with PacI
restriction endonuclease and transformed into HEK-293 cells expressing adenovirus E1
(Stratagene). The production of recombinant adenoviruses in HEK-293 cells was
examined under fluorescent microscope and collected in three weeks. The recombinant
viruses were amplified three rounds in HEK-293 cells to increase virus titer (1x1013
Pfu/ml). The viruses were collected by centrifugation and stored at -80oC. The cells were
seeded in a 48 well plate to 70% – 80% confluence. Viruses stock (50 _l at 1x1013
Pfu/ml) were added to each well and incubated for 3 – 5 hours following by changing
fresh culture medium. The expression of HA-PKM2 was examined 48 hours after
incubation.

2.5.4 Cellular Pyruvate and Lactate
Cellular pyruvate and lactate were analyzed by commercially available kits
(BioVision). Cells (WM115, WM266, SW480, and SW620) were infected with adenoviruses for overexpression of
HA-PKM2 or control vectors, and were lysed in lysis buffers that were included in the
kits. The lysates were centrifuged at 13,000g to remove the precipitates. The prepared
extracts (10 _l) were applied to the assay test. The standard curves were made using
probes included with the kits. Pyruvate and lactate amounts were measured by following
the vendor’s instructions.

66

2.5.5 Microarray Analyses of Gene Expressions
Total RNA from cells expressing HA-tagged PKM2 or control was extracted with
an RNeasy kit by following the vendor’s instructions (Qiagen). The total RNA
concentration was determined by spectrometer reading at OD 280 nm. The isolated total
RNA (10 _g) of each sample was used for synthesizing cDNA using the ImProm-II
reverse transcription system (Promega). Synthesized cDNA was purified by phenolchloroform extraction and ethanol precipitation. The cDNA was labeled using the
GeneChip® IVT Labeling Kit (Affymetrix). The labeled cDNA was fragmented in
fragmentation buffer and hybridized to a GeneChip® Human Genome U133 Plus 2.0
Array (Affymetrix). The arrays were scanned with the Affymetrix GeneChip 3000
scanner. The data were analyzed by Affymetrix GeneChip Operating Software (GCOS)
Version 1.0. The array data in table S1 obtained with SW620 cells in which PKM2 was
exogenously expressed were subtracted from a reference array where the cells were
infected with viruses carrying an empty vector. The same expression array experiments
were repeated two times.

2.5.6 Real Time PCR and RT-PCR
Total RNA was extracted from the cells using RNeasy kit by following the
manufacturer’s instruction (Qiagen). Reverse transcription process was performed with
ImProm-II reverse transcription system (Promega). Subsequent Polymerase Chain
Reactions were carried out with 1 μg of template cDNA mixed with the Fast SYBR green
master mix in an Applied Biosystems Real-Time PCR 7500 system (Applied biosystems).
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The PCR reactions using standard RT-PCR negative control primer set were performed
as reference. The primer pairs, forward 5’-CATGTCCTTGGAAGAATTGC-3’, reverse
5’-ATAGAATTCACCAGCTGAGTG-3’, that
targeted exon 12 – exon 14/15 regions of the MEK5 gene was used in our RT-PCR
experiments.The primer pair for PCR reaction in the ChIP with MEK5 promoter was,
forward

5’-GTATGCAAATTTGGCAAATTGAG-3’

reverse

5’-

CTTCAGATATTCTAGGAATTTCCC-3’, targeting nt -1,621 – -1,366 region. The
primer pair for ChIP target exon 1 of MEK5 (nt 342– nt 542) was forward 5’CAGAGACCTTCACCATAGCG-3’

and

reverse

5’-

AACAAGGGAATGGAGGATGAG-3’. The primer pair for PCR reaction in the ChIP
withGAPDH gene was forward 5’-CAATTCCCCATCTCAGTCGT-3’, reverse 5’AGTAGCCGGGCCCTACTTT-3’ span region of -360 nt - -163 nt.

2.5.7 Gel-Mobility Shift and Super-Shift Assays
The mobility shift assays were carried out with oligonucleotide that harbors a stat3
binding sequence 5’-GATCCTTCTGGGAATTCCTAGATC-3’ (Xie et al., 2006). The
oligonucleotide was 5’-end 32P-labeled. The labeled oligonucleotide (100 pmole) was
incubated with 15% nuclear extracts (20 _l) prepared from appropriate cells as indicated
in the figure legends for 30 minutes at room temperature in the binding buffer (5%
glycerol, 1mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 50mM NaCl, 10mM Tris-HCl,
0.05mg/ml poly(dI-dC)). The proteinoligonucleotide complexes were separated in 4%
native polyacrylamide gel (acrylamide: polyacrylamide 59:1). For supershift analyses, a
monoclonal antibody against stat3 (invitrogen) or the antibody PabPKM2 was added to
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the oligonucleotide-nuclear extracts mixture and incubated for additional 45 minutes. The
complexes in gel were transferred to a membrane and subjected to autoradiography.

2.5.8 ChIP, Re-ChIP
ChIP and Re-ChIP experiments were performed with a commercial ChIP/Re-ChIP
kit (Activemotif) by following vendor’s instruction. Briefly, the first round of ChIP was
carried out s described above. The DNA was recovered from the immunoprecipitates by
elution with 1% SDS, and 90% of the eluted chromatin from the first round of
immunoprecipation was diluted 10-fold with ChIP buffer. The second round of
immunoprecipitation was then carried out with the recovered immunoprecipitates. DNA
fragmentations, reverse crosslinking, and PCR reaction was subsequently performed with
the second round of immunoprecipitation.
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Figure 2.1 PKM2 Promotes Cell Proliferation
(A) Cell proliferations of ten cancer cell lines (indicated) were measured using a
commercial cell proliferation kit. The proliferation rates are presented as fold changes of
BrdU incorporation of the same cultured cells before and after 48 hours culturing by
defining the initial BrdU incorporation as 1. (B) Nuclear localization of PKM2 in
different cancer cells. Immunoblot analyses of PKM2 using the antibody PabPKM2
(IB:PKM2) in nuclear extracts (NE) and whole cell lysates (WCL) of ten different cell
lines (indicated). Blots of lamin A/C and H2A are loading controls. (C) Exogenous HAPKM2 (HAPK) expression using the adeno-viral expression kit in ten different cell lines
(indicated) were analyzed by immunoblot using anti-HA antibody (IB:HA). Immunoblot
of _-actin (IB:_-actin) were loading controls. Vec were the cells infected with virus that
carry an empty vector. (D) Cell proliferation rates of ten different cell lines (indicated) in
which PKM2 was exogenously expressed using the adeno-viral expression kit were
measured using the cell proliferation kit. Cell proliferations are presented as fold changes
in BrdU incorporation of the same cultured cells before expression of PKM2 and 48
hours after PKM2 expression. The BrdU incorporation of each cell line without PKM2
expression is defined as 1. (E) (Top) Cell proliferations of SW480 and SW620 cells were
measured using the cell proliferation kit. Cell proliferations were presented as fold
changes in BrdU incorporation before and 48 hours after knockdown of PKM2 using a
smart-pool RNAi (PK). NT represents the cells treated with non-target RNAi. The BrdU
incorporation of each cell line before PKM2 knockdown was defined as 1. (Bottom)
Immunoblot analyses of cellular PKM2 using the antibody PabPKM2 (IB:PKM2) 48
hours after RNAi knockdown of PKM2 in different cells (indicated). Immunoblot of βactin (IB:β-actin) were loading controls. NT represents the cells treated with non-target
RNAi. Error bars in (A), (D), and (E) are standard deviations for three independent
experiments.

72

73

Figure 2.2 PKM2 Upregulates MEK5 Transcription
(A) RT-PCR analyses of cellular MEK5 mRNA levels in two pairs of cancer cells
(indicated) in which PKM2 was exogenously expressed using the adeno-viral expression
kit. The results are presented as fold increase in PCR products before and 48 hours after
PKM2 exogenous expression in the same cells. The level of PCR product from each cell
line before PKM2 exogenous expression was defined as 1. (B) Expressions (IB:MEK5)
and phosphorylation (IB:p-MEK5) of MEK5 in different cancer cells (indicated on top)
were analyzed by immunoblot using antibodies against MEK5 and phosphorylated
MEK5. HA-PKM2 was expressed (HAPK) in the cells using the adeno-viral expression
kit (IB:HA). Vec were the cells infected with virus that carry the empty vector. (C)
Expressions (IB:MEK5) and phosphorylation (IB:p-MEK5) of MEK5 in SW480 and
SW620 cells (indicated) in which PKM2 was knocked down (PK) using the smart pool
RNAi were analyzed by immunoblot using antibodies against MEK5 and phosphorylated
MEK5. The cellular levels of PKM2 were analyzed by immunoblot of PKM2 (IB:PKM2).
(D) (Bottom panel) RT-PCR analyses of cellular MEK5 mRNA levels in SW620 and
WM266 cells (indicated) in which PKM2 was knocked down using a smart-pool RNAi
(PK). NT represents the cells treated with non-target RNAi. The results are presented as
fold changes in PCR products before and 48 hours after PKM2 knockdown in the same
cells. The level of PCR products from each cell line that was treated with non-target
RNAi was defined as 1. (Upper panel) Immunoblot analyses of cellular PKM2 in
SW620 and WM266 cells (indicated) in which PKM2 was knocked down using a smartpool RNAi (PK). (E) ChIP of the MEK5 promoter (MEK5 promoter) using antibody
against PKM2 in SW620 cells (_PK). ChIP using rabbit IgG was a negative control. ChIP
using PCR primer pair targeting a region of exon 1 (MEK5 exon 1) of MEK5 gene (nt
342 – nt 542) is a negative control. ChIP targeting GAPDH promoter (GAPDH promoter)
using antibody against PKM2 was another negative control. The primer pair positions are
indicated. Inputs were PCR products from DNA extracts without ChIP. In (B), (C), and
(D), Immunoblot of β-actin (IB:β-actin) is a loading control. Error bars in (A) and (D) are
standard
deviations
of
three
measurements
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Figure 2.3 Expression of MEK5 Mediates the Effects of PKM2 in Cell Proliferation
(A) (Upper panel) Cellular levels of MEK5 and exogenously expressed HA-PKM2 in
WM266 and SW620 cells were analyzed by immunoblot using antibodies against MEK5
(IB: MEK5) and HA (IB:HA). MEK5 in the cells was knocked down by RNAi (PK).
PKM2 was exogenously expressed in the cells using the adeno-viral expression kit.
(Bottom Panel) Cell proliferations of WM266 and SW620 cells were measured using the
cell proliferation kit. Proliferations of WM266 (1 – 4) or SW620 (5 – 8) cells were
measured under following conditions: 1) and 5) Open bars, HA-PKM2 expression and no
MEK5 knockdown;. 2) and 6) Gray bars, HA-PKM2 was expressed and no MEK5
knockdown; 3) and 7) Black bars, no PKM2 expression and MEK5 knockdown; and 4)
and 8) Striped bars, PKM2 expression and MEK5 knockdown. The proliferations are
presented as fold changes of BrdU incorporation before and after indicated treatments.
NT represents the cells treated with non-target RNAi. Vec were the cells infected with
virus that carry the empty vector. Error bars are standard deviations of three
measurements. (B) Cellular MEK5 levels and phosphorylation of the protein in ten
different cell lines (indicated at top) were examined by immunoblot of whole cell lysate
using antibodies against MEK5 and phosphorylated MEK5. In (A) and (B) Immunoblot
of β-actin (IB:β-actin) is a loading control. (C) Co-immunoprecipitation of PKM2 with
stat3. PKM2 was immunoprecipitated from nuclear extracts prepared from SW620 and
SW480 cells using the antibody PabPKM2 (IP: αPK). The immunoprecipitates were
analyzed by immunoblot using antibodies against stat3 (IB: Stat3) or PKM2 (IB: PKM2).
Ponceau S staining of IgG heavy chain (IgG HC) in the immunoprecipitates is the
loading control. Immunoprecipitation using rabbit IgG (IP:IgG) was the control
immunoprecipitation.
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Figure 2.4 PKM2 Upregulates MEK5 Transcription via Activation of Stat3
(A) & (C) Expressions of MEK5 (IB: MEK5) in SW620/SW480 (A) and
WM115/WM266 cells (C) (indicated) were analyzed by immunoblot the cell lysate
(WCL) prepared from the cells in which stat3 was knocked down by RNAi (stat3,
IB:Stat3). HA-PKM2 was exogenously expressed in the stat3 knockdown cells (IB:HA).
The blot of β-actin (IB: β-actin) are the loading controls. (B) & (D) RT-PCR analyses of
cellular MEK5 mRNA levels in SW620/SW480 (B) and WM266/WM115 cells (D)
(indicated) in which stat3 was knocked down by RNAi (stat3, IB:Stat3). HA-PKM2 was
exogenously expressed in the stat3 knockdown cells (IB: HA). The results are presented
as fold changes in PCR products before and 48 hours after stat3 knockdown and HAPKM2 expression in the same cells. The level of PCR products from each cell line that
was treated with non-target RNAi was defined as 1. In (A), (B), (C), and (D), NT
represents the cells treated with non-target RNAi. Vec were the cells infected with virus
that carry the empty vector. Error bars in (B) and (D) are standard deviations of three
measurements.
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Figure 2.5 PKM2 Upregulates MEK5 Transcription by Promoting Stat3 DNA Interaction
(A) (Upper panels) ChIP of the MEK5 promoter (MEK5 promoter) using antibody
against stat3 in SW620 cells (αStat3). The cells were treated non-target RNAi (left, NT)
or with RNAi target PKM2 (right, RNAi-PK), or HA-PKM2 was exogenously expressed
in the cells (middle, HAPK). ChIP using rabbit IgG (IgG) was a negative control. Inputs
were PCR products from DNA extracts without ChIP. The primer pair positions are
indicated. (Lower panels) the cellular PKM2 (right) and HA-PKM2 (left) levels in
SW620 cells that were treated with RNAi target PKM2 (PK) or with non-target RNAi
(NT), or infected with virus that carry HA-PKM2 expression vector (HAPK) or vector
alone (Vec). The blot of β-actin (IB:β-actin) is the loading control. (B) DNA-protein
complex (Complex) assembled on a 32P-labeled oligonucleotide containing the stat3
targeting sequence in nuclear extracts prepared from SW620 cells (left panel) was
detected by gel-shift and autoradiography. Probe indicates the free 32P-labeled
oligonucleotide probe without addition of nuclear extracts. The antibodies against PKM2
(αPK), stat3 (αStat3), or no antibody (NoAb) was added to the complex to create
supershift (Supershift) (right panel). (C) & (D) Supershift complex assembled with the
32P-labeled oligonucleotide and antibodies (indicated) in the nuclear extracts prepared
from SW620 cells in which (D) PKM2 was knocked down by RNAi (PK) or (C) HAPKM2 was exogenously expressed (HAPK) was detected by gel-shift and
autoradiography. NT means the cells were treated with non-target RNAi. Vec means the
cells were infected with virus that carried the empty vector. Probe only is the free probe
without addition of nuclear extracts. The free probe (low exposure) is the loading control
with 1/10 of exposure time in autoradiography. The quantification of the assembled
complex and super shift complex were presented as percentage (Shifted/total x102) of
probe in the shift complex calculated by Intensities of complex [complex (grey bars) or
supershift (open bars)] divided by Intensities of total [free probe + complex + supershift).
Immunoblots at bottom of each panel indicate cellular levels of HA-PKM2 (IB:HA) and
endogenous PKM2 (IB:PKM2). Immunoblot of β-actin is the loading control. (E) ChIP
and Re-ChIP of the MEK5 promoter (MEK5 promoter) in SW620 cells. The antibody is
against stat3 (αStat3) was used as the first ChIP antibody (ChIP). The antibody
PabPKM2 (αPK) was used as Re-ChIP antibody (Re-ChIP). ChIP and Re-ChIP using
rabbit IgG (IgG) were the negative control experiments. The primer pair targeting the
same region (-1621 nt – -1366 nt) was used in ChIP and Re-ChIP assays.
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Figure 2.6 PKM2 Phosphorylates Stat3
(A) & (B) The levels of Y705 phosphorylated stat3 (IB:p-Tyr-Stat3) in the cell nucleus
were analyzed by immunoblot of nuclear extracts (NE) prepared from SW620 cells in
which HAPKM2 was expressed (A. HAPK) or endogenous PKM2 was knocked down
using the smartpool RNAi (B, PK). The total cellular stat3 levels were analyzed by
immunoblot analyses of stat3 (IB:Stat3) in whole cell lysate (WCL). In (A), immunoblot
of HA-tag (IB:HA) indicates the HA-PKM2 expression levels in the cells. In (B),
immunoblot of PKM2 (IB:PKM2) represents cellular PKM2 levels in the cells.
Immunoblot of lamin A/C and β-actin are the loading controls. (C) & (D) Activation
JAK2 (B) or c-Src (C) in SW620 cells in which HA-PKM2 was expressed (HAPK) was
analyzed by immunoblot of cytoplasmic extracts (Cyto) using antibody against
phosphorylated JAK2 (B, IB:p-JAK2) or antibody against phosphorylated c-Src (C, IB:pc-Src). Vec means the cells were infected by virus carry the empty vector. Immunoblots
of JAK2 (IB: JAK2) in (B) and c-Src (IB:Src) in (C) are loading control. Immunoblot of
β-actin is another loading control. The expression levels of HA-PKM2 were examined by
immunoblot of HA-tag. (E) A hypothetic model for the role of PKM2 in promoting cell
proliferation.
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Figure 2.7 Expression PKM2 in Cancer Cells
(A) Immunostaining of PKM2 using the antibody PabPKM2 in SW480, SW620, and
T98G cells (indicated). The red signal represents staining of PKM2 in the cells (a). The
blue signal represents DAPI staining of DNA (b). (c) is the overlay of PKM2 antibody
staining and DAPI staining. (B) Cellular levels of PKM2 in WM115, WM266, SW480,
and SW620 cells (indicated) before and 48 hours after infection of the cells with viruses
that carry PKM2 expression vector (HAPK) or empty vector (Vec) were analyzed by
immunoblot of PKM2 (IB:PKM2) in cell lysate using the antibody PabPKM2. The
exogenously expressed HA-PKM2 was examined by immunoblot using anti-HA antibody.
The right panel is quantization of immunoblot signals of IB:PKM2 by defining the IB
signal before HA-PKM2 expression as 1 in each cell line. Error bars are standard
deviations of three measurements. (C) Levels of exogenously expressed HA-PKM2
(HAPK) in the cell nucleus (NE) and the cytoplasm (Cyto) in WM115, WM266, SW480,
and SW620 cells (indicated) were analyzed by immunoblot using anti-HA antibody
(IB:HA). Vec were the cells infected with virus carrying an empty vector. In (B) and (C),
immunoblot of β-actin (IB: β-actin) and lamin A/C (IB:Lamin A/C) were loading
controls.
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Figure 2.8 PKM2 Interacts with Stat3 to Regulate MEK5 Gene Transcription
(A) & (B) Co-immunoprecipitations of endogenous PKM2 (A) and exogenous HAPKM2
(B) with stat3 were analyzed by immunoprecipitation using antibody against stat3 (IP:
αstat3 in A) and anti-HA antibody (IP:HA in B) from nuclear extracts prepared from
SW620 and SW480 cells. The immunoprecipitates were analyzed by immunoblot using
antibodies against stat3 (IB:Stat3) or PKM2 (IB:PKM2). Ponceau S staining of IgG
heave chain (IgG HC) in the immunoprecipitates is the loading control.
Immunoprecipitation using rabbit IgG (IP:IgG) was the control immunoprecipitation. In
(B), the immunoblot using anti-HA antibody was an additional loading control. (C) &
(E), Expressions of MEK5 (IB:MEK5) in SW620/SW480 (C) and WM115/WM266 (E)
cells were analyzed by immunoblot the whole cell lysate (WCL) prepared from the cells
in which a stat3 dominant negative mutant (DNST) and HA-PKM2 (HAPK) were
expressed. Immunoblot of HA-Stat3DN (IB:HA (stat3DN) and HA-PKM2 (IB:HAPK)
indicated the exogenous expression levels. The cellular levels of phosphorylated MEK5
were also examined by immunoblot using the antibody against phosphorylated MEK5
(IB:p-MEK5). (D) & (F) RT-PCR analyses of cellular MEK5 mRNA levels in
SW620/SW480 (D) and WM266/WM115 (F) cells in which a stat3 dominant negative
mutant (DNST) and HAPKM2 (HAPK) were expressed. The results are presented as fold
changes in PCR products before and 48 hours after the dominant negative stat3 mutant
and HA-PKM2 expression in the same cells. The level of PCR products from each cell
line that was infected with virus that carry the empty vector (Vec) and no stat3 mutant
expression was defined as 1. (G) Expressions of MEK5 (IB: MEK5) in SW620/WM266
cells (indicated) were analyzed by immunoblot the whole cell lysate (WCL) prepared
from the cells in which HA-PKM2 was exogenously expressed (HAPK) and that were
treated with the stat3 inhibitor (Inhibitor). Cells treated with DMSO (the same amounts
as used in inhibitor treatments as solvent for dissolve the inhibitor) are the control
treatments. (H) RT-PCR analyses of cellular MEK5 mRNA levels in SW620/WM266
cells. The results are presented as fold changes in PCR products before and 48 hours after
the dominant negative stat3 mutant and HA-PKM2 expression in the same cells. The
level of PCR products from each cell line that was infected with virus that carry the
empty vector (Vec) and no stat3 mutant expression was defined as 1. In (C), (E), and (G),
immunoblot of β-actin (IB: β-actin) is the loading control. Error bars in (D), (F), and (H)
are standard deviations of three measurements.
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Figure 2.9 PKM2 is Associated with Stat3 Promoter Region
(A) ChIP of the MEK5 promoter (MEK5 promoter) using antibody against stat3 in
SW620 cells (α Stat3). ChIP using rabbit IgG (IgG) was a negative control. ChIP using
PCR primer pair targeting a region of exon 1 (MEK5 exon 1) of MEK5 gene (nt 342 – nt
542) is a negative control. ChIP targeting GAPDH promoter (GAPDH promoter) using
antibody against stat3 was another negative control. The primer pair positions are
indicated. Inputs were PCR products from DNA extracts without ChIP. (B-E) The
cellular levels of lactate (B, C) and pyruvate (D, E) in WM115/WM266 (B, D), and
SW480/SW620 (C, E) cells (indicated) were analyzed using commercial pyruvate and
lactate analyses kits. The results were presented as fold changes before and 48 hours after
exogenous expression of HA-PKM2 using the adeno-viral system. The cellular levels of
pyruvate and lactate measured by the kits in the cells before exogenous expression of
HA-PKM2 were defined as 1.
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Gene ID

10862691
5901887
349268
3139026
4502050
10190675
2210410
28771
13937840
3849111
13603411
13111840
3307010
219494
19756424
9945321
10437300
5361475

Table 1 List for gene expressions regulated by PKM2 overexpression in SW480 cells
Expression
Fold
Gene Name
Change
Description
(upregulated)
Homo sapiens activin A receptor, type IB (ACVR1B), transcript variant 2,
ACVR1B
2.02
mRNA
Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with
ADAMTS5
2.04
thrombospondin type 1 motif
ADCY1
3.51
Human fetal brain adenylyl cyclase mRNA, 3 end.
AF10
2.09
Homo sapiens type V AF10 protein (AF10) Mrna
ALOX12
2.31
Homo sapiens arachidonate 12-lipoxygenase (ALOX12)
ANKRD3
2.85
Homo sapiens ankyrin repeat domain 3 (ANKRD3)
AP1S2
2.24
adaptor-related protein complex 1, sigma 2 subunit
APOA1
3.65
Human mRNA for apolipoprotein AI (apo AI)
Homo sapiens, Similar to ataxia telangiectasia mutated (includes
ATM
2.19
complementation groups A, C and D), clone MGC:12371
ATP6H
2.38
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 9kD
B29
2.67
Homo sapiens B29 mRNA, complete cds.
BART1
2.18
binder of Arl Two
BCAA
2.98
RBP1-like protein
BGP
3.14
Human mRNA for biliary glycoprotein, complete cds
BIRC5
2.46
baculoviral IAP repeat-containing 5 (survivin)
Homo sapiens brain-specific Na-dependent inorganic phosphate cotransporter
BNPI
2.11
(BNPI)
C14orf85
2.88
Homo sapiens cDNA: FLJ21234 fis, clone COL00841
C21ORF23
2.20
chromosome 21 open reading frame 23
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4188559
3049661
9966860
5450397
11141862
18141077
5393570
4503086
6807697
5912137
12053074
4884089
13183072
10823629
2046909
10729178
6505954
7455945
11006648

CALR
CALR
CATX-8
CCND1
CLDN6
CNK2
CNN3
CSN2
DKFZp434A1014
DKFZp434H168
DKFZp434N1817
DKFZp564C196
DKFZP586K0717
DLG5
EIF5A
EPS15R
ETV5
ETV5
FBXL7

3.05
3.07
2.07
2.50
2.63
2.03
2.15
2.39
2.36
2.22
2.98
3.88
2.48
2.00
3.36
2.20
2.28
2.16
2.67

11056051

FCGR2A

2.24

4758357

FGD1

2.03

9622332

FGF5

2.12

13186264

FGFR2

3.72

814986
10941605

FLJ10154
FLJ10287

2.32
2.33

calreticulin
calreticulin
Homo sapiens CATX-8 protein (CATX-8), mRNA.
cyclin D1 (PRAD1: parathyroid adenomatosis 1)
Homo sapiens claudin 6 (CLDN6), mRNA
Homo sapiens connector enhancer of KSR2A mRNA
calponin 3, acidic
Homo sapiens casein, beta (CSN2), mRNA
Homo sapiens mRNA; cDNA DKFZp434A1014 (from clone DKFZp434A1014)
hypothetical protein
Homo sapiens mRNA; cDNA DKFZp434N1817 (from clone DKFZp434N1817)
Homo sapiens mRNA; cDNA DKFZp564C196 (from clone DKFZp564C196)
Homo sapiens multi-PDZ-domain-containing protein mRNA
discs, large (Drosophila) homolog 5
eukaryotic translation initiation factor 5A
epidermal growth factor receptor substrate EPS15R
ets variant gene 5 (ets-related molecule)
ets variant gene 5 (ets-related molecule)
f-box and leucine-rich repeat protein 7
Homo sapiens Fc fragment of IgG, low affinity IIa, receptor for (CD32)
(FCGR2A)
Homo sapiens faciogenital dysplasia (Aarskog-Scott syndrome) (FGD1),
Homo sapiens fibroblast growth factor 5 short variant (FGF5), alternatively
spliced
Homo sapiens fibroblast growth factor receptor 2 (bacteria-expressed kinase,
keratinocyte growth factor receptor
hypothetical protein FLJ10154
hypothetical protein
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5855915
3483211
1483671
22749176
27734816
1228635
4503734
3416539
6912371
8393383

20202213

FLJ10342
FLJ11193
FLJ13195
FLJ36779
FLJ39058
FLRT3
FOXC1
FOXD1
FOXD3
G8
GABAA receptor
gamma 3 subunit
GAD2

4406347

GCAP3

3.59

4758433
3400047
28269674

GHSR
GLP
GPR126

3.33
2.71
3.40

6006002

GRIN2A

4.39

6005773
9867563
13549111
5928292

GUCA2B
H41
HBB
HDAC3

5.02
2.02
2.33
2.28

1597725

HLA-DRB4

2.48

13489076
3461865

HOXA6
HSPA1L

2.24
2.09

1754748

2.43
2.27
2.22
2.31
2.00
2.40
2.02
2.30
4.64
2.52

hypothetical protein FLJ10342
Homo sapiens full length insert cDNA clone YP41C12
hypothetical protein FLJ13195 similar to stromal antigen 3
Homo sapiens hypothetical protein FLJ36779 (FLJ36779)
Homo sapiens hypothetical protein FLJ39058 (FLJ39058)
fibronectin leucine rich transmembrane protein 3
forkhead box C1
forkhead box D1
Homo sapiens forkhead box D3 (FOXD3), mRNA
Homo sapiens G8 protein (G8), mRNA.

2.11

GABAA receptor gamma 3 subunit (human, fetal brain, mRNA Partial, 1536 nt)

3.17

glutamate decarboxylase 2 (pancreatic islets and brain)
Homo sapiens guanylate cyclase activating protein 3 splice variant (GCAP3)
mRNA
Homo sapiens growth hormone secretagogue receptor (GHSR)
golgin-like protein
G protein-coupled receptor 126
Homo sapiens glutamate receptor, ionotropic, N-methyl D-aspartate 2A
(GRIN2A)
Homo sapiens guanylate cyclase activator 2B (uroguanylin) (GUCA2B), mRNA
hypothetical protein
Homo sapiens beta globin chain variant (HBB) mRNA, complete cds.
histone deacetylase 3
Homo sapiens HLA class II DRB4 null antigen (HLA-DRB4) pseudogene
mRNA, null allele HLA-DRB4*0201N
Homo sapiens homeo box A6 (HOXA6), mRNA.
Heat shock protein 70 testis variant
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7019420

HUMBINDC

2.54

4504590
10835102

IFNA14
IFNA4

2.98
2.71

4504706

INPP4B

2.32

13050848
4072135

INSIG1
ITGB5

2.03
2.13

6912441

KCNE1L

2.08

7657246
1193698
3327077
10828334
11445251
9792490
10940593
1552995

KCNIP1
KIAA0256
KIAA0632
KIAA0644
KIAA0847
KIAA0964
KIAA1096
KLF1

2.23
2.09
2.33
2.14
2.25
2.24
2.02
2.76

6007796

Kv4.3

3.38

8923829
4150402
21687187
16553309
24270838
3923425

LEP503
LOC145622
LOC146325
LOC149086
LOC283403
LOC284889

2.24
3.45
2.63
3.30
2.29
4.76

13277527

LOC51065

2.07

Homo sapiens DNA binding protein for surfactant protein B (HUMBINDC),
mRNA.
Homo sapiens interferon, alpha 14 (IFNA14), mRNA
Homo sapiens interferon, alpha 4 (IFNA4), mRNA.
Homo sapiens inositol polyphosphate-4-phosphatase, type II, 105kD (INPP4B),
mRNA
insulin induced gene 1
integrin, beta 5
Homo sapiens potassium voltage-gated channel, Isk-related family, member 1like (KCNE1L)
Homo sapiens Kv channel-interacting protein 1 (KCNIP1), mRNA
KIAA0256 gene product
Homo sapiens mRNA for KIAA0632 protein, partial cds.
KIAA0644 gene product
KIAA0847 protein
KIAA0964 protein
KIAA1096 protein
Human erythroid-specific transcription factor EKLF mRNA, complete cds.
Homo sapiens voltage gated potassium channel Kv4.3 short splice variant
(Kv4.3)
Homo sapiens lens epithelial protein (LEP503), mRNA.
hypothetical protein LOC145622
Homo sapiens similar to hypothetical protein FLJ13841 (LOC146325)
Homo sapiens cDNA FLJ33000 fis, clone THYMU1000191.
Homo sapiens, clone IMAGE:5268545, mRNA.
hypothetical protein LOC284889
Homo sapiens, Similar to 40S ribosomal protein S27 isoform, clone
MGC:12175
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10911294
12770474
1720456
5394758
19913482
4523295
4505016
11081627
3387766
1616780
4885476
4337095
219881

LOC286411
LOC55884
LOC56851
LOC56993
LOC57821
LOC57863
LRP6
LSP1
m6b1
MAP2K5
MB
MEGT1
MS4A1

2.97
2.10
2.65
2.46
2.38
2.77
2.67
2.50
2.02
5.04
2.05
2.25
2.23

12803920

MS4A2

2.11

5031926
4505376
6133390
11452542
7669529
18087816

MUSK
NEUROD1
NOLA2
NOV
NRG2
NY-REN-41

2.05
3.53
2.24
2.01
2.07
2.03

5110327

OGT

2.16

21104485

OKSW-cl.92

2.55

11545886

OT7T022

2.45

7524355

PAX3

2.81

hypothetical protein LOC286411
CS box-containing WD protein
chromosome 11 hypothetical protein ORF3
mitochondrial import receptor Tom22
Homo sapiens, Similar to hypothetical protein LOC57821, clone MGC:26487
hypothetical protein FLJ10698
Homo sapiens low density lipoprotein receptor-related protein 6 (LRP6), mRNA
lymphocyte-specific protein 1
glycoprotein M6B /DEF=Homo sapiens m6b1 mRNA, complete cds.
Human MAP kinase kinase MEK5c mRNA, complete cds.
Homo sapiens myoglobin (MB), mRNA
Homo sapiens MSH55 gene, partial cds; and CLIC1, DDAH, G6b, G6c,
Homo sapiens mRNA for IgE receptor beta subunit, complete cds.
Homo sapiens, membrane-spanning 4-domains, subfamily A, member 2, clone
MGC:3969
Homo sapiens muscle, skeletal, receptor tyrosine kinase (MUSK), mRNA
Homo sapiens neurogenic differentiation 1 (NEUROD1), mRNA.
nucleolar protein family A, member 2 (HACA small nucleolar RNPs)
nephroblastoma overexpressed gene
Homo sapiens neuregulin 2 (NRG2), transcript variant 3, mRNA
Homo sapiens NY-REN-41 antigen (NY-REN-41)
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-Nacetylglucosamine:polypep)
Homo sapiens OKSW-cl.92 mRNA, complete cds.
Homo sapiens neuropeptide FF 1; RFamide-related peptide receptor
(OT7T022), mRNA.
Homo sapiens paired box gene 3 (Waardenburg syndrome 1) (PAX3),
transcript variant PAX3B
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6679187

P-B

3.92

4406228

PPIE

2.09

4989070
4328589
7662589
7770170
7770218
2552941
726735
6691625
4506420
1072311
13097176
4489788
9130191
10151019
10372131
6712816
13529169
11954150
12652562
6642739
11683880
4678742
1052870
11493551
820298

PPM1A
PRO1073
PRO1073
PRO2214
PRO2706
PSMB4
RAD23B
RAGE
RARB
RGN
RPL10
RPL23A
RPL27
RPL27A
RPL37A
RPL38
RPLP2
RPS11
RPS19
RPS20
RREB1
RS1
SCCA2
SCD
SEC14L2

2.30
2.25
2.22
2.25
2.12
2.61
2.43
3.15
3.81
2.14
2.06
2.52
2.52
4.56
2.92
2.14
2.50
6.10
4.07
2.12
2.09
3.47
2.12
2.73
2.96

Homo sapiens salivary proline-rich protein (P-B), mRNA.
Homo sapiens peptidyl-prolyl cis-trans isomerase E (PPIE) mRNA,
alternatively spliced
protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform
PRO1073 protein
Homo sapiens PRO1073 protein (PRO1073), mRNA.
Homo sapiens PRO2214 mRNA
Homo sapiens PRO2706 mRNA
proteasome (prosome, macropain) subunit, beta type, 4
RAD23 (S. cerevisiae) homolog B
Homo sapiens RAGE mRNA for advanced glycation endproducts receptor
Homo sapiens retinoic acid receptor, beta (RARB), mRNA
Human mRNA for SMP-30 (senescence marker protein-30)
ribosomal protein L10
ribosomal protein L23a
ribosomal protein L27
ribosomal protein L27a
ribosomal protein L37a
ribosomal protein L38
ribosomal protein, large P2
ribosomal protein S11
Homo sapiens, ribosomal protein S19, clone MGC:1630
Homo sapiens clone FLB0708 mRNA sequence.
ras responsive element binding protein 1
retinoschisis (X-linked, juvenile) 1
Human squamous cell carcinoma antigen 2 (SCCA2)
Homo sapiens PRO1933 mRNA, complete cds.
SEC14 (S. cerevisiae)-like 2
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10031679
306441
10940859
6569554

SEL1L
SLC3A1
SMURF2
SNRPG

2.58
2.47
2.38
3.46

10863910

SPINK2

4.24

4557870
10820568

TF
TGFB2

2.67
2.54

12407428

TRIM14

2.32

3153858
3056223
6457377
4991221
22477810

TXN delta 3
UBE2H
VIL2
WNT5A

2.25
2.16
3.64
2.83
2.40

18478590

2.58

21750477
3017252
16553266
652989
21750410
21706985
3483352

2.12
2.20
3.37
3.96
2.51
3.61
2.19

5111893

2.16

18089211
13283225

2.29
2.05

sel-1 (suppressor of lin-12, C.elegans)-like
Homo sapiens amino acid transport protein
E3 ubiquitin ligase SMURF2
small nuclear ribonucleoprotein polypeptide G
Homo sapiens serine protease inhibitor, Kazal type, 2 (acrosin-trypsin inhibitor)
(SPINK2)
Homo sapiens transferrin (TF), mRNA
transforming growth factor, beta 2
Homo sapiens tripartite motif protein TRIM14 alpha (TRIM14) mRNA,
alternatively spliced.
Homo sapiens thioredoxin delta 3 (TXN delta 3) mRNA, partial cds.
ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8)
Homo sapiens cytovillin 2 (VIL2) mRNA, partial cds
wingless-type MMTV integration site family, member 5A
Homo sapiens, Similar to RIKEN cDNA 4930442L21 gene, clone MGC:34773
Homo sapiens prostate-specific KLK2 mRNA, complete cds, alternatively
spliced
Homo sapiens cDNA FLJ34667 fis, clone LIVER2000769
Homo sapiens mRNA; cDNA DKFZp564M243 (from clone DKFZp564M243)
Homo sapiens cDNA FLJ32963 fis, clone TESTI2008405.
Homo sapiens cDNA FLJ34653 fis, clone KIDNE2018287.
Homo sapiens cDNA FLJ34611 fis, clone KIDNE2014112.
Homo sapiens cDNA FLJ33147 fis, clone UTERU2000218
Homo sapiens full length insert cDNA clone YU66F10.
Homo sapiens cDNA FLJ37762 fis, clone BRHIP2024347, weakly similar to
GALECTIN-3.
Homo sapiens, clone IMAGE:4732650, mRNA
Human mRNA upregulated during camptothecin-induced apoptosis of U937
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9325152
15943770
2265537
27694447
21391489
4895021
21752222
23138779
23271185
22749602
24659364
10717930
10719117
16553158
15080371
562424
15929454
27370602
21755882
23273407
21707002
15492406
4761757
16551907
26251840
23138689
27695778

2.08
2.94
2.03
2.48
2.13
2.55
2.00
4.45
2.54
2.52
2.17
2.84
2.02
2.11
2.42
2.34
6.42
2.60
2.16
2.09
2.29
2.15
2.18
2.99
3.10
2.01
2.00

cells.
Homo sapiens full length insert cDNA clone ZD79H04
Homo sapiens, clone IMAGE:5404026, mRNA
Homo sapiens cDNA FLJ36460 fis, clone THYMU2014801.
Homo sapiens, clone IMAGE:6155889, mRNA.
Homo sapiens D21S2088E mRNA sequence.
Homo sapiens clone IMAGE:120631 mRNA sequence.
Homo sapiens cDNA FLJ36051 fis, clone TESTI2018083.
Homo sapiens, clone IMAGE:4799886, mRNA.
Homo sapiens, clone IMAGE:4723617, mRNA.
Homo sapiens, clone IMAGE:5167209, mRNA.
Homo sapiens, clone IMAGE:5762932, mRNA.
chromosome 14 open reading frame 70
Homo sapiens, clone IMAGE:4732650, mRNA
Homo sapiens cDNA FLJ32886 fis, clone TESTI2004255.
Homo sapiens, clone IMAGE:4541510, mRNA.
Homo sapiens cDNA FLJ33351 fis, clone BRACE2005063.
Homo sapiens, clone IMAGE:3885734, mRNA.
Homo sapiens, clone IMAGE:5272850, mRNA.
Homo sapiens cDNA FLJ39080 fis, clone NT2RP7018197.
Homo sapiens, clone IMAGE:4821940, mRNA.
Homo sapiens, clone IMAGE:4838775, mRNA, partial cds.
Homo sapiens, clone IMAGE:5288527, mRNA
Homo sapiens full length insert cDNA clone YP51C12.
Homo sapiens cDNA FLJ31929 fis, clone NT2RP7006160.
Homo sapiens, clone IMAGE:5270242, mRNA.
Homo sapiens, clone IMAGE:5284251, mRNA.
Homo sapiens, clone IMAGE:5287262, mRNA.
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9368862
22789247
23243297
26251897
15929532
21733910
27693443
21748888
18645132
18490345
13543960
7998994
19048193
27469480
21707013
21733665
9880662
23138784
1314791
3245917
22773448
12872929
18266902
19387911
17315156
23138810
23025744
15214740

5.02
2.21
2.44
2.45
2.93
3.02
5.55
2.02
2.38
2.24
2.03
2.28
2.56
2.46
3.17
2.06
3.25
2.14
3.24
3.30
2.16
2.28
2.06
2.13
2.22
2.05
2.09
2.54

Homo sapiens mRNA; cDNA DKFZp547B124 (from clone DKFZp547B124).
Homo sapiens, clone IMAGE:5284619, mRNA.
Homo sapiens, Similar to hypothetical protein FLJ1066
Homo sapiens, clone IMAGE:5744232, mRNA
Homo sapiens, clone IMAGE:4272661, mRNA
Homo sapiens mRNA; cDNA DKFZp451E068 (from clone DKFZp451E068).
Homo sapiens, clone IMAGE:5297745, mRNA.
Homo sapiens cDNA FLJ33360 fis, clone BRACE2005253.
Homo sapiens, clone IMAGE:4106638, mRNA, partial cds
Homo sapiens, clone IMAGE:4280848, mRNA.
Homo sapiens, clone IMAGE:3505629, mRNA, partial cds
Human mucin mRNA, partial CDS
Homo sapiens, clone IMAGE:4838884, mRNA
Homo sapiens, clone IMAGE:5303725, mRNA
Homo sapiens, clone IMAGE:5278245, mRNA.
Homo sapiens mRNA; cDNA DKFZp451E0119 (from clone DKFZp451E0119).
Homo sapiens trapped 3 terminal exon, clone B2D7
Homo sapiens, clone IMAGE:4815137, mRNA.
Human oral cancer candidate gene mRNA, clone T9, 3 end.
Homo sapiens, clone IMAGE:4828827, mRNA
Homo sapiens, clone IMAGE:4798439, mRNA.
Homo sapiens, clone IMAGE:4295896, mRNA
Homo sapiens, clone IMAGE:3920449, mRNA.
Homo sapiens, clone IMAGE:4876018, mRNA.
Homo sapiens, clone IMAGE:4622909, mRNA.
Homo sapiens, clone IMAGE:5285294, mRNA.
Homo sapiens, Similar to hypothetical protein MGC5149,
Homo sapiens, clone IMAGE:4708704, mRNA.
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23272857
21955461
22382161
19387889
18204260
22902336
22658409
14713658
18988609
21961399
13543476
897614
5053998
6698300
9368876
10435808
7947076
10432666
527579
7328007
10440237
6197723
10810430
4874618
12005981
11493436
6983841
12006208

2.61
3.82
3.48
2.74
2.21
2.34
2.32
2.43
2.07
2.05
2.18
2.17
2.05
2.10
2.22
2.10
2.28
2.35
3.28
2.30
2.11
2.32
2.35
2.64
2.06
2.41
2.73
3.44

Homo sapiens, clone IMAGE:5583231, mRNA.
Homo sapiens, clone IMAGE:4824334, mRNA.
Homo sapiens, clone IMAGE:4770655, mRNA.
Homo sapiens, clone IMAGE:4544545, mRNA.
Homo sapiens, Similar to zinc finger protein
Homo sapiens, clone IMAGE:4475530, mRNA.
Homo sapiens, clone IMAGE:5106435, mRNA.
Homo sapiens, clone IMAGE:4290767, mRNA.
Homo sapiens, clone IMAGE:3936226, mRNA
Homo sapiens, clone IMAGE:4401081, mRNA.
Homo sapiens, hyaluronoglucosaminidase 3, clone MGC:14472
Homo sapiens transmembrane tyrosine kinase mRNA, complete cds.
Human BRCA2 region, mRNA sequence CG011
Homo sapiens cDNA: FLJ21771 fis, clone COLF7779
Homo sapiens mRNA; cDNA DKFZp547N074 (from clone DKFZp547N074)
Homo sapiens cDNA FLJ13712 fis, clone PLACE2000394.
Human soluble CD44 (CD44) mRNA, with exon v9 extension, partial cds
Homo sapiens cDNA FLJ11412 fis, clone HEMBA1000876
H.sapiens mRNA for ribosomal protein L18a homologue
Homo sapiens mRNA; cDNA DKFZp434H0229
Homo sapiens cDNA: FLJ23519 fis, clone LNG04908
ESTs, Weakly similar to ALUF_HUMAN
ESTs, Weakly similar to AF208855 1 BM-013
ESTs, Highly similar to T-box-containing transcriptional activator
Homo sapiens DC37 mRNA, complete cds.
Homo sapiens clone FLB8034 PRO2158 mRNA, complete cds
Homo sapiens mRNA for tomoregulin, complete cds
Homo sapiens DC48 mRNA, complete cds.
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13623316
13603378
1126361
4610307
7246662
9867611
5448126
4997672
11263724
10030244
5854418
11130642
5054233
2874383
10825381
5513942
9704374
10585982
2898542

3.46
2.59
2.40
2.89
2.95
2.91
2.71
2.68
2.00
2.33
2.30
2.18
2.89
2.56
2.23
2.67
2.14
2.42
2.17

2878893

2.40

10301536
11593563
7799136
11007502
11016719
2261986
10433162

2.40
2.40
3.00
2.50
2.01
2.25
2.02

Homo sapiens, clone MGC:10724, mRNA, complete cds
Homo sapiens 5-nucleotidase I mRNA, complete cds
ESTs
Homo sapiens cDNA: FLJ21410 fis, clone COL03938
ESTs, Weakly similar to KIAA1204 protein (H.sapiens)
ESTs, Weakly similar to ALU7
Homo sapiens cDNA: FLJ21042 fis, clone CAE11204
ESTs
ESTs
ESTs
ESTs
Homo sapiens mRNA; cDNA DKFZp586J0720
ESTs
Homo sapiens cDNA FLJ10500 fis, clone NT2RP2000369
ESTs
ESTs, Highly similar to I38945 melanoma ubiquitous mutated protein
Homo sapiens cDNA FLJ12936 fis, clone NT2RP2005018
ESTs
ESTs
Homo sapiens cDNA: FLJ21715 fis, clone COL10287, highly similar to
AF071569 multifunctional
ESTs
ESTs
Homo sapiens EST from clone 208499, full insert
Homo sapiens cDNA FLJ12030 fis, clone HEMBB1001868
Homo sapiens cDNA FLJ10941 fis, clone OVARC1001243
Homo sapiens HSPC106 mRNA, partial cds
Homo sapiens cDNA FLJ11814 fis, clone HEMBA1006381.
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10438582
10432694
6808434
5912099
11008881
10433290
4406668
4884225
3766130
10439146
10439819
4500031
876413
4070155
7247381
10822124
4311165
5741187
4738586
3898470
696583
4896021
6702839
10939000
3052775
2782919
8909427
9703764

4.22
2.51
2.99
2.83
2.42
2.04
5.86
3.26
3.41
2.25
4.20
3.26
2.59
2.10
2.22
2.05
2.55
2.73
2.23
2.39
2.01
3.37
4.08
2.66
2.23
3.11
2.65
2.68

Homo sapiens cDNA: FLJ22266 fis, clone HRC03089.
Homo sapiens cDNA FLJ11437 fis, clone HEMBA1001226
Homo sapiens mRNA; cDNA DKFZp434E145
Homo sapiens mRNA; cDNA DKFZp566O1624
Homo sapiens cDNA FLJ12212 fis, clone MAMMA1000979
Homo sapiens cDNA FLJ11919 fis, clone HEMBB1000274.
Homo sapiens clone 24894 mRNA sequence.
Homo sapiens mRNA; cDNA DKFZp564B032
Homo sapiens PAC clone RP4-669B10 from 7q33-q35
Homo sapiens cDNA: FLJ22668 fis, clone HSI08585.
Homo sapiens cDNA: FLJ23208 fis, clone ADSE01253.
Homo sapiens mRNA; cDNA DKFZp564I103
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs, Weakly similar to alternatively spliced product using exon 13A
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
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1227643
10301882
9869489
1225259
11592084
697122
4985432
7148710
1505796
8156739
3109118
11547763
8888160
8157795
5340596
2006798
6496811
6496811
9179366
11600065
3427699
5111876
8905208
13340980
2052997
5054311
4083674
7457491

2.37
2.08
2.25
2.38
2.11
4.68
2.32
2.35
2.32
2.64
2.90
2.04
5.14
2.75
2.20
2.38
2.39
2.43
2.26
2.20
3.24
2.56
2.09
2.36
2.25
3.72
3.16
2.76

ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs, Weakly similar to AF108460 1 ubinuclein
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
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817755
648511
5054307
6661498
11598629
6444844
8007397

2.66
2.04
2.96
2.04
2.54
2.12
2.56

8472949

2.23

10032681
9867191
5887371
12057724
821774
6087291
867415
5768395
3143651
11599277
12512341
3959771
3041371
12356555
5393539
3412614
1484744
4147560
2910255

3.27
2.11
2.04
4.64
2.19
2.06
2.03
2.56
2.05
2.20
2.22
2.00
2.05
2.26
2.64
5.54
2.37
2.09
2.40

ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs, Moderately similar to pyruvate dehydrogenase E1-alpha subunit
precursor
ESTs, Weakly similar to ALUA_HUMAN
ESTs
ESTs, Weakly similar to CYA6_HUMAN ADENYLATE CYCLASE, TYPE VI
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
ESTs
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9792941

Gene ID

Gene Name

10321660

ACP1

5901889

ADAMTS8

4501922

ADCYAP1R1

5453538

ADE2H1

11061448

ADIR

1306665
2155239
5529662

AGA
AGPAT2
ANXA2

11038642

AP2S1

5848763
7662085
5031602
2094740
4757779
12275865
5437188

APLP2
ARHGEF11
ARL4
ARNTL
ARRB2
ATDC
AXIN2

13569945

BA108L7.2

3.15
ESTs
Expression
Fold
Change
Description
(down
regulated)
-4.00
Acid phosphatase 1, soluble
Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with
-2.06
thrombospondin type 1 motif, 8 (ADAMTS8), mRNA
Homo sapiens adenylate cyclase activating polypeptide 1 (pituitary) receptor
-2.05
type I (ADCYAP1R1)
Homo sapiens multifunctional polypeptide similar to SAICAR synthetase and
-2.24
AIR carboxylase (ADE2H1)
Homo sapiens mRNA for ATP-dependant interferon response protein 2 (ADIR
-2.78
gene)
-2.77
aspartylglucosaminidase
-2.15
Human lysophosphatidic acid acyltransferase-beta mRNA
-2.14
annexin A2
Homo sapiens adaptor-related protein complex 2, sigma 1 subunit (AP2S1),
-2.90
transcript variant AP17delta,
-2.02
Amyloid beta (A4) precursor-like protein 2
-2.72
Homo sapiens Rho guanine exchange factor (GEF) 11 (ARHGEF11), mRNA
-2.31
Homo sapiens ADP-ribosylation factor-like 4 (ARL4), mRNA
-2.26
Homo sapiens mRNA for BMAL1e, complete cds
-2.47
Homo sapiens arrestin, beta 2 (ARRB2), mRNA
-2.74
Homo sapiens tripartite motif protein TRIM29 beta mRNA, complete cds
-2.34
Axin 2 (conductin, axil)
Homo sapiens similar to rat tricarboxylate carrier-like protein (BA108L7.2),
-2.46
mRNA
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12751138

BAL

-2.48

4757837
4502380
13112010
9878618
17511794

BAX
BCL2L1
BENE
BIG2
bioref

-2.19
-3.30
-3.90
-3.68
-2.28

16359168

BITE

-2.24

2778778
686012
3739598
10287071
4086141
12056961
4826664

BLVRA
BRPF3
C11ORF15
CALM3
CALR
CAST
CCS

-4.31
-2.27
-2.87
-2.41
-3.46
-3.12
-2.15

1137068

CD74

-2.63

12923866
15126732
1230376
4885104

CDS2
CGI-18
CGI-56
CHAF1B

-2.02
-2.26
-2.41
-4.70

1905899

CKAP1

-2.03

4502876
6005734

CLDN4
COPE

-2.63
-3.15

3641620

CPD

-2.04

Homo sapiens B aggressive lymphoma long isoform (BAL) mRNA, complete
cds
Homo sapiens BCL2-associated X protein (BAX), mRNA
Homo sapiens BCL2-like 1 (BCL2L1), mRNA
Homo sapiens, clone MGC:4419, mRNA, complete cds
brefeldin A-inhibited guanine nucleotide-exchange protein 2
Homo sapiens, clone MGC:31940 IMAGE:4553653, mRNA, complete cds
Homo sapiens, Similar to p10-binding protein, clone MGC:22949
IMAGE:4858367, mRNA
biliverdin reductase A
bromodomain and PHD finger containing, 3
chromosome 11 open reading frame 15
calmodulin 3 (phosphorylase kinase, delta)
Calreticulin
Homo sapiens calpastatin mRNA, complete cds
Homo sapiens copper chaperone for superoxide dismutase (CCS), mRNA
CD74 antigen (invariant polypeptide of major histocompatibility complex, class
II antig
CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2
Homo sapiens, Similar to CGI-18 protein, clone MGC:8735 IMAGE:3858865
beta-parvin
Homo sapiens chromatin assembly factor 1, subunit B (p60) (CHAF1B), mRNA
Homo sapiens DNA from chromosome 19-cosmid f24590 containing CAPNS
and POL2RI
Homo sapiens claudin 4 (CLDN4), mRNA
Homo sapiens coatomer protein complex, subunit epsilon (COPE), mRNA
Homo sapiens mRNA for gp180-carboxypeptidase D-like enzyme, complete
cds
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12751066
15341933
6397524
11591983
18482479

CRI1
CRYZL1
CTL1
CTRL
CXADR

-2.15
-2.10
-2.24
-2.56
-2.46

3551833

DAGK1

-2.09

4503318
7108341
12053302
12053188
6807975
12804040
4929614
12053344
12053358
13276648
8393263
11493772
10832596
11594983
10439354

DGUOK
DHPS
DKFZp434E229
DKFZp434M182
DKFZp434P072
DKFZP564J0123
DKFZP566C134
DKFZp586H1320
DKFZp586H1322
DKFZp761J1523
DLL3
EHF
ENSA
EPB41L2
FANCA

-3.66
-2.35
-3.00
-2.07
-3.36
-2.69
-3.09
-2.82
-2.90
-2.86
-2.87
-2.77
-3.67
-2.07
-2.68

5031692

FBRNP

-2.89

10438969

FBXO5

-2.55

13186237

FGFR1

-2.54

2078479

FHL-1

-2.28

Homo sapiens PNAS-26 mRNA, complete cds
Homo sapiens, clone MGC:8826 IMAGE:3870188, mRNA, complete cds
Transporter-like protein
chymotrypsin-like
Homo sapiens coxsackie-adenovirus-receptor isoform CAR37 (CXADR)
Homo sapiens clone 24 diacylglycerol kinase alpha (DAGK1) mRNA, complete
cds
Homo sapiens deoxyguanosine kinase (DGUOK), mRNA
Homo sapiens deoxyhypusine synthase (DHPS), transcript variant 1, mRNA
Homo sapiens mRNA; cDNA DKFZp434E229 (from clone DKFZp434E229)
Homo sapiens mRNA; cDNA DKFZp434M182 (from clone DKFZp434M182)
Homo sapiens mRNA; cDNA DKFZp434P072 (from clone DKFZp434P072)
Homo sapiens, Similar to nuclear protein E3-3 orf1, clone MGC:10527, mRNA
Homo sapiens CGI-73 protein mRNA, complete cds
Homo sapiens mRNA; cDNA DKFZp586H1320
Homo sapiens mRNA; cDNA DKFZp586H1322
Homo sapiens mRNA; cDNA DKFZp761J1523
Homo sapiens delta (Drosophila)-like 3 (DLL3), mRNA
Homo sapiens ETS-family transcription factor EHF (EHF) mRNA
endosulfine alpha
Erythrocyte membrane protein band 4.1-like 2
Homo sapiens cDNA: FLJ22829 fis, clone KAIA4075, highly similar to HSCH
Homo sapiens heterogeneous nuclear protein similar to rat helix destabilizing
protein (FBRNP), mRNA
Homo sapiens cDNA: FLJ22544 fis, clone HSI00219
Homo sapiens fibroblast growth factor receptor 1 (fms-related tyrosine kinase
2, Pfeiffer syndrome) (FGFR1), transcript variant 5, Mrna
Human heart protein with four and a half LIM domains (FHL-1) mRNA
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10436956
11056001
12408251
13327692
8922343
8922412
8922425
8922643
8922715
13280012
12892919

FJH1
FKSG2
FKSG30
FLII
FLJ10308
FLJ10415
FLJ10450
FLJ10751
FLJ10851
FLJ10903
FLJ11126

-2.96
-2.55
-2.64
-2.13
-2.28
-3.95
-3.29
-2.25
-2.78
-2.05
-2.01

11967980

FLJ12538

-3.89

12597646
13376722
13376330
13529205
13376670

FLJ12572
FLJ12584
FLJ12618
FLJ12644
FLJ13087

-2.35
-3.18
-3.18
-3.21
-2.91

11968026

FLJ13258

-2.38

13376616
12654818
8923113
13581300
9134345
10435257
6228478
13376618

FLJ14038
FLJ20071
FLJ20113
FLJ20335
FLJ20452
FLJ20542
FLJ20580
FLJ21168

-3.14
-3.16
-3.10
-2.47
-2.24
-3.09
-2.85
-2.21

Homo sapiens cDNA: FLJ20982 fis, clone ADSU02018
Homo sapiens apoptosis inhibitor (FKSG2), mRNA
Homo sapiens FKSG30 (FKSG30) mRNA, complete cds
Flightless I (Drosophila) homolog
Homo sapiens homolog of rat nadrin (FLJ10308), mRNA
Homo sapiens hypothetical protein FLJ10415
Homo sapiens hypothetical protein FLJ10450
Homo sapiens hypothetical protein FLJ10751
Homo sapiens hypothetical protein FLJ10851
Hypothetical protein FLJ10903
hypothetical protein FLJ11126
Homo sapiens hypothetical protein FLJ12538 similar to ras-related protein
RAB17
Homo sapiens hypothetical protein FLJ12572 (FLJ12572), mRNA
Homo sapiens hypothetical protein FLJ12584 (FLJ12584), mRNA
Homo sapiens hypothetical protein FLJ12618 (FLJ12618), mRNA
Homo sapiens, hypothetical protein FLJ12644, clone MGC:12483
Homo sapiens hypothetical protein FLJ13087 (FLJ13087), mRNA
Homo sapiens hypothetical protein FLJ13258 similar to fused toes (FLJ13258),
mRNA
Homo sapiens hypothetical protein FLJ14038 (FLJ14038), mRNA
Homo sapiens, Similar to hypothetical protein FLJ20071, clone MGC:4975
Homo sapiens hypothetical protein FLJ20113 (FLJ20113), mRNA
hypothetical protein FLJ20335
Hypothetical protein FLJ20452
Homo sapiens cDNA FLJ13294 fis, clone OVARC1001232
Hypothetical protein FLJ20580
Homo sapiens hypothetical protein FLJ21168 (FLJ21168), mRNA
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12232416
12759062
22749272

FLJ22059
FLJ22313
FLJ35954

-2.01
-2.00
-2.14

5803018

FSHPRH1

-2.74

4503800

FUBP1

-2.02

4503870

GABRR2

-2.14

2459950

GART

-2.08

4503942

GCDH

-2.26

5729839
9970082

GCP2
GFPT1

-2.36
-2.21

4557626

GLE1L

-2.94

4504036

GNA11

-2.69

4504184
2687868

GSTT1
GTBP

-2.07
-2.38

4504200

GTF2H4

-2.32

595266
8118720
5001538
5855963
1575443
17736799

HADHA
HDAC8
HIBADH
HKE2
HLA-Cw*1701
hMCLC-3

-2.09
-2.66
-2.39
-2.07
-2.30
-2.30

Homo sapiens hypothetical protein FLJ22059 (FLJ22059), mRNA
hypothetical protein FLJ22313
Homo sapiens hypothetical protein FLJ35954 (FLJ35954), mRNA
Homo sapiens FSH primary response (LRPR1, rat) homolog 1 (FSHPRH1),
mRNA
Homo sapiens far upstream element (FUSE) binding protein 1 (FUBP1),
mRNA
Homo sapiens gamma-aminobutyric acid (GABA) receptor, rho 2 (GABRR2),
mRNA
Homo sapiens GARS-AIRS-GART mRNA, partial cds
Homo sapiens glutaryl-Coenzyme A dehydrogenase (GCDH), nuclear gene
encoding mitochondrial protein, transcript variant 1
Homo sapiens gamma-tubulin complex protein 2 (GCP2), mRNA
glutamine-fructose-6-phosphate transaminase 1
Homo sapiens GLE1 (yeast homolog)-like, RNA export mediator (GLE1L),
mRNA
Homo sapiens guanine nucleotide binding protein (G protein), alpha 11 (Gq
class) (GNA11), mRNA
Homo sapiens glutathione S-transferase theta 1 (GSTT1), mRNA
Homo sapiens GTBP mRNA for GTBP-ALT, complete cds
Homo sapiens general transcription factor IIH, polypeptide 4 (52kD subunit)
(GTF2H4), mRNA
Human 78 kDa gastrin-binding protein mRNA, complete cds
Homo sapiens class I histone deacetylase (HDAC8) mRNA, complete cds
Homo sapiens BAC clone GS1-98E2 from 7p11.2-p21
HLA class II region expressed gene KE2
Homo sapiens HLA class I heavy chain (HLA-Cw*1701) mRNA, complete cds
Homo sapiens hMCLC-3 mRNA for Mid-1-related chloride channel 3, complete
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16416450

hMtCCA

-3.47

10434948

HN1L

-3.17

10365758

HNRPC

-2.36

5031752

HNRPH1

-2.07

11875212
11291478
2853276
5110914
12006357
10703387
5579469
7661727
7661735
7661741
7661793
12654148
7106781
5031770
4617892
7542379
9970542
4826773
11252643
4504808
577300

HPC2
HPIP
HPRP4
HRB
HRIHFB2122
HRMT1L1
HSPA1A
HSPC003
HSPC018
HSPC023
HSPC134
HSPC154
HSPC196
HSPF2
ICAM1
IDS
IGHG3
ISG15
ITGB4
JUNB
KIAA0090

-2.98
-3.35
-2.66
-2.38
-2.02
-2.44
-2.29
-2.19
-3.53
-3.60
-2.02
-2.77
-2.56
-3.11
-2.40
-2.14
-3.69
-2.31
-3.82
-2.79
-2.45

cds
Homo sapiens hMtCCA mRNA for tRNA-nucleotidyltransferase, complete cds
Hypothetical protein similar to mouse HN1 (Hematological and Neurological
expressed sequence 1)
Heterogeneous nuclear ribonucleoprotein C (C1C2)
Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (H) (HNRPH1),
mRNA
Homo sapiens putative prostate cancer susceptibility protein (HPC2), mRNA
Hematopoietic PBX-interacting protein
Homo sapiens WD splicing factor Hprp4p (HPRP4) mRNA, complete cds
HIV-1 Rev binding protein
Homo sapiens Tara mRNA, complete cds
HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1
Homo sapiens heat shock 70kD protein 1A (HSPA1A), mRNA
Homo sapiens HSPC003 protein (HSPC003), mRNA
Homo sapiens HSPC018 protein (HSPC018), mRNA
Homo sapiens HSPC023 protein (HSPC023), mRNA
Homo sapiens HSPC134 protein (HSPC134), mRNA
Homo sapiens, HSPC154 protein, clone MGC:4897, mRNA, complete cds
Homo sapiens HSPC196 mRNA, complete cds
Homo sapiens heat shock 40kD protein 2 (HSPF2), mRNA
Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
Homo sapiens normal control W-IDS fusion transcript, mRNA sequence
immunoglobulin heavy constant gamma 3 (G3m marker)
Homo sapiens interferon-stimulated protein, 15 kDa (ISG15), mRNA
integrin, beta 4
Homo sapiens jun B proto-oncogene (JUNB), mRNA
Human mRNA for KIAA0090 gene, partial cds
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7661901
10439023
11286290
832234
5113513
2887434
1686271
7023392
18256839
7662331
4665833
12784477
11546048

KIAA0095
KIAA0197
KIAA0273
KIAA0285
KIAA0414
KIAA0432
KIAA0470
KIAA0713
KIAA0826
KIAA0844
KIAA0872
KIAA1150
KIAA1247

-4.69
-2.39
-2.41
-2.29
-2.37
-2.36
-2.05
-2.05
-3.92
-2.11
-3.88
-2.05
-4.09

10434518

KIAA1250

-2.06

7959294
10047238
12697944
1928356
2588629
10435318
9910351
12768600

KIAA1514
KIAA1582
KIAA1700
KNS2
LOC51666
LOC51729
LOC56904
M11S1

-2.95
-2.63
-2.08
-2.14
-2.81
-4.73
-3.13
-2.10

5454183

MAP3K12

-2.58

4505098
795931
13128987

MAP4
MFAP3
MGC3103

-3.16
-2.70
-3.01

Homo sapiens KIAA0095 gene product (KIAA0095), mRNA
Homo sapiens cDNA: FLJ22583 fis, clone HSI02596
KIAA0273 gene product
KIAA0285 gene product
KIAA0414 protein
Homo sapiens KIAA0432 mRNA, complete cds
KIAA0470 gene product
Homo sapiens cDNA FLJ10999 fis, clone PLACE1002529
Homo sapiens, clone MGC:25069 IMAGE:4498553, mRNA, complete cds
Homo sapiens KIAA0844 protein (KIAA0844), mRNA
KIAA0872 protein
KIAA1150 protein
Human DNA sequence from clone RP5-1049G16 on chromosome 20q12-13.2
Likely homolog of rat kinase D-interacting substance of 220 kDa; KIAA1250
protein
Homo sapiens mRNA for KIAA1514 protein, partial cds
Homo sapiens mRNA for KIAA1582 protein, partial cds
Homo sapiens mRNA for KIAA1700 protein, partial cds
Kinesin 2 (60-70kD)
Human BAC clone GS1-303P24 from 7q21-22
Homo sapiens cDNA FLJ13336 fis, clone OVARC1001879
Homo sapiens SH3-containing protein SH3GLB2 (LOC56904), mRNA
Membrane component, chromosome 11, surface marker 1
Homo sapiens mitogen-activated protein kinase kinase kinase 12 (MAP3K12),
mRNA
Homo sapiens microtubule-associated protein 4 (MAP4), mRNA
microfibrillar-associated protein 3
Homo sapiens hypothetical protein MGC3103
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22749020
5803089
7019460
6006024
13549066

MGC39558
MLN64
MLX
MPP1
MST4

-2.52
-2.25
-2.15
-2.02
-3.78

5174602

MYRL2

-2.57

9502399
6912523
1480645

MYRL2
NARF
NCOA1

-2.70
-2.28
-2.51

4826853

NDUFB8

-3.68

4505370

NDUFS8

-2.17

506817
17391108
1669493
10864008
4534208

NFE2
NFS1
NFYC
NLI-IF
NMT1

-2.75
-2.14
-2.36
-2.07
-2.24

12803666

NR2F6

-2.81

4505274

NUDT1

-2.25

7019476
5663957

OMI
OSBP

-3.11
-2.59

13699862

OTRPC4

-2.47

4505548

P2RX4

-2.67

Homo sapiens hypothetical protein MGC39558
Homo sapiens steroidogenic acute regulatory protein related
Homo sapiens MAX-like bHLHZIP protein (MLX), mRNA
Homo sapiens membrane protein, palmitoylated 1 (55kD)
Homo sapiens serinethreonine protein kinase MST4 (MST4) mRNA
Homo sapiens myosin regulatory light chain 2, smooth muscle isoform
(MYRL2), mRNA
Homo sapiens chromosome 19, BAC CIT-HSPC_204F22 (BC228680)
Homo sapiens nuclear prelamin A recognition factor (NARF), mRNA
Human steroid receptor coactivator-1 F-SRC-1 mRNA, complete cds
Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8
(19kD, ASHI)
Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 8 (23kD)
(NADH-coenzyme Q reductase)
Human leucine zipper mRNA, complete cds
Homo sapiens, Similar to nitrogen fixation gene 1 (S. cerevisiae, homolog)
Human transcription factor NF-YC subunit mRNA
Homo sapiens nuclear LIM interactor-interacting factor (NLI-IF)
N-myristoyltransferase 1
Homo sapiens, nuclear receptor subfamily 2, group F, member 6, clone
MGC:4277, mRNA, complete cds
Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 1
(NUDT1), mRNA
Homo sapiens HtrA-like serine protease (OMI), mRNA
Oxysterol binding protein
Homo sapiens vanilloid receptor-related osmotically activated channel;
OTRPC4 protein (OTRPC4)
Homo sapiens purinergic receptor P2X, ligand-gated ion channel, 4 (P2RX4),
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12906073
10824430
10818329

PHB
PICALM
PICALM

-2.07
-2.23
-2.35

1743874

PIP5K1A

-2.08

9966876
10742618
12654620
4505944

PIST
PL6
PMP24
POLR2E

-3.33
-2.08
-2.30
-2.12

10435912

PPFIA3

-2.42

4505990

PPIC

-2.09

5031988

PPP3CC

-2.71

13699864
12771232
6807722
8924201

PRO1853
PRO2706
PRO2730
PRO2801

-2.21
-2.08
-3.71
-2.47

4506192

PSMB1

-2.08

11445036
16580750
4506278
4506310
2281288
13376819
4896040

PSMD11
PTBLP
PTMS
PTPRF
PTPRN2
PUS1
RASA3

-2.48
-3.47
-2.18
-3.22
-4.50
-5.14
-3.20

mRNA
Prohibitin
Phosphatidylinositol binding clathrin assembly protein
Phosphatidylinositol binding clathrin assembly protein
Human 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha mRNA,
clone PIP5KIa3
Homo sapiens PIST (PIST), mRNA
PL6 protein
Homo sapiens, 24 kDa intrinsic membrane protein, clone MGC:1213
Homo sapiens polymerase (RNA) II (DNA directed) polypeptide E (25kD)
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting
protein (liprin), alpha 3
Homo sapiens peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA
Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit, gamma
isoform (calcineurin A gamma)
Homo sapiens hypothetical protein PRO1853 (PRO1853), mRNA
Hypothetical protein PRO2706
Homo sapiens mRNA; cDNA DKFZp434C0814
Homo sapiens hypothetical protein PRO2801 (PRO2801), mRNA
Homo sapiens proteasome (prosome, macropain) subunit, beta type, 1
(PSMB1), mRNA
Proteasome (prosome, macropain) 26S subunit, non-ATPase, 11
Homo sapiens PTBLP mRNA for PTB-like protein S, complete cds
Homo sapiens parathymosin (PTMS), mRNA
Homo sapiens protein tyrosine phosphatase, receptor type
Human tyrosine phosphatase IA-2beta mRNA, complete cds
Homo sapiens pseudouridine synthase 1 (PUS1), mRNA
RAS p21 protein activator (GTPase activating protein) 3 (Ins(1,3,4,5)P4-
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9256633

RASSF1

-3.54

8400719

RBMS1

-3.09

6677700
6677722
5231227
12656362
10811717
13528944
4506680
4506690
4506762
13540474
758680
5730024
10584719
7023794
7661681
7021892
15430748
11141876
5803168
5436769

RE2
RFC5
RNASE6PL
RNF6
RP42
RPA3
RPS11
RPS16
S100A3
SAA2
SAA2
SAD1
SAT
SEC15L
SENP3
SENP3
SEPTIN6
SIGIRR
SIPA1
SLC12A4

-2.50
-2.79
-2.39
-2.47
-3.57
-2.08
-2.48
-2.09
-3.22
-2.51
-2.10
-3.08
-2.06
-3.77
-2.05
-2.49
-2.92
-2.69
-2.69
-2.49

4759111

SLC16A3

-2.12

4507006

SLC25A12

-2.01

binding
Homo sapiens Ras association (RalGDSAF-6) domain family 1, mRNA
Homo sapiens RNA binding motif, single stranded interacting protein 1,
transcript variant MSSP-3
Homo sapiens G-protein coupled receptor
Homo sapiens replication factor C (activator 1) 5 (36.5kD), mRNA
Homo sapiens ribonuclease 6 precursor
Homo sapiens RNF6 protein, alternatively spliced
RP42 homolog
Homo sapiens, replication protein A3 (14kD), clone MGC:12305
Homo sapiens ribosomal protein S11
Homo sapiens ribosomal protein S16
Homo sapiens S100 calcium-binding protein A3
Homo sapiens serum amyloid A2
Homo sapiens serum amyloid A2-alpha mRNA, complete cds
Homo sapiens SnRNP assembly defective 1 homolog, mRNA
Spermidinespermine N1-acetyltransferase
Homo sapiens cDNA FLJ11251 fis, clone PLACE1008813
Homo sapiens sentrinSUMO-specific protease 3 (SENP3), mRNA
Homo sapiens cDNA FLJ10061 fis, clone HEMBA1001413.
Homo sapiens SEPTIN6 type IV (SEPTIN6) mRNA, complete cds
Homo sapiens single Ig IL-1R-related molecule
Homo sapiens signal-induced proliferation-associated gene 1
solute carrier family 12 (potassiumchloride transporters), member 4
Homo sapiens solute carrier family 16 (monocarboxylic acid transporters),
member 3
Homo sapiens solute carrier family 25 (mitochondrial carrier, Aralar), member
12
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4826715

SLC29A1

-2.52

4507022

SLC4A2

-2.80

10946127

SMARCA4

-2.03

10432598

SMARCB1

-2.63

21739263

-2.91
-2.28

Homo sapiens SYTSSX4v fusion protein (SSXTSSX4v fusion) mRNA

7305524
2443360
12893045
6991686

Spir-1
SSXTSSX4v
fusion
ST7
STATI2
STIP1
SYK

Homo sapiens solute carrier family 29 (nucleoside transporters), member 1
Homo sapiens solute carrier family 4, anion exchanger, member 2 (erythrocyte
membrane protein band 3-like 1)
SWISNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 4
SWISNF related, matrix associated, actin dependent regulator of chromatin,
subfamily b, member 1
Homo sapiens mRNA; cDNA DKFZp434O034

-2.85
-3.19
-2.11
-2.50

5454101

TACC3

-3.67

10439398
2961148
4507372
4507384
5886115
529172
339577

TAF1B
TASR1
TBCC
TCEA2
TCF7
TCF8
TGM2

-2.67
-2.13
-2.99
-3.12
-2.24
-2.20
-2.66

13097680

TGM2

-2.20

11024699

TIMM13B

-2.02

5802826

TIMM8B

-2.38

Homo sapiens potential tumor suppressor (ST7), mRNA
Homo sapiens mRNA for STAT induced STAT inhibitor-2, complete cds
Stress-induced-phosphoprotein 1 (Hsp70Hsp90-organizing protein)
spleen tyrosine kinase
Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3),
mRNA
Homo sapiens cDNA: FLJ22868 fis
Homo sapiens TLS-associated protein TASR mRNA, complete cds
Homo sapiens tubulin-specific chaperone c (TBCC), mRNA
Homo sapiens transcription elongation factor A (SII), 2 (TCEA2), mRNA
transcription factor 7 (T-cell specific, HMG-box)
Human zinc finger homeodomain protein mRNA, complete cds
Human transglutaminase mRNA, complete cds
Similar to transglutaminase 2 (C polypeptide, protein-glutamine-gammaglutamyltransferase), clone MGC:1193
Homo sapiens translocase of inner mitochondrial membrane 13 (yeast)
homolog B (TIMM13B)
Homo sapiens DDP-like protein mRNA, complete cds

11127696
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9257247
2460248
7706580
5032188

TIMP2
TNNC1
TOK-1
TP53BP1

-2.04
-4.61
-2.25
-3.39

14010353

TPM3

-2.15

12803958
7317562
4759277
13376853
13506764

TPM4
TPP2
U5-100K
UBXD1
UCK1

-2.03
-2.84
-2.62
-3.48
-3.84

4557872

UROS

-2.24

2735306
2881843
5454161
2631843
11141864
5730119
4096984
6005977
23510456
11129064
405730
824338

VDAC3
VDUP1
VDUP1
VIL2
VPS11
YKT6
YWHAE
ZNF258
ZNF41

-2.27
-2.40
-2.01
-3.19
-3.06
-3.21
-2.86
-2.19
-3.10
-2.09
-3.23
-2.04

13623280

-2.80

12385360

-2.24

Homo sapiens tissue inhibitor of metalloproteinase 2 (TIMP2), mRNA
Homo sapiens cardiac ventricular troponin C mRNA, complete cds
Homo sapiens cdk inhibitor p21 binding protein (TOK-1), mRNA
Homo sapiens tumor protein p53-binding protein, 1 (TP53BP1), mRNA
Homo sapiens tropomyosin 4-anaplastic lymphoma kinase fusion protein minor
isoform mRNA
Homo sapiens, tropomyosin 4, clone MGC:3641, mRNA, complete cds
Tripeptidyl peptidase II
Homo sapiens prp28, U5 snRNP 100 kd protein (U5-100K), mRNA
Homo sapiens UBX domain-containing gene 1 (UBXD1)
Homo sapiens uridine-cytidine kinase 1 (UCK1) mRNA, complete cds
Homo sapiens uroporphyrinogen III synthase (congenital erythropoietic
porphyria) (UROS), mRNA
Human voltage dependent anion channel form 3 mRNA, complete cds
Upregulated by 1,25-dihydroxyvitamin D-3
Homo sapiens upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA
Villin 2 (ezrin)
Homo sapiens vacuolar protein sorting 11 (yeast homolog) (VPS11), mRNA
Homo sapiens SNARE protein (YKT6), mRNA
Human epsilon isoform 14-3-3 protein mRNA, complete cds
Homo sapiens zinc finger protein 258 (ZNF258), mRNA
Homo sapiens zinc finger protein 41 (ZNF41), transcript variant 1, mRNA
ESTs
H.sapiens protein-serinethreonine kinase gene, complete CDS
ESTs
Homo sapiens, hypothetical protein FLJ10647, clone MGC:11318, mRNA,
complete cds
ESTs
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12749776
405744
1265017
5769385
10736104
3308527
3178040
11008259
1437008
13281338
2457916
4174746
16553977
6506313
13591689
10821160
27469755
15930214
1849639
4072178
3430180
3451333
1641998
10836767
19731133
18255994
22800482
3085925

-2.49
-2.55
-5.13
-2.86
-2.10
-2.91
-2.77
-4.12
-3.17
-4.03
-4.31
-2.94
-2.14
-2.13
-2.30
-2.58
-2.24
-3.10
-2.24
-2.05
-2.18
-5.58
-2.29
-3.44
-2.51
-2.89
-3.19
-2.53

ESTs
H.sapiens protein-serinethreonine kinase gene, complete CDS
Homo sapiens cDNA, 3 end
ESTs, Moderately similar to zinc finger protein (H.sapiens)
ESTs
Homo sapiens clone 25129 mRNA sequence
ESTs
Homo sapiens cDNA FLJ11985 fis, clone HEMBB1001356
ESTs
Homo sapiens, clone IMAGE:3908672, mRNA, partial cds
Homo sapiens cDNA FLJ30840 fis, clone FEBRA2002442
ESTs
Homo sapiens cDNA FLJ25255 fis, clone STM03941
ESTs
Homo sapiens PUMAJFY1 protein mRNA, complete cds
Homo sapiens cDNA: FLJ23031 fis, clone LNG01932
Homo sapiens, clone IMAGE:5310953, mRNA
Homo sapiens, clone IMAGE:3884761, mRNA
ESTs
ESTs, Weakly similar to T12540 hypothetical protein DKFZp434J214.1
Homo sapiens cDNA: FLJ21781 fis, clone HEP00223
Homo sapiens chromosome 19, cosmid F22162
ESTs
ESTs
Homo sapiens cDNA FLJ31833 fis, clone NT2RP6000130
Homo sapiens, clone MGC:30053 IMAGE:5139119, mRNA, complete cds
Homo sapiens, clone IMAGE:4552615, mRNA.
ESTs
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2984582

-2.13

8331754

-2.22

5232294
20362593
12661587
4188996
21734157
9513134
22477667
10951966
2012170
4888084
1278185
10914577
1422999
10434882
13575205
11683355
13045294
1301533
4703703
770394
11100686
12654762
5037961
11009912
3808147

-2.97
-2.18
-2.75
-2.06
-2.01
-2.31
-2.24
-2.48
-2.61
-2.48
-2.02
-2.38
-2.27
-2.15
-2.06
-2.15
-2.60
-3.37
-2.31
-2.07
-2.24
-3.48
-2.66
-2.90
-2.25

Homo sapiens chromosome 9, P1 clone 11659
Homo sapiens X28 region near ALD locus containing DUSP9, ribosomal
protein L18a
ESTs
Homo sapiens cDNA FLJ38785 fis, clone LIVER2001329
ESTs
ESTs
Homo sapiens mRNA; cDNA DKFZp686F0137
ESTs
Homo sapiens, clone IMAGE:5223521, mRNA
Human clone JkA8 mRNA induced upon T-cell activation, 3 end.
ESTs
ESTs, Weakly similar to WASP-family protein
Homo sapiens cDNA, 5 end
ESTs
Homo sapiens cDNA, 3 end
Homo sapiens cDNA FLJ13049 fis, clone NT2RP30014
Homo sapiens cDNA FLJ11901 fis, clone HEMBA1007347
ESTs, Weakly similar to S69890 mitogen inducible gene mig-2
ESTs
Homo sapiens 14q32 Jagged2 gene, complete cds
ESTs
ESTs
ESTs, Weakly similar to KIAA0681 protein
Homo sapiens, clone MGC:982 IMAGE:3354306, mRNA, complete cds
Homo sapiens mRNA; cDNA DKFZp434C1714
Homo sapiens cDNA FLJ12532 fis, clone NT2RM4000200
Homo sapiens ASMTL gene
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5924742
405728
7921055
5854235
12917064

-2.27
-2.38
-2.65
-2.72
-2.14

10456093

-3.75

12669922
4664062
4884256
4738836

-2.38
-2.09
-2.28
-2.71

1869771

-2.32

13477192

-2.64

21040444
12384240
2839126

-2.87
-2.09
-2.20

10348509

-2.13

9812380
10151243

-3.48
-2.06

5657550

-2.08

6656370
2094759
4002364
12654408

-2.44
-2.38
-2.45
-2.16

Homo sapiens, clone IMAGE:4642241, mRNA
H.sapiens protein-serinethreonine kinase gene, complete CDS
Homo sapiens chromosome 14 BAC 98L12
ESTs
ESTs
Homo sapiens partial mRNA for FUSCHOP chimaeric fusion protein (type 9
transcript variant)
ESTs
ESTs
Homo sapiens mRNA; cDNA DKFZp564O222
Homo sapiens cDNA, 3 end
Human DNA sequence from PAC 296K21 on chromosome X contains
cytokeratin exon, delta-aminolevulinate synthase (erythroid)
Homo sapiens, Similar to CG5078 gene product, clone MGC:12945, mRNA,
complete cds
Homo sapiens, Similar to syndecan binding prote
ESTs
Homo sapiens mRNA; cDNA DKFZp434F0217
ESTs, Moderately similar to T43492 hypothetical protein DKFZp434A219.1
(H.sapiens)
ESTs
Homo sapiens cDNA: FLJ22482 fis, clone HRC10859
ESTs, Moderately similar to ADHUA fructose-bisphosphate aldolase
(H.sapiens)
ESTs
Human beta-cytoplasmic actin (ACTBP9) pseudogene
Homo sapiens clone 24627 mRNA sequence
Homo sapiens, Similar to phosphatidylinositol glycan, class O, clone
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6143075
10964796
13663829
1470308

-2.09
-2.56
-2.12
-2.34

MGC:3079
Homo sapiens cDNA: FLJ22807 fis, clone KAIA2887
Homo sapiens mRNA; cDNA DKFZp564N1272
Human mRNA for heat shock protein 90kDa, 5UTR
Phosphoglycerate kinase {alternatively spliced}

Note* For up-regulated genes, totally 359 genes were up-regulated and 153 genes were named.
For down-regulated genes, totally 360 genes were down-regulated and 273 genes were named.
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CHAPTER 3
NUCLEAR PYRUVATE KINASE M2 IS A PROTEIN KINASE
3.1 Abstract
Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme catalyzing
conversion of phosphoenolpyruvate (PEP) to pyruvate with transferring a phosphate from
PEP to ADP. We report here that PKM2 is also a protein kinase using PEP as phosphate
donor. The protein substrate is bound at the ADP binding site. Our experiments suggest
that PKM2 dimer is an active protein kinase, while the tetramer is an active pyruvate
kinase. Binding of the tyrosyl phosphorylated proteins at the FBP binding site converts
the tetrameric PKM2 to a dimer, and reciprocally regulates the pyruvate kinase and
protein kinase activities of PKM2. Expression a PKM2 mutant that exists as a dimer
promotes cell proliferation. Growth factor stimulations significantly increase the
dimer/tretramer PKM2 ratio in cells. Thus, our study reveals that the regulation of
pyruvate kinase and protein kinase activities of PKM2 by growth signals plays an
important role in promoting cell proliferation.

3.2 Introduction
An important molecular feature of tumor development is the expression of
pyruvate kinase isoenzyme M2 (PKM2) (Elbers, van Unnik et al. 1991; Hacker,
Steinberg et al. 1998). The glycolysis catalytically active PKM2 exists as a tetramer and
associates with a glycolytic enzyme complex in normal cells (Dombrauckas, 2005;
Zwerschke, 1999; Altenberg, 2004). In tumor cells, it is believed that PKM2 dominantly
forms a dimer, and appears to be catalytically inactive for conversion of PEP to pyruvate
(Ashizawa, McPhie et al. 1991; Mazurek, Boschek et al. 2005). It is believed that the
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inactive PKM2 actually provides growth advantage for tumor progression as it helps to
channel the carbon source from glycolytic intermediates to biosynthesis, especially
syntheses of nucleic acids, lipids, and proteins, to meet the demands for tumor cell
proliferation. Recent studies have suggested that PKM2 changes its pyruvate kinase
activity, consequently facilitating cell proliferation by binding to tyrosine phosphorpeptide (Christofk, Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008),
indicating that growth signals regulate the activity of PKM2 in glucose metabolism.

3.3 Results
3.3.1 PKM2 is a Protein Kinase
We previously reported that nuclear PKM2 upregulated the MEK5 gene
transcription by activating the transcription co-activator stat3. We showed that expression
of PKM2 increased stat3 phosphorylation at Y705 (Gao, et.al. Oncogene revision 2009).
We questioned whether PKM2 could act as a protein kinase that directly phosphorylated
stat3. However, an in vitro phosphorylation using both the E. coli expressed recombinant
PKM2 (rPKM2) and the protein purified from nuclear extracts of mammalian cancer
cells in the presence of ATP did yield phosphorylation of a commercially available GSTstat3. Since PKM2 use PEP as phosphate donor to phosphorylate ADP in the glycolysis,
we reasoned that the protein may use the same phosphate donor to phosphorylate a
protein substrate. Thus, we replaced ATP by PEP in our in vitro phosphorylation
reaction. Immunoblot using a commercially available antibody against Y705
phosphorylated stat3 demonstrated that the GST-stat3 was phosphorylated by both the
rPKM2 and a HA-tagged PKM2 (HA-PKM2) immunopurified from nuclear extracts of
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SW620 cells in the presence of PEP. As observed previously, stat3 was not
phosphorylated in the presence of ATP (Fig. 3.1 A&B). These experimental results
indicated that PKM2 is a protein kinase using PEP as the phosphate donor.

3.3.2 Dimeric PKM2 is the Active Protein Kinase
We and others previously reported that PKM2 localized to the cell nucleus
(Hoshino, Hirst et al. 2007), Gao,et.al. Oncogene revision, 2009). In addition, we
observed that the kinase activity of the nuclear HA-PKM2 in phosphorylation of stat3
was substantially higher than that of the rPKM2 expressed in E. coli. We therefore sought
to compare the protein kinase activity of the nuclear PKM2 and the cytoplasmic PKM2.
We immunopurified the HA-PKM2 from nuclear or cytoplasmic extracts prepared from
SW620 cells. The same in vitro phosphorylation reactions using the GST-stat3 as
substrate were carried out with the immunopurified HA-PKM2 in the presence of PEP or
ATP. It was evident that both the HA-PKM2 purified from the nuclear extracts and the
cytoplasmic extracts were active in phosphorylating stat3. However, it was also clear that
the HA-PKM2 purified from the nuclear extracts had much higher activity in
phosphorylating stat3 than that of protein purified from the cytoplasmic extracts (Fig. 3.1
C&D).
It was reported that the catalytically active tetramer and inactive dimer of PKM2
co-exist in cells with high proliferation rate (Mazurek et al., 2005). Fructose-1,6bisphosphate (FBP) and tyrosine phosphorylation by viral oncogenic products were
identified as the regulators for the conversion between these two forms (Ashizawa,
McPhie et al. 1991; Mazurek, Boschek et al. 2005). We therefore questioned whether the
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differences in the protein kinase activity of nuclear/cytoplasmic PKM2 and the rPKM2
expressed in E. coli. were due to dimer or tetramer of the protein. To investigated
whether PKM2 is a dimer or a tetramer both in the nucleus and in the cytoplasm, we first
fractioned the nuclear extracts and cytoplasmic extracts of SW620 cells by size exclusion
chromatography. Non-specific protein-protein interactions were disrupted by treatment of
the extracts with 600 mM 6-aminocaproic acid (6-AcA). The levels of PKM2 in each
chromatography fraction were examined by immunoblot using the antibody PabPKM2.
Nuclear PKM2 was only detected in fractions 14 – 16, while cytoplasmic PKM2 was
mainly detected in fractions 10 – 16 with the highest concentrations in fractions 10 – 12.
According to the molecular weight calibration standard (Fig. 3.6 A&B), fraction 11 coelutes with a molecular weight near 240 kDa, while fraction 14 co-elutes with a
molecular weight near 120 kDa (Fig. 3.1E). The gel-filtration chromatography
experiments suggested that nuclear PKM2 was completely dimer (120 kDa), while the
cytoplasmic PKM2 existed in both dimer and tetramer with a higher population of
tetramers. The same chromatography procedure was also employed to analyze whether
the rPKM2 is a dimer or tetramer. It was evident that the rPKM2 was detected in the
fractions 11 – 14, which indicates that the bacterially expressed rPKM2 is mostly
tetramer with very small amount of dimer (Fig. 3.2B). To further probe the
dimer/tetramer status of nuclear and cytoplasmic PKM2, nuclear extracts and
cytoplasmic extracts made from SW620 cells were separated by a non-denaturing PAGE
(8% acrylamide:bis-acrylamide = 40:1) and subjected to immunoblot analyses using the
antibody PabPKM2. The extracts were also treated with 600 mM 6-AcA prior to
electrophoresis. It was clear that the nuclear PKM2 migrated slightly faster than the BSA
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dimer (132 kDa). Conversely, the majority of the cytoplasmic PKM2 approximately comigrated with Urease (272 kDa) (Fig. 3.6C). Thus, both non-denaturing gel
electrophoresis and size exclusion chromatography results strongly suggested a division
of PKM2 between a dimer form in the nucleus and mainly a tetramer form in the
cytoplasm. The bacterially expressed rPKM2 mainly exist as tetramer. Based on the
proceeding experimental observations, we speculated that the dimer form of PKM2 is the
active protein kinase, while tetramer is an active pyruvate kinase. Closely examination of
the crystal structure of the tetramer human PKM2 (Dombrauckas, Santarsiero et al. 2005)
reveals that a positive charged residue R399 may plays a critical role in forming the
tetramer of PKM2. It is notable that the R399 forms stable charge-charge interactions
with residues E418, D357, and E396 of PKM2 located on the other dimer of the tetramer
PKM2 (Fig. 3.2A). We therefore created a mutant R399E to disrupt the charge-charge
interaction. Size exclusion chromatography analyses of the wt rPKM2 and the R399E
mutant demonstrated that the wild-type rPKM2 existed most as a tetramer with residue
amounts of dimer, while the R399E mutant was mostly dimer (Fig. 3.2B). We reasoned
that the dimeric R399E mutant would be more active in phosphorylating stat3 compared
to the wild-type rPKM2. Thus, the in vitro phosphorylation reactions were carried out
with the wild-type rPKM2 and the R399E mutant. It was evident that the protein kinase
activity of the R399E mutant was substantially higher than that of the wild-type rPKM2
(Fig. 3.2C), while the pyruvate kinase activity of the mutant was dramatically lower than
that of the rPKM2 (Fig. 3.2D). The results supported our speculation that dimeric PKM2
is the active protein kinase.
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To further verify the phosphorylation of stat3 by PKM2, we prepared [32P]labeled PEP according to the methods described by Roossien FF. and co-workers
(Roossien, Brink et al. 1983). The same in vitro phosphorylation reaction was carried out
with the rPKM2, the rPKM1, and the R399E mutant using the [32P]-labeled PEP. The
phosphorylation reaction mixture was separated by SDS-PAGE and subjected to
autoradiography. It was clear that the GST-stat3 was phosphorylated by the R399E
mutant. The phosphorylation of the GST-stat3 by the rPKM2 was very weak (can only be
visualized by a substantial overexposure in autoradiograph). The GST-stat3 was not
phosphorylated by the recombinant PKM1 in the presence of the [32P]-PEP (Fig. 3.6D).
No phosphorylation can be detected even under very high overexposure in the
autoradiograph.

3.3.3 Binding Tyrosyl Phosphor-protein at the FBP Site Converts the Tetramer
PKM2 to the Dimmer and Reciprocally Regulates the Protein Kinase and Pyruvate
Kinase Activities
Christofk and co-workers reported that PKM2 interacts with phosphor-tyrosine
peptide and the interaction plays an important role in promoting cell proliferation
(Christofk et al., 2008a; Christofk et al., 2008b), suggesting a possible pathway that
growth signals promotes proliferation via protein tyrosine phosphorylation and
subsequent action on PKM2. Nevertheless, the interaction between PKM2 and a
particular cellular tyrosine phosphor-protein is not revealed. We previously demonstrated
that P68 RNA helicase is phosphorylated in cancer cells, and tyrosine phosphorylation of
p68 correlates with cancer progression (Yang, Lin et al. 2005). Phosphorylation of p68 at
Y593 promotes EMT (Yang, Lin et al. 2006), while phosphorylation of p68 at Y593 and
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Y595 mediated resistance to apoptotic-induction (Yang, Lin et al. 2007). In an effort to
probe interacting protein with the tyrosyl phosphorylated p68, we used a 14 amino acid
sequence segment that includes the Y593 or Y593/595 phosphorylation site (aa 587 to
600). The peptides either carried no phosphorylation (Ref to as PepY593), Y593
phosphorylation (Ref to as PhosPepY593), or Y593/595 double phosphorylations (Ref to
as D-PhosPepY593). We also used another control peptide that span different region of
p68 (aa 561 – 574) with Y567 phosphorylation (Ref to as PhosPepY567). The peptides
were conjugated to agarose beads. Precipitation experiments from nuclear extracts made
from T98G cells demonstrated that the DPhosPepY593 pulled-down a nuclear protein
that migrated at ~60 kDa (Fig. 3.7A). The interacting protein was identified by MALDI
(tof/tof) as PKM2 (pyruvate kinase type M2) (Fig. 3.7A right panel). To verify the
interaction of p68 with PKM2, the precipitates by the phosphorylated/nonphosphorylated p68 peptides were examined by immunoblot assay using a polyclonal
antibody developed against PKM2. It was clear that the ~60 kDa protein precipitated by
the tyrosine phosphorylated p68 peptide was recognized by the PKM2 antibody (Fig.
3.7B). The interaction between p68 and PKM2 was also verified by reciprocal pull-down
with the nuclear extracts made from T98G cells using recombinant PKM2 as bait (Fig.
3.7C). PKM2 is a glycolysis enzyme that predominantly localizes in the cytoplasm. Thus,
we asked whether p68 also interacts with PKM2 in the cytoplasm. To this end, PKM2
was immunoprecipitated from both the cytoplasmic extracts and nuclear extracts made
from T98G cells. Co-imunoprecipitation of p68 with PKM2 was examined by
immunoblot using the antibody p68-RGG. It was evident that p68 co-immunoprecipitated
with PKM2 both in the cytoplasmic extracts and the nuclear extracts (Fig. 3.7D right

125

panel). Similar co-immunoprecipitation results were also observed with exogenously
expressed HA-PKM2 (Fig. 3.7D, left panel). To further verify that PKM2 and p68
interaction is the p68 phosphorylation dependent, we carried out co-immunoprecipitation
experiment with the nuclear extracts of T98G cells in which HA-p68, wt or Y593F (a p68
mutant that can not be phosphorylated), was expressed. It was clear that wt HA-p68 coprecipitated with PKM2, while the Y593F mutant did not (Fig. 3.7E), suggesting that p68
tyrosine phosphorylation is required for PKM2 and p68 interaction.
We questioned whether the interaction of PKM2 with the tyrosine phosphor-p68
might promote the conversion of PKM2 from tetramer to the dimer form, To test this
conjecture, we employed three phosphorylated/unphosphorylated peptides, the double
tyrosine phosphorylated peptide D-PhosPepY593, the peptide that spans different region
of p68 PhosPepY567, and the PepY593. We first examined the interaction of the selected
phosphor/unphosphor-peptides with the rPKM2 by monitoring the Trp fluorescence
changes of the rPKM2 upon interaction with the peptides. It was clear that the DPhosPepY593 interacted with the rPKM2 with Kd around 30 μM, while the
PhosPepY567 and the PepY593 did not (Fig. 3.8 A, B, and C). It was demonstrated that
the tyrosine phosphor-peptide interacts with PKM2 at FBP binding site (Christofk,
Vander Heiden et al. 2008). To test whether the phosphor-tyrosine peptide interact with
the rPKM2 at FBP binding site, we examined the interaction between the peptide DPhosPepY593 with the rPKM2 in the presence of excessive amounts of FBP. It was clear
that FBP competed with the D-PhosPepY593 for binding to the rPKM2 (Fig. 3.8 A, B,
and C). The competition of FBP with p68 for binding to PKM2 was also revealed by coimmunoprecipitation experiment. It was clear that coimmunoprecipitation of p68 with
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HA-PKM2 in T98G cell extracts decreased by supplementing the extracts with different
concentrations of FBP (Fig. 3.8D). The similar coimmunoprecipitation experiment was
also carried out with the rPKM2 and the HA-p68 immunopurified from T98G cell
extracts in the presence of various concentrations of FBP. High concentration of FBP
decreased the HA-p68 and the rPKM2 interaction (Fig. 3.8E). It is reported that W515–
G520 located at the activating loop of C-terminal of PKM2 is critical for the FBP binding
(Dombrauckas, Santarsiero et al. 2005). Thus, we created a truncation mutant with
deletion of W515 – G531. The interaction of the phosphor-p68 with the PKM2 truncation
was examined by the co-immunoprecipitation procedure. It was evident that the deletion
of the FBP binding activating loop abolished the interaction between p68 and PKM2
(Fig. 3.8F). Meanwhile, a mutation (K270M) that affects the glycolytic substrate binding
(Dombrauckas, 2005) did not affect the interaction between p68 and PKM2 (Fig. 3.8F).
These results are consistent with the observations by Christofk and co-workers
(Christofk, Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008), indicating
the phosphor-peptides D-PhosPepY593 and phosphor-p68 interact with PKM2 at the
FBP binding site.
To examine the effects of binding the phosphor-peptides on the tetramer and
dimmer formation, we used the same size exclusion chromatography method to analyze
the molecular sizes of the rPKM2 in the presence or absence of the three tyrosine
phosphor/unphosphorpeptides and compared to the chromatography profile of molecular
size standard. It was evident that there were substantially more dimeric PKM2 in the
presence of phosphor-peptides, DPhosPepY593, while the tetramer and dimer ratio of the
rPKM2 was not affected in the presence of the phosphor-peptide PhosPepY567 and non-
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phosphor-peptide PepY593 (Fig. 3.3A). The experiments apparently suggested that
binding the tyrosyl phosphor-protein converts tetramer PKM2 to a dimeric form.
We further questioned whether binding of the tyrosyl phosphor-protein/peptide
would activate the protein kinase activity and inactive pyruvate kinase activity of PKM2.
To this end, the in vitro phosphorylation reactions were carried out with the rPKM2 in
the presence of different tyrosine phosphor/unphosphor-peptide. Examination of
phosphorylation of stat3 by the immunoblot using the anti-phospho-stat3 antibody
indicated that phosphorylation of stat3 at Y705 by the rPKM2 was dramatically increased
in the presence of phosphor-peptide DPhosPepY593 (Fig. 3.3B). The phosphorylations of
stat3 by the rPKM2 were not affected in the presence of the peptide PepY593 without
tyrosine phosphorylation. The phosphorylation of stat3 was also not affected in the
presence of another tyrosine phosphor-peptide PhosPepY567 that did not bind to PKM2
(Fig. 3.3B). We next tested whether indeed presence of phosphor-p68 would activate the
protein kinase activity of PKM2. To this end, we immunopurified HA-p68 from nuclear
extracts prepared from T98G cells. Phosphorylation of GST-stat3 by the rPKM2 in the
presence or absence of the immunopurified HA-p68 was examined. Clearly, stat3 was
much strongly phosphorylated by the rPKM2 in the presence of the purified HA-p68
compared to that in the absence of the purified HA-p68 (Fig. 3.3C). The results support
the notion that binding of the tyrosyl phosphor-protein activates the protein kinase
activity of PKM2.
PKM2 is a glycolysis enzyme. It is believed that the tetramer form of the protein
is catalytic active in catalyzing the conversion of PEP to pyruvate in the glycolysis. Since
the binding of the tyrosine phosphor-protein promoted the conversion from tetramer to
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dimer, we reasoned that binding the tyrosine phosphor-protein/peptide to PKM2 should
result in protein that is less active in catalyzing the conversion of PEP to pyruvate. We
used the method similar to that is described by Christofk and coworkers (Christofk,
Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008) to monitor the pyruvate
kinase activity of the rPKM2 in the presence of the tyrosine phosphor-peptides. The
rPKM2 catalytic activity was dramatically reduced in the presence of D-PhosPepY593,
while the activity was not affected in the presence of the peptides PhosPepY567 and
PepY593 (Fig. 3.3D), which indicate that binding of PKM2 to the tyrosine phosphorproteins converted the protein to dimer and consequently reduced the glycolytic enzyme
activity. The notion was further supported by the experiments that the enzymatic activity
of the R399E in converting PEP to pyruvate was dramatically decreased compared to that
of recombinant wild-type (Fig. 3.2D).

3.3.4 PKM2 Kinase Substrates Bind to the ADP Binding Site for Phosphorylation
PKM2 directly phosphorylates stat3. One interesting question is how the protein
substrate is bound to PKM2. Our results showed that PEP was used as phosphate donor
by PKM2 in phosphorylation of a protein substrate. It is established that in the catalysis
of ADP phosphorylation in glycolysis, PKM2 binds phosphate donor PEP at one site and
substrate ADP at the other. Thus, a very logic assumption based on this knowledge is that
the protein substrate may bind to the ADP site. To test this conjecture, we carried out
competition binding analyses. Co-immunoprecipitation was carried out to detect the
interaction between PKM2 and Stat3 mutant in the presence of ADP. The results showed
that ADP competed the interaction between Stat3 and PKM2. The interaction between
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Stat3 and PKM2 mutants were also probed. Co-IP results showed that the mutant at
glycolytic substract binding site, K270M, abolished the interaction between Stat3 and
PKM2 (Fig. 3.4B). Our experiments thus far demonstrate that tyrosine phosphor-p68
interacts with PKM2 at the FBP site and strengthen the protein kinase activity of the
protein. We therefore predict a three ways interaction among the phosphor-p68, PKM2,
and GST-stat3. To test this possible protein interaction, we carried out the GST-pull
down using the GST-stat3. Immunoblot demonstrated that both recombinant PKM2 and
p68 purified from cell extracts of T98G cells were co-precipitated with GST-stat3 (Fig.
3.4C).

3.3.5 PKM2 Protein Kinase Substrates Bind to the ADP Binding Site
PKM2 directly phosphorylates stat3. One interesting question is how the protein
substrate is bound to PKM2. Our results showed that PEP was used as phosphate donor
by PKM2 in phosphorylation of a protein substrate. It is established that in the catalysis
of ADP phosphorylation in the glycolysis, PKM2 binds phosphate donor PEP at one site
and substrate ADP at the other. Thus, a very logic assumption based on this knowledge is
that the protein substrate may bind to the ADP site. To test this conjecture, we carried out
competition binding analyses. The R399E mutant and stat3 interaction was analyzed in
the presence and absence of ADP, PEP, and FBP. The GST-stat3 was immobilized on the
glutathione-agarose beads. Recombinant R399E in mixing with buffer, ADP, PEP, or
FBP were incubated with the beads. Binding of R399E to the immobilized GST-stat3 was
then analyzed by SDS-PAGE followed by immunoblot of R399E and stat3. It was very
clear that the interaction of R399E with stat3 was not affected in the presence of 5 mM
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FBP, while the interaction was almost not detectable in the presence of 5 mM ADP. The
R339E and stat3 interaction was also weakened in the presence of 5 mM of PEP. This
was most likely due to phosphorylation of stat3, as the reduction in stat3 and R399E
interaction was not PEP concentration dependent, while the R399E and GST-stat3
interaction showed a clear ADP concentration dependent reduction (Fig. 3.3E), indicating
the competition of ADP with stat3 in binding R399E. Our experiments thus far
demonstrate that tyrosine phosphor-p68 interacts with PKM2 at the FBP site and
strengthen the protein kinase activity of the protein. We therefore predict a three ways
interaction among the phosphor-p68, PKM2, and stat3. To test this possible protein
interaction, we carried out the GST-pull down using the GST-stat3. Immunoblot
demonstrated that both the HA-PKM2 and p68 purified from cell extracts of T98G cells
were co-precipitated with GST-stat3 (Fig. 3.3F). The three ways interaction was also
probed by co-immunoprecipitation experiments using anti-HA antibody. The rPKM2 and
GST-stat3 were co-precipitated with HA-p68 that was immunopurified from cellular
extracts of T98G cells (Fig. 3.9A). These results provided additional support for the
notion that PKM2 protein kinase substrate binds to the ADP binding site. The notion that
protein kinase substrate is bound at the ADP binding site of PKM2 was also supported by
our early observations that addition of ADP decreased the activity of PKM2 in
phosphorylation of stat3, while addition of FBP did not (see Fig. 3.1C and 3.2C).

3.3.6 Expression of R399E Increased Stat3 Phosphorylation in Cells and Promoted
Cell Proliferation
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We employed a PKM2 mutant R399E. Our experiments showed that the
recombinant R399E existed mostly as a dimer and the mutant exhibited strong activity in
phosphorylation of GST-stat3. We therefore questioned whether the R399E mutant
would be active in phosphorylation of stat3 in cells. To this end, the HA-R399E was
exogenously expressed in SW480 cells. Immunoblot examination of the phosphor-stat3
in the nuclear extracts indicated a significantly increase in the levels of Y705
phosphorylated stat3. This increase was not due to increase in cellular levels of stat3 as
immunoblot of cell lysate indicated very similar stat3 levels in cells with/without
expression of the R399E or wt PKM2 (Fig. 3.4A). The exogenously expressed HAR399E

was

subsequently

immunopurified

from

cell

lysate.

Size

exclusion

chromatography experiments showed that, unlike the exogenously expressed wild-type
HAPKM2, the HA-R399E was almost completely dimer in cell lysate (Fig. 3.4B) In vitro
phosphorylation assays indicated that the immunopurified HA-R399E phosphorylated
GST-stat3 (Fig. 3.4B). We previously observed that expression of PKM2 led to upregulation of MEK5 and cell proliferation (Gao et.al., Oncogene 2009 revision). Thus,
we tested here if exogenous expression of R399E in SW480 cells would lead to MEK5
up-regulation and cell proliferation. RT-PCR analyses clearly demonstrated that the
cellular levels of mRNA of MEK5 increased significantly (Fig. 3.4C). Examination of
cell proliferation using a commercial kit that monitoring the cooperation of BrdU
demonstrated that expression of R399E led to a strong increase in cell proliferation (Fig.
3.4D).

3.3.7 Growth Factor Stimulations Result in Increase in Dimeric PKM2 in Cells
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It is well documented that stimulation of cells by growth factors and cytokines
results in activation of various protein tyrosine kinases that subsequently phosphorylates
many protein substrates at tyrosine residue (Hunter and Cooper 1985). For instance, we
previously demonstrated that PDGF or EGF stimulation led to tyrosine phosphorylation
of p68 RNA helicase (Yang, Lin et al. 2005; Yang, Lin et al. 2006). Presently our
experiments demonstrated that binding to tyrosine phosphor-protein converted PKM2
from tetramer to dimer therefore activated the protein kinase activity of the protein. We
reason whether treatment of cells with growth factors would affect PKM2. Thus, SW480
cells were treated with EGF. The same chromatography procedure used for detecting the
PKM2 tetramer vs dimer in crude cell extracts was employed here to analyze the tetramer
and dimer ratio of PKM2 in cells under the stimulation of EGF. It was clear that the
levels of dimer PKM2 in growth factor stimulated cells were significantly higher than
that in corresponding unstimulated cells (Fig. 3.5A). Immunoblot analyses of PKM2 in
nuclear and cytoplasmic extracts suggested that growth factor stimulation led to increase
in nuclear PKM2 levels (Fig. 3.5B). Analyses of protein tyrosine phosphorylation and
p68 tyrosine phosphorylation revealed that there was a substantial increase in protein
tyrosine phosphorylation and tyrosine phosphorylation of p68 at tyrosine residue (Fig.
3.5C). These experiments suggested that indeed there is a clear correlation between the
levels of protein tyrosine phosphorylations and dimeric PKM2 in cells, which is
inducible by growth factors and cytokines.

3.4 Discussion
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During tumor progression, growth signals stimulate the conversion of
glycolytically active PKM2 to an inactive form, consequently regulating the glycolysis
pathway to channel the carbon source from glucose for biosynthesis (Deberardinis, 2008;
Garber, 2006; Mazurek, 2003; Christofk, 2008). It is conceivable that tumor cells need to
coordinate the metabolism alterations with expression of genes that are related to cell
proliferation during tumor progression. Thus, at the same token, the growth signals will
also activates protein kinase activity of PKM2, which subsequently target transcription
factor and activate transcription of genes that closely associated with cell proliferation.
PKM2 has long been recognized as a so-called ‘moonlight’ enzyme that plays a very
important role in tumor progression (Sriram, 2005). Clearly, the protein kinase activity of
PKM2 and subsequent activity in transcription regulation is an important ‘moonlight’
activity of the protein. The functions of PKM2 in regulating expression of genes fulfill
the role of feedback signaling from metabolic alterations to gene regulation during tumor
malignancy transformation (see model in Fig. 3.5D).
It is intriguing that a glycolytic enzyme can function as a protein kinase and
translocate to the nucleus acting on gene transcription. Our studies suggested a molecular
base for the activity conversion (Fig. 3.5D). Growth signal (growth factors or cytokines)
stimulations lead to activation of protein tyrosine kinases, which phosphorylate a number
of downstream targets. A number of tyrosine phosphor-proteins subsequently act on
PKM2 by interacting with the protein at the FBP binding site. The tyrosine phosphorprotein and PKM2 interaction results in the conversion of PKM2 from tetramer to a
dimer, which consequently lead to decrease in pyruvate kinase activity and increase in
protein kinase activity. It was revealed from x-ray crystallography structural analyses of
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the tetramer PKM2 that the ADP binding site is formed by a large hydrophobic hole,
indicating a great flexibility for nucleotide binding (Muirhead, Clayden et al. 1986;
Dombrauckas, Santarsiero et al. 2005). The large hydrophobic hole at the nucleotide
binding site is almost completely buried in a tetramer structure, while it would be
completely accessible with the dimeric form. Thus, it is conceivable that the nucleotide
binding site may be able to accommodate a protein substrate when PKM2 is converted to
a dimer. Alternatively, binding the tyrosine phosphor-protein to the FBP site would
results in a significant conformation change that will allow PKM2 to accommodate a
protein substrate binding. Stat3 is a transcription activator that is activated in response to
inflammatory cytokines, such as IL-6 (Gao, 2007; Watson, 2008). Strikingly, activation
of stat3 represents probably one of the most important molecular signatures involved in
promoting cancer progression. It has been observed that activation of stat3 is detected in
almost all cancer types (Frank 2007; Huang, Qiu et al. 2007; Kim, Chan et al. 2007;
Groner, Lucks et al. 2008). However, it is generally believed that activations of stat3 in
response to growth factor and cytokines are usually transient. A long standing question is
“How do the malignant cancer cells maintain constitutive activation of stat3?” Currently,
mutation(s) that lead to constitutive activation of stat3 have not been identified. Thus,
activation of stat3 by PKM2 in malignant cancer cells potentially provides a very
attractive explanation for this long-standing question. Whether stat3 is the only PKM2
substrate for its protein kinase activity is an open question. PKM2 interacts with several
other proteins (Garcia-Gonzalo, Cruz et al. 2003; Lee, Kim et al. 2008; Spoden,
Morandell et al. 2009). It was also reported that PKM2 purified from hepatoma tumour
cells can phosphorylate histone H1 in vitro (Ignacak and Stachurska 2003). Thus, it will
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be very interested to identify other PKM2 protein kinase substrates and uncover the
putative cellular function of the corresponding protein phosphorylations.

3.5 Materials and Methods
3.5.1 Reagents, Cell lines, and Antibodies
The

KLH

conjugated

peptide

spans

aa

399

–

412

of

PKM2

(IYHLQLFEELRRLAPI) was synthesized by Global Peptide Services. PKM2
polycolonal antibody and anti-HA antibody was raised in the animal facility of Georgia
State University. The peptides, D-PhoPepY593, PepY593, and PhosPepY567, were
synthesized by AnaSpec. Antibodies against stat3, stat3 (pY705), HA-tag, GAPDH,
Lamin A/C, and β-actin were purchased from Cell Signaling, Abnova, SantaCruz,
Abcam, and AnaSpec respectively. Recombinant GST-stat3 was purchased from Abcam.
Cell lines SW480, SW620, T98G were purchased from ATCC and cultured by following
the vendor’s instructions.

3.5.2 Plasmids Construction
Human full length cDNA of PKM2 and PKM1 were purchased from OriGene
Technologies. The cDNA of PKM2 and PKM1 was subcloned into bacteria expression
vector pET30a (+) as well as mammalian expression vectors pHM6. The PKM2 or its
mutants were fused at the C-terminal of HA protein tag in pHM6 mammalian expression
vector. Site directed mutagenesis were performed using QuikChange® Multi SiteDirected Mutagenesis Kit (Stratagene). All the DNA clones and mutations were verified
by auto-DNA sequencing at GSU. The HA-tagged full length p68 (wild type, Y593F
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mutant) expression plasmids were constructed in pHM6 vectors as indicated in the
previous papers from our lab (Yang, Lin et al. 2006).

3.5.3 Expression and Purification of Recombinant PKM2
Recombinant 6×his-PKM2, 6xhis-PKM1, or 6xhisPKM2 mutants was expressed
in bacterial BL21-CodonPlus (DE3)-RIPL. The recombinant protein was expressed and
accumulated in the bacterial inclusion body. After extensive washes, the bacterial
inclusion bodies were dissolved into 8 M Urea pH = 7.5. The protein was then purified
over a HiTrap® his-affinity column. The purified recombinant PKM2, PKM1, and PKM2
mutants was then refold by slow dilution into 10 folds refolding buffer (10 mM tris
pH=7.5, 20% glycerol, 0.1 M KCl, 0.1 M EDTA, 1 mM DTT) and dialysis against
refolding buffer. Purified protein was verified by immunobloting using antibody against
PKM2.

3.5.4 Transfection and RNA Interference, Subcellular Extracts Preparation,
Immunoprecipitation and Immuno Blots, and PCR and RT-PCR
The experimental procedures for transfection, cellular extracts preparation,
immunoprecipitation and immuno blots, and PCR and RT-PCR were similar to our
previous reports (Yang, Lin et al. 2006; Yang, Lin et al. 2007). The primer pairs used in
present study were, for RT-PCR analyses of MEK5 gene expression, forward 5’CATGTCCTTGGAAGAATTGC-3’, reverse 5’-ATAGAATTCACCAGCTGAGTG-3’,
targeted exon 12 – exon 14/15 regions of the MEK5 gene.
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3.5.5 Size-exclusion Chromatography and Non-denaturing Gel Electrophoresis
Size exclusion chromatograph was performed with a Superdex 200 10/300GL
column using Akta purifier 100 FPLC system. The samples of cytoplasmic extracts,
nuclear extract, the rPKM2, the recombinant PKM2 mutants, and the immunopurified
HA-PKM2/HA-R399E were prepared in tris-HCl buffer (50 mM tris, 0.15 M NaCl pH
7.2). 6-AcA (600 mM) was added to the protein samples to disrupt the non-specific
protein-protein interactions. For the crude cellular extracts, the samples were prepared in
5 – 7 mg/ml of total protein. For the recombinant or the immunopurified proteins, the
samples were prepared in concentration of 15 µM. 100 µl of prepared sample was loaded
into the Superdex 200 10/300GL column and eluted with elution buffer (50 mM
phosphate, 0.15M NaCl pH7.2). The fraction of 300 µl was collected, and 50 µl of each
fraction was analyzed by 10 % SDS-PAGE and followed by immunoblot using
appropriate antibody. A size exclusion chromatograph calibration kits was purchased
from GE Healthcare. The protein standard samples (six high MW proteins) were
dissolved in the same buffer with 600 mM AcA at concentrations instructed by the
manufacture. Proteins were eluted with the same elution buffer. The fractions (300 µl)
were collected with the same FPLC system and conditions. The elution profile was
recorded based on the absorbance of elution fractions at 280 nm. The elution profile was
plotted against LogMW according to vendor’s instructions.
The treated cytoplasmic or the nuclear extracts (6 µl) were loaded on an 8% nondenaturing polyacrylamide gel (40:1 – acrylamide:bis-acrylamide). The gel was subject
to immunoblot using the antibody PabPKM2. The molecular weight markers, BSA and
Urease (Sigma), were loaded on the same gel and were visualized by ponceau S staining.
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3.5.6 PKM2 and Peptide Interaction
Interactions between the rPKM2 and its derived mutants were analyzed by
monitoring the changes of tryptophan fluorescence of the recombinant protein PKM2 or
the mutants (λex =285 nm, λem =310-410 nm). The binding analyses were carried out
with protein concentration 4 µM in the reaction buffer (50 mM tris, pH7.5, 100 mM
KCl). Different peptides (100 µM) were titrated into the protein solution. All spectra
were recorded at ambient temperature using a PTI spectrofluorimeter with a 1 cm path
length cuvette. FBP was added in the protein solution with a final concentration of 2 mM.

3.5.7 In vitro Protein Kinase and Pyruvate Kinase Assays
The bacterially expressed recombinant rPKM2/R399E or HA-PKM2/HA-R399E
immunopurified from cellular extracts (10 µg/ml) were incubated with GST-stat3 (10
µg/ml) under various conditions (indicated in the figure legends) with kinase buffer (50
mM Tris-HCl pH = 7.5, 100 mM KCl, 50 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, and
1 mM DTT) in 100 µl at room temperature for 1 hours. The phosphorylation reactions
were carried out in the presence either 5 mM ATP or 5 mM PEP. The phosphorylation
reactions were terminated by addition of 20 µl of 4 x SDS-PAGE loading buffer and
heated to 100 °C for 8 minutes. The reaction mixtures were then subjected to 10% SDSPAGE separation and subsequent analyses.
Pyruvate kinase activity was analyzed by following the experimental procedure
similar to that was described by Christofk and co-workers (Christofk, Vander Heiden et
al. 2008). Briefly, the rPKM2 or the mutant R399E (at 1 µM) was incubated with the
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buffer (100 mM Tris-HCl, pH=7.5, 100 mM KCl, 5 mM MgCl2) containing 1 mM ADP
and 0.5 mM PEP. The reaction also contained 200 µM NADH and 10 µM FBP. After
incubation at room temperature for 30 minutes, 8 units of LDH (Calbiochem) were added
to the reaction. The reactions were then subsequently analyzed by measuring the
absorbance at 340 nm. The pyruvate kinase activity was presented as relative pyruvate
kinase activity by define the activity of the rPKM2 as 100.

3.5.8 Peptide Pull Down and Protein Identification by Mass Spectroscopy
The

peptides,

CGMNQQA[pY]AYPATAA,

PepY593

CGMNQQAYAYPATAA,

D-PhosPepY593

PhosPepY593

CGMNQQA[pY]A[pY]PATAA,

and

PhosPepY567 CGNPTGT[pY]QNGYDST were purchased from Anaspec Inc. The
peptides were conjugated to agarose beads using AminoLink Plus Immobilization kit
(Pierce). The peptide-conjugated beads were incubated with 3 mg (total protein) fresh
nuclear extract in NETs buffer (150 mM NaCl, 50 mM tris, pH 7.5, 5 mM EDTA, 0.1%
NP-40) overnight at 4 °C. The next day, the beads were separated and washed with NETs
buffer five times. The proteins precipitated with the peptide beads were separated in 10%
SDS-PAGE and stained with GelCode blue stain (Pierce) or silver staining. After
destaining, the identified protein bands were excised from the gel and digested with
trypsin. The digested peptides were extracted from gel with Trypsin Profiel IGD kit
(Sigma). The samples were concentrated with vacuum centrifugation and desalted with
ZipTip C18 pipette tips (Millipore). After ZipTip purification, the peptides were eluted
from the ZipTip with 50% acetonitrile (ACN)/0.1% trifluoroacetic (TFA) and spotted
directly onto a wax-coated MALDI target plates. The peptides were analyzed by
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TOF/TOF-MS analysis in Applied Biosystems 4700 Proteomics Analyzer. Peptides with
“ion scores” above 30 were considered significant. The MS/MS data was searched in the
NCBInr database (Mascot; All Taxa, Human).
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Fig 3.1 PKM2 Phosphorylates GST-stat3
Phosphorylation of GST-stat3 by the rPKM2 (A) and HA-PKM2 immunopurified from
nuclear extracts of SW620 cells (B) in the presence of 5 mM ATP (ATP) or 5 mM of
PEP (PEP) was revealed by immunoblot assays using antibody against Y705
phosphorylated stat3 (IB:pY-stat3). Immunoblot analyses using antibody against stat3
(IB:Stat3) indicates the amounts of GST-stat3 used in each phosphorylation reaction. The
bottom panels in (A) & (B) are the quantitative analyses of immunoblot signals. The
error bars represent the standard deviations of four measurements. Phosphorylation of
GST-stat3 by the HA-PKM2 (HA-PK) immunopurified from the nuclear (C) and the
cytoplasmic (D) extracts of SW620 cells in the presence of 5 mM ATP (ATP) or 5 mM
of PEP (PEP) was revealed by immunoblot assays using antibody against Y705
phosphorylated stat3 (IB:pY-stat3). The phosphorylation reactions were also carried out
in the presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The
immunoblot of HA (IB:HA) indicates the amounts of HA-PKM2 used in each reaction.
IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of
antibody used in immunopurification of HA-PKM2 from the extracts. Coomassie blue
staining (CBS) indicates the amounts of GSTstat3 and BSA used in each phosphorylation
reaction. Vec were the cells infected with virus that carry an empty vector. (E) Size
exclusion chromatography fractionation of nuclear (NE) and cytoplasmic (Cyto) extracts
(100 μl) from SW620 cells. The fractions were collected using a FPLC at 300 μl per
fraction. The collected fractions 6 to 17 from cytoplasmic extracts and fraction 9 to 18
from nuclear extracts were immunoblotted using the antibody PabPKM2. Fraction 11
(F11) co-eluted with 240 kDa and fraction 14 (F14) co-eluted with 120 kDa on the same
column under identical conditions determined by size exclusion chromatography
molecular weight calibration standard (see on-line supplementary Fig. S1 B&C).
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Fig 3.2 Dimeric PKM2 is Active Protein Kinase
(A) Part of x-ray crystal structure of human PKM2. The structure was obtained from
PDB bank DOI: 10.1021/bi0474923. The residue R399 and its interactive residues E418,
D357, and E396 are high lighted in color. (B) Size exclusion chromatography
fractionation of the wild-type rPKM2 and R399E mutant. The recombinant proteins 100
μl in 1.5 μM were loaded onto column. The chromatography fractions F10 – F18 were
collected using a FPLC at 300 μl per fraction. The collected fractions were analyzed by
immunoblot using the antibody PabPKM2 (IB:PKM2). (C) Phosphorylation of GST-stat3
by the rPKM2 (10 μg/ml) (lower panel) and R399E mutant (10 μg/ml) (upper panel) in
the presence of 5 mM ATP (ATP), 5 mM of PEP (PEP), 5 mM of FBP (FBP), and/or 5
mM ADP (ADP) was revealed by immunoblot assays using antibody against Y705
phosphorylated stat3 (IB:pY-stat3). Immunoblot analyses using antibody against stat3
(IB:Stat3) indicates the amounts of GST-stat3 used in each phosphorylation reaction. (D)
Pyruvate kinase activity of the rPKM2 or R399E mutant (5 μg/ml) was analyzed by the
method described by Christofk and co-workers. The pyruvate kinase activity was
expressed as relative pyruvate kinase activity by define the activity in the rPKM2 as 100.
The error bars represent the standard deviations of four measurements.
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Figure 3.3 Tyrosine Phosphor-peptide Converts Tetramer PKM2 to a Dimer and
Activates Protein Kinase Activity
(A) Size exclusion chromatography fractionation of the wild-type rPKM2 in the presence
of different peptides (3 μM) D-phosPepY593 (lower panel), PepY593 (upper panel), and
phosPepY567 (middle panel). The rPKM2 100 μl in 1.5 μM were loaded onto column.
The chromatography fractions F10 – F18 were collected using a FPLC at 300 μl per
fraction. The collected fractions were immunoblotted using the antibody PabPKM2
(IB:PKM2). (B) Phosphorylation of GST-stat3 by the rPKM2 (10 μg/ml) and the R399E
mutant (10 μg/ml) in the presence of different peptides (3 μM) D-PhosPepY593,
PepY593, and PhosPepY567 was revealed by immunoblot assays using antibody against
Y705 phosphorylated stat3 (IB:pY-stat3). (C) Phosphorylation of GST-stat3 by the
rPKM2 (10 μg/ml) or the rPKM1 (10 μg/ml) in the presence of HA-p68 that was
immunopurified from nuclear extracts of T98G cells and 5 mM of PEP was revealed by
immunoblot assays using antibody against Y705 phosphorylated stat3 (IB:pY-stat3). In
some phosphorylation reactions, 5 mM of FBP (FBP) or 5 mM ADP (ADP) was added to
the reaction. Immunoblots of stat3 (IB:Stat3), HA-p68 (IB:HA), and PKM2 (IB:PKM2)
indicate the amounts of GST-stat3, HA-p68, and the rPKM2 used in each
phosphorylation reaction. (D) Pyruvate kinase activity of the rPKM2 (5 μg/ml) in the
presence of different peptides (2 μM) D-PhosPepY593, PepY593, PhosPepY567, or
buffer was analyzed by the method described by Christofk and co-workers. The pyruvate
kinase activity of the rPKM2 was expressed as relative pyruvate kinase activity by define
the activity in the presence of Buffer as 100. The error bars represent the standard
deviations of four measurements. (E) Interaction of GST-stat3 and R399E mutant in the
presence of FBP (5 mM), PEP (5 mM), or various concentrations of ADP (10, 100, 1000
and 5000 μM) was analyzed by GST-pull-down using the glutathione beads. The coprecipitation of R399E with GST-stat3 was detected by immunoblot using the antibody
against PKM2 (IB:PKM2). Immunoblots of precipitates using antibody against stat3
(IB:Stat3) indicate the amounts of GST-stat3 that was pulled-down by the glutathione
beads. (F) Interaction of GST-stat3, the bacterially expressed rPKM2, and the HAp68
immunopurified from T98G cells was analyzed by GST-pull-down using the glutathione
beads. The GST-stat3 (2 μg/ml), the rPKM2 (2 μg/ml), and the HA-p68 were incubated
in 500 μl at room temperature. The GST-stat3 was precipitated by the GST beads. Coprecipitations of the HA-p68 and the rPKM2 from the mixture were analyzed by
immunoblot using antibodies against p68 (IB:p68) and PKM2 (IB:PKM2). The strip blot
using anti-phosphor-tyrosine indicates the tyrosine phosphorylation of the precipitated
HA-p68. Immunoblot of stat3 (IB:Stat3) indicates the amounts of GST-stat3 that were
precipitated by GST beads.
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Fig 3.4 The R399E Mutant Phosphorylates Stat3 in Cells and Expression of the Mutant
Promotes Cell Proliferation
(A) Phosphorylation of stat3 in SW480 cells was examined by immunoblot analyses of
the nuclear extracts (NE) using antibody against the Y705 phosphorylated stat3 (IB:pYStat3). PKM2 wild-type (HAPK) or the R399E (R399E) mutant was expressed in the
cells by transient transfection. Immunoblots using anti-HA antibody (IB:HA) and antistat3 antibody (IB:Stat3) in the nuclear extracts and whole cell lysate (WCL) indicate the
levels of stat3 and HA-PKM2/HAR399E in the nuclear extracts and whole cell lysate.
(B) Phosphorylation of GST-stat3 by the HA-p68 and the HA-R399E mutant that were
immunopurified from cell lysate of SW480 cells in the presence of 5 mM of PEP was
revealed by immunoblot analyses using antibody against the Y705 phosphorylated stat3
(IB:pY-Stat3). The phosphorylation reactions were also carried out in the
presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The immunoblot of
HA (IB:HA) indicates the amounts of HA-PKM2 or HA-R399E used in each reaction.
IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of
antibody used in immunopurification of the HA-PKM2 or the HA-R399E mutant from
the extracts. (C) Expression of MEK5 mRNA in SW480 cells was analyzed by RT-PCR
HA-PKM2 (HAPK) or HA-R399E (R399E) was exogenously expressed in the cells. The
results are presented as fold changes in PCR products before and 48 hours after HAPKM2 or HA-R399E expression. (D) Cell proliferations of SW480 cells were measured
using the cell proliferation kit. Cell proliferations were presented as fold changes in BrdU
incorporation before and 48 hours after HA-PKM2 (HAPK) or HA-R399E (R399E)
expression. The BrdU incorporation of the cells that were transfected with the empty
vector (Vec) was defined as 1. Error bars in (C) and (D) are standard deviations of three
independent measurements. Vec in (A), (B), (C), and (D) are the cells transfected with
the empty vector.
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Fig 3.5 Growth Factor Stimulation Leads to Tetramer to Dimer Conversion of PKM2
(A) Size exclusion chromatography fractionation of cell lysate prepared from SW480
cells that were treated/untreated by 25 ng/ml EGF for 8 hours. The cell lysate (100 μl)
were loaded onto the column. The chromatography fractions F9 – F20 were collected
using a FPLC at 300 μl per fraction. The collected fractions were immunoblotted using
the antibody against PKM2 (IB:PKM2). (B) The PKM2 levels in the nuclear extracts
(NE) of SW480 cells that were treated with EGF (25 ng/ml) at different time points
(indicated) were examined by immunoblot of the nuclear extracts using antibody against
PKM2 (IB:PKM2). Immunoblot analyses of PKM2 (IB:PKM2) in the whole cell lysate
(WCL) indicate the cellular levels of PKM2. Immunoblot of β-actin (IB:β-actin) and
lamin A/C (IB:Lamin A/C) were the loading controls. (C) Tyrosine phosphorylation of
p68 in the in the nuclear extracts (NE) of SW480 cells that were treated with EGF (25
ng/ml) at different time points (indicated) were examined by immunoblot analyses of p68
that was immunoprecipitated (IP:68) from the extracts using the anti-phosphor-tyrosine
antibody (IB:pY20). Immunoblot analyses of p68 (IB:p68) in the whole cell lysate
(WCL) indicate the cellular levels of PKM2. Immunoblot of β-actin (IB:β-actin) was the
loading control. (D) A hypothetic model that illustrates the functions of PKM2 in the
glycolysis and gene expression, and the regulation between protein kinase or pyruvate
kinase active of the protein.

152

153

Figure 3.6 Nuclear PKM2 is a Dimeric Form
(A) Chromatographic elution profile of the molecular weight calibration kit proteins
(indicated) on the Superdex 200 10/300GL column. The x-axis is the elution volume. The
y-axis is the absorbance of the elution at 280 nm. (B) The standard curve of elution of the
molecular weight calibration kit proteins on the Superdex 200 10/300GL column. The
elution volumes were plotted against LogMW. (C) Immunoblot analyses of PKM2 in the
cytoplasmic (Cyto) and nuclear (NE) extracts of SW620 cells. The extracts (6 µl) were
treated (as described in methods) and loaded on an 8% non-denaturing gel
electrophoresis. The gel was subjected to immunoblot using the antibody PabPKM2
(IB:PKM2). The molecular weight markers, BSA (dimer) and Urease (trimer), were
loaded on the same gel and were visualized by ponceau S staining (ponceau S stain). (D)
Phosphorylation of GST-stat3 by the rPKM2 (10 µg/ml), the rPKM1 (10 µg/ml), or the
R399E mutant (10 µg/ml) in the presence of 32P-PEP (~0.002 µCi) and unlabeled PEP (5
mM). The reaction mixture were separated by 10 SDS-PAGE and subjected to
autoradiograph
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Figure 3.7 Tyrosine-phosphorylated p68 RNA Helicase Interacts with PKM2 both in
vivo and in vitro
(A) (Left panel) GelCode staining SDS-PAGE analyses of proteins pulled down from
nuclear extracts of T98G cells by different peptides coupled to agarose beads. The
peptides used are: Non-p is the peptide PepY593, Y593-p is the peptide PhosPepY593,
Y593/595-p is the peptide D-PhosPepY593, and Y567-p is the peptide PhosPepY567.
The arrow indicates the protein band that was cut out and subjected to trypsin digestion
followed by MALDI-tof/tof analyses. M is molecular weight markers. (Right panel) The
amino acid sequence of PKM2. The bold and underlined sequence indicates the peptide
fragments identified by MALDI-tof/tof. (B) Interaction of the peptides Non-p and
Y593/595-p with recombinant PKM2 (rPKM2). The recombinant PKM2 pull-downs
(PD) by the peptides were examined by immunoblot using antibody against PKM2
(IB:PKM2). Beads are the control pull-down using agarose beads alone. (C) Pull-down
(PD) of p68 from nuclear extracts (NE) of T98G cells by recombinant PKM2 (rPKM2)
was examined by immunoblot using antibody p68-RGG (IB:p68-RGG). The tyrosine
phosphorylation of p68 was indicated by strip-blot of the pull-down using antibody
against phospho-tyrosine (IB:PY20). Beads is the control pull-down using agarose beads
alone. (D) (Left panel) Co-immunoprecipitations of p68 with exogenously expressed HAPKM2 from nuclear (NE) and cytoplasmic (Cyto) extracts of T98G cells were examined
by immunoblot with antibody p68-RGG (IP:HA, IB:p68-RGG). IBs of HA-PKM2
indicate the immunoprecipitateded HA-PKM2 from the extracts. (Right panel) Coimmunoprecipitations of p68 with endogenous PKM2 from nuclear (NE) and cytoplasmic
(Cyto) extracts of T98G cells were examined by immunoblot with antibody p68-RGG
(IP:PKM2, IB:p68-RGG). IBs of GAPDH (IB:GAPDH) and lamin A/C (IB:Lamin A/C)
are the loading controls. (E) Co-immunoprecipitations of exogenously expressed HAp68s (WT and Y593F, Vec is vector alone) with endogenous PKM2 from nuclear
extracts (NE) of T98G cells were examined by immunoblot with anti-HA (IP:PKM2,
IB:HA). IBs of the nuclear extracts using anti-HA indicate the expression of HA-p68
(IB:HA). IBs of histone 2A (IB:H2A) are the loading controls.
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Figure 3.8 p68 RNA Helicase Interacts with PKM2 at Its FBP Binding Site
(A) Trp fluorescence emission spectrum of the rPKM2 (4 µM) with the titration of
various different concentrations (indicated) of peptide D-PhosPepY593. Binding of the
peptide to the rPKM2 was indicated by the decrease in fluorescence intensity at 334 nm.
(B) Trp fluorescence emission intensity of the rPKM2 at 334 nm in the presence of
various peptides (2 µM) D-PhosPepY593 (red circles), PepY593 (blue crosses),
PhosPepY567 (green diamonds), and D-PhosPepY593 + 2 mM FBP (black squares). Yaxis is the flurescence intensity at 334 nm. X-axis is peptide concentrations. (C) The
dissociation constant (Kd) of the rPKM2 with the peptides D-PhosPepY593, PepY593,
and PhosPepY567 were determined by the data fitting to langmuir equation (assume 1:1
binding). The Kds were determined based on data fitting on three independent
measurements. (D) Co-immunoprecipitation of p68 (IP:p68) with exogenously expressed
HA-PKM2 in cellular extracts of T98G cells supplementary with various concentrations
of FBP was examined by immunoblot using the anti-HA antibody (IB:HA). IgG HC is
the ponceau S stain of antibody heavy chain, representing the amounts of antibody used
in immunopurification of p68. (E) Pull-down of the rPKM2 by the HA-p68
immunopurified from T98G cellular extracts (PD:HA-p68) was analyzed by immunoblot
using antibody against PKM2 (IB:PKM2). The Pull-down experiments were performed
in the presence of various concentrations of FBP (indicated in figure). IgG HC is the
ponceau S stain of antibody heavy chain, representing the amounts of antibody used in
immunopurification of HA-p68. IB:p68 indicate amounts of HA-p68 used in the pulldown. (F) Co-immunoprecipitation of p68 with the exogenously expressed HA-PKM2
and mutants (indicated) in the cellular extracts prepared from T98G cells. In (upper
panel), the antibody p68-RGG was used as immunoprecipitation antibody (IP:p68). Coimmunoprecipitations of HA-PKM2 and mutants with p68 were examined by
immunoblot using antibody against PKM2. Immunoblot of p68 (IB:p68) indicated
amounts of p68 that was immunoprecipitaed down. In (lower panel), the anti-HA
antibody was used as immunoprecipitation antibody (IP:HA). Co-immunoprecipitations
of p68 with HA-PKM2 and mutants were examined by immunoblot using antibody
against p68 (IB:p68). IgG HC is the ponceau S stain of antibody heavy chain,
representing the amounts of antibody used in immunoprecipitations.
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Figure 3.9 PKM2, Stat3 and p68 Forms a Protein Complex
(A) Co-immunoprecipitations of PKM2 and stat3 with HA-p68 in the cellular extracts of
T98G cells. The exogenously expressed HA-p68 was immunoprecipitated using anti-HA
antibody. The amounts of p68 precipitated from the extracts were examined by
immunoblot using antibody against p68. The co-precipitation of PKM2 and stat3 were
probed by immunblot using antibodies against PKM2 (IB:PKM2) and against stat3
(IB:Stat3). IgG HC is the ponceau S stain of antibody heavy chain, representing the
amounts of antibody used in immunoprecipitation of HA-p68 from the extracts. (B) Size
exclusion chromatography fractionation of the wild-type HA-PKM2 (wtPKM2) or HAR399E (R399E) that were immunopurified from SW480 cell lysate. The HA-PKM2 or
HA-R399E (100 µl in 0.4 µg/µl) was loaded onto the column. The chromatography
fractions F9 – F18 were collected using a FPLC at 300 µl per fraction. The collected
fractions were immunoblotted using the anti-HA antibody (IB:HA).
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CHAPTER 4: NUCLEAR PKM2 REGULATES CDC14A EXPRESSION TO
INDUCE MULTINUCLEUS

4.1 Abstract
The mammalian cell cycle is tightly regulated by multiple protein kinases and their
phosphorylation substrates. Exit from anaphase is controlled by anaphase promoting
complexes (APC). Cdc14A is a key regulator for cell to exit from anaphase.
Overexpression of Cdc14A induces formation of multi-nuclei in cancer cells. The
regulatory mechanism governoning the gene Cdc14A transcription is not well defined,
yet. We demonstrated here that PKM2 and p68 RNA helicase co-regulated the
transcription of Cdc14A gene in less aggressive cancer cells, such as SW480, T98G and
LN686. Chromatin immunoprecipitation analysis indicated that the nuclear PKM2 and
p68 RNA helicase associated with the Cdc14A promoter. Expression nuclear localization
of PKM2 induced formation of multi-nuclei cells. Our experiments suggested that
regulation of Cdc14A may mediate the effects of PKM2 expression on the inducation of
multi-nuclei cells.

4.2 Introduction
In Saccharomyces cerevisiae, exit from mitosis is regulated by a cascade of signals
named Cdc Fourteen Early Anaphase Release (FEAR) and Mitosis Exit Network (MEN)
(Jensen and Johnston 2002; Bowerman 2004). In anaphase, Cdc14, is induced to export
from the nucleolus into the cytoplasm (Bowerman 2004). Cdc14, a serine/tyrosine
phosphatase, dephosphorylates and inactivates cyclin B–dependent kinase (Cdk), which
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allows the exit from mitosis to continue into a new G1 phase (Bembenek and Yu 2003;
de Bettignies and Johnston 2003; Kipreos 2004; Toth, Queralt et al. 2007). In budding
yeast, Cdc14 is located in the nucleolus during interphase and is blocked by inhibitors
Cfi1/Net1 until metaphase and released into the cytosol in late anaphase (Pereira,
Manson et al. 2002; Buonomo, Rabitsch et al. 2003; Bloom and Cross 2007).
In mammalian cells, Cdc14 has two orthologs: Cdc14A and Cdc14B, encodedg by
two distinct genes. Cdc14A and Cdc14B have distinct cellular localizations during
different stages of the cell cycle. The cellular localization of Cdc14A depends on cell
cycle progression. The protein resides in the centrosome during interphase while Cdc14B
locates in the nucleolus. During the process of mitosis, Cdc14A is released into the
cytoplasm. As an important physiological regulator for cell cycle processes, expression
of either Cdc14A or Cdc14B affects genomic stability (Mailand, Lukas et al. 2002).
Studies show that Cdc14A overexpression induces the formation of multi-nuclei in
mammalian cells by disrupting the process of separation of centrosomes, as well as
blocking cytokinesis (Mailand, Lukas et al. 2002). Meanwhile, the depletion of Cdc14B
in mammalian cells results in amplification of centrioles (Wu, Cho et al. 2008). Although
the biological functions of Cdc14A have been well studied, so far, the molecular
mechanism that governs Cdc14A transcription is not well defined.
Pyruvate kinase is an enzyme acting in the glycolysis process. There are four
isoforms of pyruvate kinases in mammals: type L, R, M1 and M2. L and R types are
generated from one gene with different transcriptional start sites. During tumorigenesis
M1 type expression is replaced by M2 type. The replacement of M1 type by M2 type
changes the glycolysis rate to produce more phosphoryl intermediates for cell
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proliferation. Besides its well-known glycolytic function in the cytosol, little is known for
its function in the nucleus. Under the stimulation of interleukin 3 (IL-3), more PKM2
localizes the nucleus to regulate cell proliferation in the IL-3-dependent hematopoietic
cell line, Ba/F3 (Hoshino, Hirst et al. 2007). It is reported that PKM2 interacts with Oct4, an important transcription factor for regulating the pluripotence of embryonic stem
cells (Lee, Kim et al. 2008). Interestingly, the N-terminal (a.a.1–348) of PKM2, interacts
together with the SUMO-E3 ligase PIAS3 (inhibitor of activated STAT3) in the nucleus
of cell of many cell lines, such as NIH3T3 and U-2 OS (Spoden, Morandell et al. 2009).
A, Somatosatin, anti-cancer analogue TT-232 interacts with pyruvate kinase in cos-7
cells. The interaction induces nuclear accumulation of PKM2 from the cytosol to trigger
caspase-independent apoptosis (Stetak, Veress et al. 2007). PKM2 also plays a role in
regulating virus replication. PKM2 interacts with NS5B, the Hepatitis C virus (HCV)
RNA-dependent RNA polymerase, in the HCV replicon 9B cells (Wu, Zhou et al. 2008).
The downregulation of PKM2 by shRNA in n HCV replicon 9B cells reduces the
replication of HCV (Wu, Zhou et al. 2008).
P68 RNA helicase belongs to the DEAD-box family of RNA helicase and has
multiple physiological functions in diverse cellular processes, such as cell proliferation,
epithelial-mesenchymal transition (EMT) and pre-mRNA splicing. Evidences show that
p68 RNA helicase plays an important role in regulating gene transcription by interacting
with a number of transcription factors as a co-activator (Warner, Bhattacherjee et al.
2004; Fuller-Pace, Jacobs et al. 2007). P68 interacts with p53 at the C-terminal region of
p53 to regulate p53 targeted genes, such as p21, Fas, PIG3 and mdm2 (Bates, Nicol et al.
2005). P68 RNA helicase is reported to be recruited to the pS2 gene promoter, a
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downstream target of estrogen receptor alpha (ERα), to regulate pS2 transcription
(Watanabe, Yanagisawa et al. 2001). Neither the ATPase activity nor the RNA helicase
activity of p68 is required for the function. P68 also interacts with CBP in the C-terminal
of CBP to enhance CBP-mediated transcription (Rossow and Janknecht 2003). P68 RNA
helicase interacts with Smad3 at the MH2 domains, to form an active transcription
regulator complex (Warner, Bhattacherjee et al. 2004). Recently, it was reported that p68
RNA helicase interacts with the androgen receptor (AR) in the nucleus and regulate gene
transcription as a co-activator for androgen-dependent and androgen-independent gene
expression in malignant prostate cancer cells (Clark, Coulson et al. 2008).
In prsent study, we demonstrated that nuclear PKM2 and p68 RNA helicase
induced the formation of multi-nuclei by upregulating Cdc14A expression in cancer cells.
Nuclear PKM2 and p68 interacted with the promoter region of Cdc14A to regulate its
transcription.

4.3 Results
4.3.1 Exogenous Overexpression of PKM2 and p68 RNA Helicase Induces Multinuclei in Cancer Cells
To understand functions of PKM2 in the cell cycle, we analyzed the morphology
changes in SW480 cells overexpressing HA-PKM2. Staining nuclear DNA revealed the
formation of multinuclei in SW480 cell expressing HA-PKM2 (Fig1A). Statistical
analysis indicated that 34% of transfected cells had non-identical double nuclei. 9% of
transfected cells had triple nuclei, and 4% of transfected cells showed more than triple
nuclei (Fig1B). Very similar phenomenon was also observed with T98G, U87MG and
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HEK cells where HA-PKM2 was overexpressed. The results suggested that formation of
multi-nucleus by exogenous PKM2 overexpression is a common phenomenon in
mammalian cells.
It was reported that Cdc14A overexpression in U-2-OS human osteosarcoma cells
induces formation of multi-nucleus due to interfering centrosome separation (Mailand,
Lukas et al. 2002). To identify genes that are subject to PKM2 regulation, we carried out
expression analyses. PKM2 was expressed in SW480 cells. The RNA profile was
examined via Affimetrix human 2.0 microarray. The array analyses revealed that Cdc14A
mRNA level was increased to 4 folds in SW480 cell upon expressing PKM2, which
indicated a possible transcriptional regulation of Cdc14A by PKM2 in SW480 cells.
Thus, we hypothesized that PKM2 regulates Cdc14A expression in SW480 cells and
consequently induce the formation of multiple nuclei. To test this hypothesis, the
expression level of Cdc14A was examined in SW480 cells with epitoptic PKM2
expression. The Cdc14A expression level was increased more than 4 folds (Fig 2A).
Meanwhile, mRNA level of Cdc14A was also examined via RT-PCR. The RT-PCR
primers were designed according to Cdc14A pre-mRNA sequence as extended from exon
11 to exons 13-14 interrupted by intron 13-14. It was clear that 3.2 folds increase in
Cdc14A mRNA in SW480 cells in which PKM2 was overexpressed (Fig 3B). To verify
whether PKM2 overexpression induces multiple nuclei, SW480 cells overexpressing
PKM2 were stained with the Lamin B1 antibody. It was clear that PKM2 overexpression
induced multiple nuclei in SW480 cells (Fig2 B).
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4.3.2 Nuclear PKM2 Regulates the Expression of Cdc14A
PKM2 is an enzyme acting in the glycolysis. The protein is highly expressed and
mainly localizes in the cytosol to catalyze ATP production. To investigate whether the
regulatory function of PKM2 in controlling Cdc14A expression was by cytoplasmic
PKM2 or a nuclear protein, we constructed a mutant PKM2 with addition of nuclear
localization signals (NLS) at C- and N- terminal ends. Western blot results showed that
over 95% NLS-PKM2 localized in the nucleus. The analyses function of NLS-PKM2 in
regulating Cdc14A expression was examined in SW480 cells. Western blot analyses
showed that Cdc14A levels were increased when NLS-PKM2 was expressed in SW480
cells (Fig3A). Immunofluorescence stainging results showed that NLS-PKM2 induced
formation of mutli-nucleus in SW480 cells

4.3.3 PKM2 and p68 RNA Helicase Co-regulate Cdc14A Protein Expression
Our previous study showed that PKM2 interacts with p68 RNA helicase both in the
cytosol and nucleus. p68 RNA helicase is a transcription co-activator (Warner,
Bhattacherjee et al. 2004; Bates, Nicol et al. 2005). We questioned whether p68 RNA
helicase also plays a role in regulating Cdc14A expression. To this end, p68 RNA
helicase was overexpressed in SW480 cells and the Cdc14A expression levels was
examined by immnoblot using a commercially avaible Cdc14A antibody. The results
showed that Cdc14A expression level was up-regulated upon the overexpression of p68
RNA helicase (Fig2A). RT-PCR analyses showed that Cdc14A mRNA was upregulated
2.3 folds when p68 RNA helicase was expressed in SW480 cells. Meanwhile, the mRNA
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level increased 3.8 folds when exogenous NLS-PKM2 was overexpressed in SW480
cells. Cdc14A mRNA level was also upregulated to 2.5 folds when HA-PKM2 was
overexpressed (Fig3B).
It is believed that the transcription regulation of p68 RNA heliase does not depend
on its ATPase activity (Yang, Lin et al. 2007). To investigate whether the function of p68
RNA helicase in regulating Cdc14A transcription is dependent on its ATPase activity, a
p68 mutant (RGLD), which lacks of ATPase activity, was overexpressed in SW480 cells.
Western-blot analyses showed that the p68 mutant and wild type have very similar effect
in regulating Cdc14A expression (Fig4a). The result indicated that the function of p68
RNA helicase in regulating Cdc14A most likely was ATPase independent.
In our previous study, we showed that PKM2 and p68 RNA helicase interact with
each other. However, we speculated that the regulatory function of p68 RNA helicase and
PKM2 in Cdc14A are inter-related. To test this conjecture, p68 was knocked down via
the RNAi and PKM2 was expressed in p68 knockdown cells. As controls, wild-type p68
and the Y593F mutant were also expressed in the p68 knockdown cells. It was clear that
the function of PKM2 in regulating Cdc14A expression was abolished if p68 RNA
helicase was knocked down (Fig4b). To further verify that p68 RNA helicase was
required for regulating Cdc14A by nuclear PKM2, NLS-PKM2 was introduced in p68
knocked down cells. Consistently, Cdc14A expression level was not affected by the
overexpression of cytosolic and nuclear PKM2 (Fig4c). On the other hand, the
requiremtn of PKM2 for p68 RNA helicase in regulating Cdc14A expression was tested.
PKM2 was knocked down by RNAi in SW480 cells and wild type p68 RNA helicase
were introduced into the p68 knocked down cells. The experiments showed that the
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function of p68 RNA helicase in regulating Cdc14A transcription was almost abolished
(Fig4d). Taken together, our results showed that the p68 and nuclear PKM2 co-regulate
Cdc14A transcription.

4.3.4 PKM2 and p68 RNA Helicase Bind to Cdc14A Promoter Region
PKM2 and p68 RNA helicase co-regulated the transcription of Cdc14A gene. It is
reported that p68 RNA helicase is a gene transcriptional co-activator (Bates, Nicol et al.
2005). In our previous report, nuclear PKM2 associated with the promoter region of
MEK gene to regulate its transcription. To investigate transcriptional role of PKM2 in
cancer cells, the ChIP-on-chip experiments were carried out to examine the interaction of
PKM2 with promoter. The ChIP-on-chip data showed that PKM2 was associated with the
Cdc14A promoter. ChIP-on-chip analyses using antibody against p68 also showed that
p68 RNA helicase associated with the same promoter region of Cdc14A promoter. The
Chip-on-Chip analyses suggested a possibility that nuclear PKM2 and p68 RNA helicase
bind to the same promoter region of Cdc14A gene to regulate its transcription. To
confirm the Chip-on-chip analyses, chromatin immunoprecipitation experiment was
carried out. Primers were designed according to Chip-on-chip analyses. Chip analyses
showed that p68 RNA helicase and nuclear PKM2 indeed interacted with Cdc14A
promoter at the same region (Fig5).

4.3.5 Cdc14A Mediates the Effect of PKM2 in Induction of Formation of
Multinuclei
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To further investigate whether Cdc14A is the target mediating the effects of PKM2
in induction of multinucleus, PKM2 was knocked down in SW480 cells using
SMARTpool RNAi and the expression level of Cdc14A was then examined. The
expression of Cdc14A in both protein and mRNA levels were decreased around 3 folds
when PKM2 was knocked down (Fig 6 c, d). Immunostaining experiments were carried
out to examine the multinuclei in PKM2 knocked down cells. The cell numbers with
multi-nuclei was decreased 2 folds when PKM2 was knocked down in SW480 cells (Fig
6E).

4.3.6 PKM2 Overexpression Induces formation of Multi-nucleus Only in Less
Aggressive Cancer Cells
The effects of PKM2 on induction the formation of multi-nuclei were different
from cell line to cell line. We suspected the expression of Cdc14A in different cancer cell
line were different. Thus, Cdc14A expression level in 13 cancer cell lines were examined
including LN686, M4C1, SW480, SW620, WM115, WM266, H146, H460, T98G,
U87MG, HeLa and HEK cells. Expression of Cdc14A in T98G, U87MG, SW480, HEK
cells was clearly evident. The expression of Cdc14A in other cell lines, such as SW620,
HeLa, WM115 and WM266 could not be detected (Fig 7). To examine whether
expression of PKM2 induces formation of multi-nucleus in these cell lines, the cells
expression of PKM2 were stained with antibody against γ-tubulin 48 hours after PKM2
overexpression. The formation of multi-nucleus was not observed with WM115,
WM266, HeLa and SW620 cells (data not shown). The formation of multi-nuclei clearly
correlated with Cdc14A expression in testing cancer cells. Furthermore, expression of
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Cdc14A was examined in SW620 cells where the epitogic PKM2 was expressed.
Western blot analyses showed that Cdc14A expression level was not increased, even
when PKM2 reintroduced in SW620 cells. Consequently, immunofluorescence staining
did not show the formation of multi-nucleus in SW620 cells in which epitomic PKM2 or
p68 RNA helicase were expressed (Fig7C right panel). All these data indicated that
PKM2 regulated Cdc14A expression results in formation of multi-nucleus.

4.4 Discussion
The glycolysis is an important metabolic pathway which provides energy as well as
phosphor intermediates for macromolecules synthesis in cancer cells. Many glycolytic
enzymes have cellular functions other than glycolysis. Oxidative stress induces
cytoplasmic

Glyceraldehyde-3-phosphate

dehydrogenase

(GAPDH)

nuclear

translocation. Nuclear GAPDH induces ATG12 expression lead to resist to caspaseindependent cell death (Colell, Ricci et al. 2007). Studies from ours and other
demonstrated that, PKM2, translocate to the nucleus of cancer cells. PKM2 translocate
into the nucleus under the stimulation of Interleukin-3 in BB13 cells and nuclear PKM2
promotes Ba/F3 cells proliferation (Hoshino, Hirst et al. 2007) . Contrary, Stetak et al
reported that nuclear PKM2 may induce apoptosis in Cos-7 cells by a caspase
independent pathway (Stetak, Veress et al. 2007). In our study, nuclear PKM2 regulates
Cdc14A expression to induce the formation of multi-nuclei in less proliferation cancer
cells. The different functions of nuclear PKM2 may be due to the difference of cell types.
Cdc14A was identified as a downstream target of PKM2 for multi-nuclei cells. The
localization of PKM2 in the nucleus may inhibit the action of PKM2 in induction of
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centrosome separation. The centrosome is the microtubule organization center, which
regulates the formation of bipolar spindle during mitosis (Khmelinskii and Scheibel
2008). Abnormal regulation of the centrosome separation may lead to aneuoploidy.
Centrosomes duplicate in S phase and the number is tightly controlled in normal
mammalian cells. Recently, studies showed that Cdc14B knockdown induces the
amplification of centrosomes (Wu, Cho et al. 2008). Meanwhile, centrosome separation
is critical for cells to maintain chromosome numbers. One possibility is the
overexpression of Cdc14A may deregulate the dephsophorylation of Cdh1, which cause
the malfunction of APC complex resulting in aneuploidy in the tumor cells.
The background level of multi-nucleus cells for SW480 is around 5±2%. As shown
in Fig7A, The multi-nucleus caused by Cdc14A overexpression was not completely
abolished by Cdc14A knocked down. This is probably due to incomplete knocked down.
Alternatively, additional mechanism contributes to the formation of multinucleus cells. In
this study, 11 cell lines were screened for the expression of Cdc14A. The expression
levels of Cdc14A vary in different cell lines. However, there is a clear correlation
between the expression levels of Cdc14A with the formation of multinuclei in less
proliferation cancer cell lines. The multinuclei cells may undergo apoptosis. This
indicated the distinct functions of nuclear PKM2 in different cancer cells. That is, in
more proliferating cancer cells, expression of PKM2 in the nucleus promotes cell
proliferation via regulating MEK5 gene transcription (Gao et al, Oncogene, revised,
2009). In less proliferating cancer cells, expression of PKM2 in the nucleus may lead to
cell apoptosis by regulating Cdc14A gene transcription to form multinuclei.
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4.5 Materials and Methods
4.5.1 Plasmids Construction, Reagents and Antibodies
cDNA of PKM2 and PKM1 were purchased from OriGene Technologies. The
cDNA of PKM2 was cloned into bacteria expression vector pET30a and mammalian
expression vectors pHM6, PC3.1 et al. The primers and empty pET30a vector were
digested with EcoR1 and Not1 two enzymes. The digestion products were purified with
mini kit from QIAGENE and ligated with ligase enzyme. The HA-tagged full length of
p68 (wild p68, Y593F, Y595F, and LGLD) expression plasmids were constructed in
pHM6 vectors as indicated in the previous papers from our laboratory. Mutations in
pHM6 vector were obtained via multisites mutation method (QuikChange® Multi SiteDirected Mutagenesis Kit, Stratagene). Cdc14A, γ-tubulin, Lamin A/C, GAPDH and βactin antibodies were purchased from Abcam and Cellsignal.

4.5.2 Cell culture, Transient Transfection Assays
SW480, SW620, T98G, HeLa, U87MG, H146, H460 Cell lines were purchased
from ATCC and cultured by following the vendor’s instructions. Cells were transiently
transfected using Fugene-HD reagent (Roche) according to the manufacture’s instruction.
Briefly, 2ug of the plasmid was combined with 5ul of the HD reagent in 100ul of
optimum medium, the mixture was added to the wells after 20 minutes incubation. For
fluroscent immunostainning experiments, cells were seeded into chambers 24 hours
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before transfection. For IP or western-blot experiments, cells were harversted 48 hours
after transfection.

4.5.3 Relative Real Time PCR (RT-PCR)
Total RNA was extracted from cells under appropriate treatments using RNeasy kit
by following the manufacturer’s instruction (Qiagen). Reverse transcription process was
performed with ImProm-II reverse transcription system (Promega). RT-PCRs were
performed with 1 µg of cDNA and Fast SYBR green master mix (Applied biosystems).
RT-PCR process was performed in Applied Biosystems Real-Time PCR 7500. Standard
RT-PCR primer set was purchased from RealTimePrimers.com. RT-PCR primers was
designed as 5’-CCTAGATGATATGTCTATTGGTGG-3’
5’-TGAACTTAATCTGAAAGGCTGG-3’

4.5.4 Chromatin Immunoprecipitation
Chromatin immunoprecipitation method was performed as we describe before
(Yang et al, Cell, 2006). Generally, for one T-150 flask of SW620 cells, cells was fixed
with 1% formaldehyde solution by incubating 10min in 37°C and stopped with 125mM
glycine. The fixed cells were washed with cold PBS supplemented with protease
inhibitors three times and lysated in 1ml SDS lysis buffer (Imgenex) with protease
inhibitors. The cell lysate was sonicated on ice 2 min and centrifuged at 15,000 rpm to
pellet insoluble material. The shearing performance was examined with 1% TAE agarose
gel. The supernatant was aliquot and pre-cleared with 100ul salmon sperm DNA/protein
G agarose by incubating for 2 hours. The antibody was added to the clear supernatant and
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rotated at 4°C overnight. 100 ul of salmon sperm DNA/protein G agarose was added to
each tube and rotated for 2 hours. The immuno-complex was eluted with elution buffer
(Imgenex) after extensive washing 8 times. The cross-link was reversed by adding 4ul of
5M NaCl and incubating at 65°C overnight. The released DNA was purified using the
phenol chloroform extraction method. Regular PCR was performed in Mastercycle®
Gradient PCR machine (Eppendorf) and the result was analyzed with 2% agarose.

4.5.5 RNA Interference
The duplex RNA oligonucleotides of SMARTpool for PKM2 and Cdc14A were
purchased from Dharmocon. The RNA interference method was performed as described
below. Briefly, cells were grown to 30-50% confluence and transfected with siRNA (150
pmole) using lipo2000 transfection agent. 24 hours later, mutants were transfected using
FuGene HD following the manufacturer’s instrument. For transient expression of WT
p68 or mutants in p68 knockdown cells, the cells were harvested with an additional 48
hours after knockdown.

4.5.6 Subcellular Extracts Preparation, Co-immunoprecipitation and Western blot
Whole cell lysate, nuclear extract, cytoplasm were made fresh. Briefly, for whole
cell lysate, cells with appropriate treatments were harvested and lysated in RIPA buffer
supplemented with complete proteases inhibitors. Co-IP experiments were performed in
RIPA buffer supplemented with complete proteases inhibitors as well as phosphatase
inhibitors (1mMSoV, 5mMNaF). Whole cell lysate or subcellular extracts were diluted
with RIPA buffer and incubated with appropriate primary antibody overnight at 4 . The
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next day, 30ul of protein G agarose bead slurry was added into reaction tube and was
rotated for 2h at 4°C. The immuno-complexs were harvested with centrifuging at 800
rpm for 10min. The immuno-complex samples were washed with 600 µl of NETS buffer
(150 mM NaCl, 50 mM tris-HCl [pH 7.5], 5 mM EDTA, 0.05% NP-40) five times and
were denatured with SDS-PAGE loading buffer by incubating at 95°C for 8 mins. The
immuno-complexes were separated in SDS-PAGE and transferred to nitrocellular
membranes. Appropriate primary antibodys were incubated with the membranes
overnight at 4°C. After washing with TBST buffer three times, secondary antibody was
incubated with the membranes for additional 2 hours at room temperature. The blotting
signals were detected with SuperSignal West Dura Extended Duration Substrate (Pierce).

4.5.7 Immunostaining and Multinucleated Cells Analysis
SW480, SW620, T98G, HeLa cells were seeded in 6 cell plates to 30% density. 24
hours later cells were fixed with cold methanol for 15 min at -20°C. The cells were
washed with PBS 3 times and peameablized with 1%Trixon-X for 20 min. The cells were
blocked with 2.5% BSA (in PBS) for 30min at room temperature. The cells were
incubated with γ-tubulin or HA-flurescent primary antibody with appropriate dilutions
overnight at room tempature. The next day, the cells were washed with PBS three times
and secondary Goat anti-Rabbit antibody was incubated with cells for additional two
hours. For multinucleated cell analysis, DAPI (1mg/ml) was applied to stain transfected
cells and examined with Confocal microscope. 150 cells were counted from each slide to
analyze the percentage of multinucleated cells.
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Fig 4.1 HA-PKM2 Expression Induces the Formation of Multinuclei in SW480 Cells
(A) Fluroscent immunostaining of exogenous expressed PKM2 using the antibody
PabHA in SW480. The green signal represents staining of exogenous PKM2 in the cells
(a). (b) is the overlay of HA antibody staining and DAPI staining. The blue signal
represents DAPI staining of DNA. (B) shows the percentage of the number of multinuclei
cells in the whole populations of expressing HA-PKM2. (a) is the population of two
nuclei in the whole populations of expressing HA-PKM2. (b) is the percentage of triple
nuclei population in the whole populations expressing HA-PKM2. (c) is the percentage
of single nucleus population in the whole population expressing HA-PKM2. Error bars in
(B) are standard deviations of three measurements
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Figure 4.2 Cdc14A Expression is Up-regulated by PKM2 and p68 RNA Helicase
(A) Cellular levels of Cdc14A in SW480 cells 48 hours after transfection of the cells with
plasmids vectors that carry PKM2 cDNA expression vector (HAPK), p68 RNA helicase
(WTp68), Y593F mutant of p68 RNA helicase (593F) or empty vector (Vec) were
analyzed by immunoblot with anti-Cdc14A (IB: Cdc14A). The exogenously expressed
HA-PKM2 or p68 was examined by immunoblot using anti-HA antibody. Immunoblot of
β-actin (IB:β-actin) were loading control. (B) is the centrosome staining in multi nuclei
cell induced by PKM2 overexpression. (a) The red signal represents staining of γ-tubulin.
(b) The blue signal represents DAPI staining of DNA. (c) The green signal represents
staining of exogenous expression of PKM2 in in the cells. (d) is the overlay of HA
antibody, γ-tubulin and DAPI staining.
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Figure 4.3 Nuclear PKM2 Regulates Cdc14A Expression
(A) Cellular levels of Cdc14A in SW480 cells 48 hours after transfection of the cells with
plasmids vectors that carry PKM2 cDNA expression vector (HAPK), p68 RNA helicase
(WTp68), nuclear localization signal mutant of PKM2 (NLS-PK) or empty vector (Vec)
were analyzed by immunoblot of anti-Cdc14A (IB:Cdc14A) in whole cell lysate. The
exogenously expressed HA-PKM2, p68 was examined by immunoblot using anti-HA.
immunoblot of β-actin (IB:β-actin) is loading control. (B) RT-PCR experiment was
applied to examine Cdc14A mRNA expression level. The RT-PCR primers were
designed according to Cdc14A pre-mRNA sequence as extend from exon 11 to exon 1314 interrupted with intron 13-14. Error bars are standard deviations of three
measurements. (C) Immunostaining of exogenous nuclear PKM2 induced multinuclei in
SW480. The red signal represents staining of Lamin B1 (a). The blue signal represents
DAPI staining of DNA (b). The green signal represents staining of HA. (d) is the overlay
of HA antibody and DAPI staining.

183

184

Figure 4.4 Cdc14A Expression is Co-regulated by PKM2 and p68 RNA Helicase.
(A) The regulatory function of p68 for Cdc14A transcription was helicase activity
independent. Cellular levels of Cdc14A and exogenously expressed p68 RNA helicase
(WTp68), Y593F mutant of p68 RNA helicase (593F) , RNA helicase inactive mutant of
p68 RNA helicase (RGLD) or empty vector (Vec) in SW480 were analyzed by
immunoblot using antibodies against Cdc14A (IB:Cdc14A) and HA (IB:HA). (B) p68
was required for the regulatory function of PKM2 to Cdc14A transcription. Endogenous
p68 was knocked down with RNAi (sip68). Exogenous PKM2, wild type or mutant p68
was expressed in p68 knocked down cells. (C) p68 was required for the regulatory
function of nuclear PKM2. p68 in the cells was knocked down with RNAi (sip68). Wild
type or mutant PKM2 was exogenously expressed in p68 knocked down cells. (D) PKM2
was required for the regulatory function of p68. PKM2 was knocked down with RNAi
(siPK). Wild type or mutant p68 was exogenously expressed in PKM2 knocked down
cells. In (A), (B), (C) and (D) Immunoblot of β-actin (IB:β-actin) is a loading control.
The exogenously expressed PKM2 or p68 (wild type or mutants) was examined by
immunoblot using anti-HA antibody.
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Fig 4.5 PKM2 Interacts to Cdc14A Gene Promoter
ChIP analyses of Cdc14A promoter using PKM2antibody in SW480 cells (αPKM2).
ChIP analyses using rabbit IgG (IgG) was a negative control. Inputs were PCR products
from DNA extracts without ChIP. (a) ChIP-using PCR primer pair targeting to promoter
reion Cdc14A gene. Chip-1 primers: Forward 5’-GAAGGAGGATCCGGAGCAG-3’
Reverse
5’-CCTGGGAAACGCAGACCAG-3’ (b) ChIP-using anthour PCR
primer targeting to promoter region of Cdc14A gene. Chip-2 primers: Forward 5’TCGGGTTCCCCTCGGAATG-3’ Reverse 5’-AAGCGAGATACGCACGGGG-3’ (c)
ChIP− using PCR primer pair targeting a down stream region of exon 1 of Cdc14A gene
is a negative control. (d) ChIP targeting GAPDH using antibody against PKM2 was
another negative control
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Fig4.6 Cdc14A Transcription is Regulated by PKM2 Expression
(A) & (C) Expressions of Cdc14A (IB: Cdc14AMEK5) in SW480 were analyzed by
immunobloting whole cell lysate (WCL) prepared from the cells in which PKM2 was
knocked down by RNAi (PKM2, IB: PKM2). Expression of HA-PKM2 in SW480 was
examined by immunobloting whole cell lysate with anti-HA (IB: HA). The blot of βactin (IB:β-actin) are the loading controls. (B) & (D) were RT-PCR results
corresponding to (A), (C). (E) shows the percentage of the number of multinuclei cells in
the whole populations of PKM2 knocked down cells. (a) is the population of two nuclei
in the whole populations of PKM2 knocked down cells. (b) is the percentage of triple
nuclei population in the whole populations PKM2 knocked down cells. (c) is the
percentage of single nucleus population in the whole population PKM2 knocked down
cells. Error bars in (E) are standard deviations of three measurements
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Fig 4.7 Cdc14A Expression in Cancer Cell Lines
Expressions of Cdc14A in SW620/SW480, LN686/M4C1, and H146/H460 were
analyzed by immunobloting whole cell lysate (WCL) with anti-Cdc14A. The blot of βactin (IB: β- actin) are the loading controls.
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CHAPTER 5 CONCLUSIONS AND DISCUSSIONS

5.1 Conclusions
The Warburg effect has been known for decades. The detailed mechanism of the
Warburg effect is still not known. It has been shown that metabolic adjustment benefits
cancer cells in many aspects. For example, the change provides phosphor intermediates
for macromolecule synthesis as well as help cancer cells to avoid apoptosis. In this study,
we discovered that there were more nuclear PKM2 in metastatic cancer cells than the nonmetastatic cancer cells. The nuclear PKM2 levels were correlated with cancer cell
proliferation rates. PKM2 regulated MEK5 gene transcription to promote cell proliferation.
Nuclear PKM2 phosphorylated Stat3 at Y705 site using PEP as a phosphoryl group donor
to regulate MEK5 gene transcription. Our study also showed that double phosphorylated
p68 RNA helicase at Y593/595 residues interacted with PKM2 at its FBP binding site.
Under the stimulation of growth factors, p68 interacted with PKM2 to promote its protein
kinase activity. The transcription regulatory function of nuclear PKM2 was also defined
in regulating Cdc14A gene transcription resulting in a multi-nucleus phenomenon in less
aggressive cancer cells. These results provided part explanations for Warburg effect.

5.2 Nuclear PKM2 Interacts with Tyrosine-phosphorylated p68 RNA Helicase
p68 RNA helicase is a multifunctional protein dominantly localized in the nucleus,
and plays a crucial role in RNA biogenesis as well as tumorigenesis. The
phosphorylations of p68 RNA helicase have diverse functions (Huang and Liu 2002; Liu
2002). In 2007, Yang et al reported that p68 RNA helicase is double phosphorylated at
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Y593 and Y595 residues in some cancer cells, such T98G and HeLa cells (Yang, Lin et
al. 2007). The double phosphorylated p68 RNA helicase facilitates cancer cells in
resistance of TRAIL induced-apoptosis. To further examine p68’s physiological
functions in cancer cells, it was important to uncover proteins that interacted with
phosphorylated p68 RNA helicase in the nucleus. PKM2 was found to interact with pY593/595 peptides. However, this method did not detect other associated proteins with
low enrichment to tyrosine-phosphorylated peptides due to the limitation of its
sensitivity, or the weak interactions with phoshprylated p68. Meanwhile, whether nuclear
PKM2 has functions in regulating RNA biogenesis with p68 RNA helicase remains
elusive.

5.3 Tyrosine-phosphorylated p68 Peptides Change the Quaternary Structure of
PKM2
In 2008, Cantley’s group reported that PKM2 binds to tyrosine phosphorylated
peptides in tumor cells. The binding of phosphorylated peptides to PKM2 releases
fructose-1,6-bisphosphate (FBP), the allosteric activator of PKM2. Binding to the
phopshorylatd peptides also inhibits its pyruvate kinase activity (Christofk, Vander
Heiden et al. 2008; Christofk, Vander Heiden et al. 2008). The inhibitory effect of
tyrosine phosphopeptides on PKM2 also exists in living cells. However, the interaction
example of a tyrosine phospho protein with PKM2 is not yet revealed. In our study, we
found a tyrosine phospho peptides, p-Y593/595, derived from p68 RNA helicase,
interacted with PKM2 at FBP binding site. Our experiments further demonstrate the
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interaction of the phosphor-p68 with PKM2. The pyruvate kinase activity of PKM2 was
decreased when interacting with p68 RNA helicase.
During tumorigenesis, PKM2 is converted to dimeric form in tumor cells. The
dimeric form has a low affinity to PEP. The low affinity to PEP slows down the
glycolysis so that more phosphorylated intermediates from glycose are used to synthesize
nucleic acids and amino acids for cell proliferation. One interesting question is how to
convert the tetrameric PKM2 to a dimer in living cells. It is conceivable to think that the
binding of tyrosine phosphopeptides to PKM2 changes its quaternary structure from a
tetramer to a dimer so that the glycolytic activity of PKM2 is decreased and FBP is
released. In our study, the binding of p-Y593/595 to PKM2 changed its quaternary
structure from tetrameric to dimeric. The pyruvate kinase activity of PKM2 is decreased
to certain level to benefit cancer cells for macromolecule synthesis. On the other hand,
the dimeric PKM2 was shuttled into the nucleus by p68 RNA helicase to regulate gene
transcription for promoting cell proliferation. Therefore, PKM2 plays a central role to
modulate both cancer cell motabism and gene transcription.
In addition, phosphorylation can occur at Serine, Threonine as well as Tyrosine
residues. What are the functions of Serine and Theronine phosphorylated proteins
binding to PKM2? Do they have the similar functions as Tyrosine phosphorylated
proteins binding to PKM2 to affect cell proliferation as well as the glycolysis process? It
will be very interesting to find out the physiological roles of these phosphorylated
proteins to PKM2.
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5.4 Nuclear PKM2 Regulates MEK5 Gene Transcription to Promote Cell
Proliferation
To analyze the function of nuclear PKM2, we screened the nuclear PKM2 levels in
five pairs of cancer cell lines. The levels of nuclear PKM2 correlated with the
proliferation status of cancer cells. According to these studies, we hypothesized that
nuclear PKM2 may function in gene transcription in cancer cells to promote cell
proliferation. Both expression array and Chip-on-chip suggested that PKM2 plays a role
in MEK5 gene transcription. Our results showed that regulation of MEK5 gene
transcription mediated the role of PKM2 in promoting cell proliferation. Our results also
indicated that MEK5 was highly expressed in more metastatic cancer cells than in less
aggressive cancer cells from the same tissues, such as lung, melanoma and colorectal
cancer cells. According to our expression array analysis, there were also many other
genes related to cell proliferation, such as ribosomes proteins and cyclin D1. Further
studies will be carried out with these genes.
Interestingly, PKM2 is not the only metabolism enzyme acting in gene
tranascription in the nucleus. It was reported that some other glycolytic proteins played
roles in the regulation of gene transcription in the nucleus, such as GAPDH. GAPDH
interacts with the Oct-1 transcriptional factor in the nucleus as a co-activator to regulate
H2B gene transcription (Zheng 2003). Nuclear GAPDH binds to DNA as well as RNA to
play multiple roles in many other cellular processes, such as nuclear tRNA transport,
DNA replication and repair (Sirover, 2005). It was also reported that GAPDH induces
ATG12 expression to resist the caspase-independent cell death process {Colell, 2007
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#6009}. Another example is Lactate dehydrogenase (LDH), which catalyzes the pyruvate
to lactate conversion, was also discovered as a DNA-helix-destabilizing protein, which
plays roles in gene transcription in the nucleus. LDH-A and LDH-B are transcriptional
co-activators

with

functions

in

cell-cylce

regulation.

Hexokinase

2

induces

transcriptional repression in the nucleus of yeast {Rodriguez, 2001 #6013}. An isoform
of Enolase 1 represses the transcriptional activity of the c-Myc gene in HeLa cells
[Ghosh et al., 1999]. In addition, some other glycolytic proteins, such as
phosphoglycerate kinase and aldolase, are also detected in the nucleus {Ronai, 1993
#6010}. It is very interesting to investigate whether nuclear PKM2 also regulates other
gene transcriptions to perform diverse biological functions, such as nuclear tRNA
transport, DNA processing and apoptosis.

5.5 Nuclear PKM2 Phosphorylates Stat3 in the Nucleus to Regulate its
Transcriptional Activity
PKM2 does not have a clearly defined DNA binding motif. Thus, an open question
is how PKM2 is able to function in gene transcription. We hypothesized that nuclear
PKM2 acts as a co-activator to regulate gene transcription and PKM2 may target other
transcription factors. It was reported that Stat3 regulateed MEK5 transcription (Song, Jin
et al. 2004). It was also shown that Stat3 was a tyrosine phosphopeptides binding
proteins. Thus, we questioned whether Stat3 interacted with PKM2 in the nucleus. Our
experiments indeed showed the interaction between nuclear PKM2 and Stat3. In this
study, the transcription activity of the downstream target of Stat3 is MEK5. MEK5 is the
major effector in the control of cell proliferation regulated by nuclear PKM2. The
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transcriptional activity of other downstream targets of Stat3, such as Cyclin D1, remains
to be elusive. Whether nuclear PKM2 interacts with other transcriptional related-factors
to play a role in regulating gene transcription is not yet known. Further study needs to be
carried out in this direction.

5.6 Overexpression PKM2 Forms Multinucleus in Less aggressive Cancer Cells
The overexpression of PKM2 in less aggressive cancer cells, such as T98G,
SW480 cells, induces formation of multinucleus cells. The molecular mechanism that
leads to the formation of multinuclear cells is not clear. Gene array analysis demonstrated
that PKM2 control Cdc14A expression. The regulation function of PKM2 in regulating
Cdc14A expression depends on the expression of p68 RNA helicase, which provided
another example of the function of p68 RNA helicase as a co-activator. In addition, p68
RNA helicase activity was not related to its gene regulation function. One possible
mechanism for formation multinucleus phenomenon induced by PKM2 overexpression is
the overexpression of Cdc14A dephosphorylated Cdh1, which activated the APC
complex to exit mitosis, resulting in aneuploidy, an abnormal number of chromosomes,
in tumor cells. The aberrant mitosis may result in apoptosis in these cancer cells after a
certain number of generations. Under these circumstances, overexpression of PKM2 may
not promote cell proliferation, which explains well why PKM2 does not promote cell
proliferation in less aggressive cancer cells. On the other hand, aneuploidization is found
in many cancer cells. After more than a hundred years, it is still debatable whether
aneuploidy, is a cause of cancer (von Hansemann, D. (1890) Boveri, T. (1914)). It was
also reported that Cdc14A upregulation induced aberrant, premature centrosome
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splitting. The centrosome is the microtubule organization center, which plays pivotal
roles in regulating the formation of bipolar spindles during mitosis. The pre-mature
splitting of centrosomes in the S phase may cause formation of multinucleus in these
cancer cells.

5.7 Dimeric PKM2 Phosphorylates Stat3 Using PEP as Phosphoryl Group Donor
Both nuclear and cytoplasmic PKM2 exist in different quaternary structures in
many cancer cell lines, such as SW480 and SW620 cells. Nuclear PKM2 does not form a
tetramic structure like the cytosolic version. Whether nuclear PKM2 forms a dimer or
exists as a monomer is not yet determined. We observed that nuclear PKM2 purified
from SW620 cells migrated at 120KD position in a native gel. However, it is not known
whether nuclear PKM2 has a post-translational modification that lead to the change in
mobility in PAGE. Recently, it was reported that PKM2 was sumoylated and the
sumoylation promotes nuclear localization (Spoden, Morandell et al. 2009). It will be
interesting to test whether the band shift is due to PKM2 sumoylation or possibly other
modifications.
Tetrameric forms of PKM2 have a higher affinity to PEP, which is regulated by
FBP binding. Our results showed that nuclear PKM2 phosphorylated Stat3 uses PEP as a
phosphoryl group donor. The phosphorylation of Stat3 by PKM2 was also observed with
PKM2 purified from cytosolic extract. However, the cytosolic PKM2 exhibited much
week activity in phosphorylating Stat3 compared to that of nuclear PKM2. This is most
likely due to cytosolic PKM2 exists mostly as a tetramer. Another possibility is that the
tetrameric PKM2 can not bind to Stat3 because the binding sites for Stat3 are buried
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according to structural analysis of PKM2. The binding site for Stat3 on PKM2 is located
an ADP binding cleft, which is located between the two dimers. In the glycolysis process,
ADP is small enough to access to the site. Stat3 is a large molecule, around 80 KDa.
Thus, the access to the binding site is blocked.

5.8 Arginine 399 Changes the Quaternary Structure of PKM2
Arginine 399 is crucial for maintaining the tetrameric structure of PKM2 by
forming charge-charge interaction with Glutamic Acid 418, Aspartic Acid 357, Glutamic
Acid 396. To test the conjecture, a mutant was made to eliminate the interactions. Studies
showed that this mutant interfered with the interaction between the two dimers of PKM2
both in vivo and in vitro. Interestingly, an NES signal was detected in the PKM2
sequence using the peptide graft technique. The NES signal is also expressed in the
interface between the two dimers. The mutant in this region destroyed the formation of
tetrameric PKM2. This NES mutant also diminishes the FBP binding site of PKM2.
Interestingly, the recombinant R399E mutant protein was shown to phosphorylate Stat3
proteins in vitro. This result also confirmed that R399E mutant may share a similar
function with nuclear PKM2 to phosphorylate Stat3.
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CHAPTER 6 MATERIAL AND METHODS
6.1 Nucleic Acids Related Techniques
6.1.1 Mini Preparation for DNA
DNA Spin Mini Kit (Qiagen) was applied to isolate DNA plasmids from bacteria.
Single colony was picked using a sterile inoculation loop from agar plates and
resuspended in 1 ml LB culture medium containing appropriate antibiotics (50 ng/ml
Kanamycin or Ampicillin). The bacteria were incubated at 37°C on a rotary shaker with
220 rpm overnight. The next day, the bacteria medium was transferred into an Eppendoft
tube and centrifuged at 13,000 rpm for 2 min. Then, the bacteria pellet was completely
resuspended in 250 ul resuspension buffer. 250 ul of lysate buffer, P2, containing RNase
was added into the tube. The tube was gently inverted back and forth 5-6 times to
completely lysate the bacteria. Then, 350ul of neutralization buffer, N3, was added into
the tube and inverted gently 5-6 times to completely neutralize the lysate. The lysate
solution was then transferred into a spin column and centrifuged at 13,200 rpm for 1 min
to allow DNA to be captured to the membrane. Then, the membrane was washed with
500 ul of buffer PB by centrifuging at 13,000 rpm for 1 min to remove trace nuclease
activity. Next, the membrane was washed with 0.75 ml of PE buffer to purify DNA by
centrifuging at 13,000 rpm for 1 min. With additional 1 min centrifuging at 13,000 rpm,
the membrane was dried. 20~30 ul ddH2O or TE buffer was loaded to the membrane to
elute DNA from the membrane by centrifuging at 13,000 rpm for 1 min. The eluted DNA
was confirmed by either gel electrophoresis or DNA sequencing.
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6.1.2

Midi Preparation for DNA
Bacteria containing DNA plasmid were cultured in 1 ml LB medium supplemented

with appropriate antibiotics (50 ng/ml Kanamycin or Ampicillin). Then, the bacteria
culture was transferred into 150 ml warm LB medium and cultured overnight to amplify
plasmid DNA. The next day, the culture was centrifuged at 6,000 rpm for 10 min to get
cell pellet. The bacteria pellet was resuspended in 3 ml of resuspension buffer and lysated
with 3 ml of lysate buffer. The lysate was neutralized with the adding of 3 ml of
neutralization buffer. Then, the solution was centrifuged at 15,000 for 20 min and the
supernatant was carefully collected into a 50 ml conical tube. 10ml of DNA purification
resin provide with the kit was added to the tube and mixed gently with the supernatant
containing DNA plasmids. The mixture was loaded to a midi preparation column and
applied to vacuum equipment to remove supernatant. The resin beads with DNA plasmids
were washed with washing buffer twice (10 ml each time). After the washing buffer
completely passed through the column, the vacuum was applied to the column for
additional 1 min to dry the resin. The leftover of washing buffer was removed by
centrifuging at 10,000 rpm for 1 min. During this time, 2 ml of ddH2O or TE buffer was
heat to 70°C in a heat blocker. 300 ul of warmed ddH2O was added into the column and
incubated for 2 min. Then, DNA plasmid was eluted from the column by centrifuging at
13,200 rpm for 1 min. The DNA plasmid was purified with Phenol/Chloroform/Ethanol
method and the concentration was measured with spectrometry at OD260nm.
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6.1.3

Agarose Gel Electrophoresis and Gel Extraction of DNA
DNA plasmids or DNA fragments could be visualized by using a double stranded

DNA binding dye, Ethidium Bromide, under a UV transilluminator. 1 % agarose gel was
prepared by adding 1 g of agarose beads into 100 ml TAE buffer. The solution was heated
with microwave to completely liquefy agarose beads. The solution was quickly cooled
down to 50-60 °C with a water bath for 1 min. 6 ul of Ethidium Bromide was added into
100 ml warmed agarose solution and the solution was poured into a gel casting apparatus.
Well inserts was set up in the gel casting apparatus to make suitable wells. 10 ul of DNA
ladder was loaded into one well to refer to molecular weight of DNA fragments. The gel
was run at constant voltage of 120 V until the blue dye reached to the middle of agarose
gel.

6.1.4

Quantification of DNA and RNA
Nucleic acids concentration was measured using a spectrophotometer (UV-1700

Spectrophotometer, Shimadzu Co.) at OD260 nm. The absorbance obtained at OD260 nm
was applied to this formula: DNA concentration (ug/ml) = (OD260nm) X (dilution
factor) X (50 ug DNA/ml) / (1 OD260nm unit). The purity of DNA was measured by the
ratio of the absorbance of OD260nm /OD280nm. The purify was acceptable when the
ratio was between 1.8 and 2.0.

6.1.5

Polymerase Chain Reaction (PCR) Method
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PCR method was applied to amplify a target sequence from plasmid DNA or
mutate specific nucleic acids of a plasmid vector. Generally, 0.5 ug of template DNA was
mixed with 1 mM dNTP, 0.5 ug forward and reverse primers, and 2 unit of pfu
polymerase in 1X reaction buffer. The reaction mixture was denatured at 95 °C for 2 min
and then was followed by 25-35 cycles: 95 °C denaturation for 30 seconds, 57-62 °C
annealing for 45 seconds, 72 °C elongation for 45 seconds. An additional elongation step
at 72 °C for 10 min was performed to stabilize the double strands. The PCR product
might be visualized by agarose gel electrophoresis.

6.1.6

Restriction Enzyme Digestion and Plasmids Construction.
To exogenous introduce proteins into mammalian cells or express recombinant

proteins in bacteria, cDNA of target genes must be constructed into expression vectors.
Restriction enzyme digestion was applied to generate the specific restriction enzyme
digestion sites. DNA sequence maps of these vectors were available from companies.
According to the detailed description of these restriction enzyme sites, two suitable
restriction enzymes would be chosen to digest PCR products or targeting cDNA
sequences. To apply the restriction enzymes correctly, cDNA or PCR products sequence
must be scanned by computer with the sequences of restriction enzymes to avoid mistargeting. All restriction enzymes have optimum conditions for their activities. To
perform two restriction enzymes digestion simultaneously (double digestion), two
enzymes must have compatible reaction conditions. Otherwise, the restriction digestions
should be carried out one by one. In general, for 1ug DNA or 30ul PCR product, 1ul
enzyme (20 unit) was used. ddH2O was added to the tube to make the final digestive
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system to 30 ul or 50 ul. The mixture was incubated at a temperature ranging from 30 °C
to 37 °C for 1 to 2 hours. Agaorse gel electrophoresis was performed to separate the
digested vectors.
T4 ligase was applied to ligase the digested DNA into the vector. T4 ligase can join
the 3’-OH of one nucleic acid and the 5’ phosphate of the other nucleic acid. The ratio of
insert DNA to vector was critical to make the ligation successful. An optimum ratio of
insert DNA to plasmid vector was around 3:1. The ligation process was performed in 1x
ligation buffer with 2 ul of T4 ligase. The mixture was incubated at 4 °C overnight. The
next day, the ligation product was transformed into competent bacteria.

6.1.7

Site-directed Mutation Method
Site-directed mutation was carried out using QuikChange II XL site-directed

mutagenesis kit (Stratagene). The primers were designed using an on-line program--The
QuikChange®Primer Design Program. 0.5 ug of primers was applied to PCR system. 2 ul
of Dpn1 enzyme (20 unit) was added to the reaction system to digest unmutated plasmid
vectors. The reaction was performed at 37°C for 2 hours. After purification, the mutated
plasmid vectors were transformed into XL1-Blue competent cells. The transformed XL1Blue cells were cultured in agar plates containing appropriate antibiotics overnight. The
next day, 6-12 colonies were picked to be cultured in 1 ml LB medium overnight. The
following day, mini-prep was performed to isolate plasmid DNA from XL-1 Blue cells
and the mutated DNA sequences were confirmed with DNA sequencing technique at the
core facility of Georgia State University.
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6.1.8

DNA Sequencing
DNA sequencing experiment was performed to examine a DNA sequence from a

mutation or ligation experiment. The sequencing primer was designed according to
plasmid vector maps, which was 50-100 nucleic acids upstream of the target sequence.
The sequencing primer was diluted in 20 uM. The plasmid vector was diluted to 0.1-0.2
ug/ul. Some sequencing primers were provided by the core facility of Georgia State
University, such as T7, S4 primers.

6.1.9

Ethanol Purification of DNA
Ethanol purification was performed to remove any salt or protein contaminations in

DNA samples. Firstly, 1/10 volume of 3 M sodium acetate was added to DNA sample
and mixed thoroughly. 2 volumes of 100% ethanol was added into the mixture and placed
in -20°C for 30 min. the mixture was centrifuged at full speed for 10 min at room
temperature to pellet DNA. The DNA pellet was washed with cold 70% ethanol twice
and centrifuged at 4°C. DNA pellet was dried by air at room temperature until the pellet
becomes transparent. Then, the pellet was dissolved in ddH2O and the concentration was
measured with a spectrophotometer at OD260nm.

6.1.10 RNA Extraction
Total RNA was isolated from mammalian cells by using RNeasy Plus Kit
(Qiagen). Mammalian cells were cultured in a 6-well plate and washed with cold PBS
twice. Then, 350 ul of RLT buffer supplemented with 3ul of 2-Mercaptoethanol was
added to each well. The attached cells were lifted from the culture plate with a cell lifter
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and loaded onto a QiaShredder column (Qiagen) to be homogenized. The loaded column
was centrifuged at full speed for 2 min in a microcentrifuge machine. The eluted samples
were loaded onto a gDNA eliminator spin column to remove genomic DNA. After
centrifuging at 13,200 rpm for 2 min, the eluted solution was mixed thoroughly with one
equivalent volume of 70 % ethanol. The mixture was loaded onto an RNeasy spin column
and centrifuge at full speed for 1 min. Then, the column was washed with 700 ul of RW1
buffer once and RPE buffer twice. The column was centrifuged for one more minute to
dry the membrane. Finally, RNA was eluted with 30 ul of RNase-free H2O twice. The
elution was combined together and RNA concentration was measured with a
spectrophotometer at OD260 nm. RNA samples were stored at -80°C for a couple
months.

6.1.11 Reverse Transcription PCR
Reverse transcription was performed to generate cDNA from mRNA. 1 ug of total
RNA extract was mixed with 1 ul of oligo dt15 to a final volume of 5 ul with adding of
RNase-free H2O. The mixture was incubated at 25 °C for 5 min and followed by
incubating at 70 °C for 5 min. Then, the mixture was incubated on ice for 5 min. To each
reaction, 1 ul of reverse transcriptase, 1 ul of RNase inhibitor, 4 ul of MgCl2 (25 mM)
and 4 ul 5X reaction buffer were mixed thoroughly. The reaction was incubated at 25 °C
for 5 min, 45 °C for 1 hour and 70 °C for 15 min. The final products were stored at -80
°C.
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6.1.12 Relative Real Time PCR
Total RNA was extracted from cells using a RNeasy kit. Reverse transcription
process was performed with ImProm-II reverse transcription system (Promega). RT-PCR
process was performed in Applied Biosystems Fast Real-Time PCR 7500. RT-PCRs were
performed with 1 µg of cDNA and 25 ul of Fast SYBR green master mix (Applied
biosystems). The solutions were mixed in a 0.5 ml PCR tube and loaded to a RT-PCR
plate. The plate was tightly sealed with a piece of adhesive film. The plate was
centrifuged at 1,000 rpm for 2 min at room temperature and loaded onto real-time PCR
machine. The amplification process was carried out by the following the cycles: 95 °C
for 15 seconds, 95 °C for 3 seconds and 60 °C for 30 seconds. The amplification was
analyzed with the Applied Biosystems SDS v1.4 program. After the cycles, a dissociation
curve was generated by increasing the temperature to 95 °C for 30 min. Standard RTPCR primer set was purchased from RealTimePrimers.com.

6.1.13 Chromatin Immunoprecipitation
Mammalian cells were cultured in normal medium to 70% confluence. Then, cells
was fixed with 1% formaldehyde solution by incubating 10 min at 37 °C and the reaction
was stopped with the adding of 125 mM glycine. The fixed cells were washed with cold
1X PBS three times supplemented with protease inhibitors and lysated in 1 ml SDS lysis
buffer (Imgenex). The cell lysate was sonicated on ice for 2 min and centrifuged at
15,000 rpm to pellet insoluble material. The success of shearing was examined with
agarose gel. The supernatant was aliquoted and pre-cleared with 100 ul salmon sperm
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DNA/protein G agarose by incubating for 2 hours. The primary antibody (10~20 ul) was
added to the supernatant and incubated at 4 °C overnight. The next day, 100 ul of salmon
sperm DNA/protein G agarose was added to each tube and incubated for 2 hours. The
immuno-complex was eluted with 200 ul elution buffer. The cross-link was reversed with
4 ul of 5 M NaCl incubating at 65° overnight. The released DNA was purified using the
phenol chloroform extraction method. Regular PCR was performed in Mastercycle®
Gradient PCR machine (Eppendorf) and the result was analyzed on a 2% agarose gel.

6.1.14 ChIP-on-chip
For ChIP-on-chip analysis, GeneChip human promoter 1.0R array was applied in
this research. The immuno-complex from Chromatin Immunoprecipitation was cleaned
up with phenol chloroform extract method. The immunoprecipitated DNA targets were
amplified with PCR method with random primers. The amplified DNA targets were
fragmented using cDNA fragmentation buffer (GeneChip WT Double-stranded DNA
terminal labeling kit). The fragmented DNA was labeled with DNA labeling reagent
(GeneChip WT Double-stranded DNA terminal labeling kit) and examined with gel-shift
analysis. The labeled target was hybridized with arrays in hybridization oven
(Hybridization Oven 640 Affymetrix) at 60 rpm for 16 hours. The arrays were then
scanned with Affymetrix GeneChip 3000 scanner. The ChIP-on-chip data was analyzed
with affymetrix Tiling Analysis software 1.1 and Integrated Genome Browser. All
parameters were set up as described in the tiling analysis software tutorial from
Affymetrix website.
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6.1.15 Microarray analysis
GeneChip® Human Genome U133 Plus 2.0 Array was performed in this research.
Total RNA from cells expressing HA-tagged PKM2 or control was extracted with
RNeasy kit by following the manufacturer’s instruction (Qiagen). The total RNA
concentration was determined by spectrometer reading at OD 280 nm. 10ug of total RNA
of each sample was used for synthesizing the (−) strand cDNA with ImProm-II reverse
transcription system (Promega). Synthesized cDNA were purified with the phenolchloroform extraction method. In vitro transcription reaction was performed by using the
GeneChip® IVT Labeling Kit (Affymetrix). The labeled cRNA was fragmented in
fragmentation buffer (Affymetrix) and hybridized to GeneChip® Human Genome U133
Plus 2.0 Array. The arrays were scanned with Affymetrix GeneChip 3000 scanner. The
data were analyzed by Affymetrix GeneChip Operating Software (GCOS) Version 1.0.

6.1.16 Electrophoretic Mobility Shift Assay.
Stat3 consensus binding probe 5’-GATCCTTCTGGGAATTCCTAGATC-3’ was
purchased from Santa Cruz. The DNA probes were labeled with γ-32P using T4
polynucleotide kinase. Nuclear protein extracts (10 ug each) were incubated with the 32P
labeled Stat3 consensus-binding probe for 20 minutes at room temperature in binding
buffer (5 % glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM
Tris-HCl, 0.05 mg/ml poly(dI-dC)). For supershift analyses, the nuclear extracts were
preincubated with Stat3 monoclonal antibody (invitrogen) for 1hour at room temperate
before loading. The protein-DNA complexes were separated in 4 % native
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polyacrylamide gel (acrylamide: polyacrylamide 60:1). The 4 % native polyacrylamide
gel was pre-run at 200 V for 45 min in 0.5X TBE buffer at 4 °C. Protein-DNA complexes
were loading in wells with loading buffer and run at 200 V until the blue dye migrated to
¾ length of the gel. The gel was transferred to Whatman paper. The gel was covered with
Saran Wrap and dried at 80 °C in vacuum dryer for 2hours. The gel was placed in
phosphoimagine plate in 4 °C overnight. The gel plate was read in Storm 840
phosphoimager, Amersham Biosciences and analyzed with ImageQuant TL.

6.2 Bacterial Techniques
6.2.1 Bacterial Culture and Storage
The E. coli strains, such as JM109, XL1-blue, BL-21 were used for plasmid DNA
amplification or recombinant protein expression. E. coli stains were inoculated in
autoclaved Luria Broth (LB) medium prepared in 1 % bacto-tryptone w/v, 0.5 % bactoyeast-extract w/v and 1 % NaCl w/v. 50μg/ml of Ampicillin or Kanamycin was added
into warmed LB medium (50~60 ºC) for antibiotic resistant strains selection. The bacteria
were cultured in shakers or incubators in 37 ºC. Agar plates were prepared in LB medium
with the addition of 1.5% Agar prior to autoclaving. For long term storage of transformed
bacteria, the transformed strains were mixed with sterile 30 % glycerol w/v and preserved
at -80 ºC.

6.2.2 Transformation
For large scale plasmid DNA preparation, transformation was carried out in JM109
E.coli strain. JM109 competent cells were thawed on ice and 100ul of JM109 was
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aliquoted into a test tube. 1~5 μg of plasmid DNA was added into the tube and incubated
with JM109 competent cells for 30min on ice. Heat shock was performed to the mixture
at 42 ºC for 90 seconds. The mixture was chilled on ice for additional 2 min and 200 ul of
warmed LB were added into the tube. Then, the tube was incubated at 37 ºC in a shaker
with 220 rmp for 1 hour. The transformed bacteria were spread onto agar plates
containing appropriate antibiotics and incubated at 37 ºC overnight. The next day,
colonies were picked with sterile plastic sticks from the agar plates and dipped into
antibiotics containing LB medium for large scale amplification.

6.3 Protein Techniques
6.3.1 Recombinant PKM2 Protein Expression and Purification
Human PKM2 cDNA was constructed into pET30a bacteria expression vector. BL21 expression host was transformed with PKM2-pET30a vector and cultured in LB
medium containing 50 ng/ml Kanamycin. BL-21 was cultured in 50 ml LB and the next
day was transferred into 1L warmed LB medium shaking at 220 rmp at 37 °C until
OD600nm reached between 0.4 and 0.6. Isopropyl-β-D-thiogalactoside (IPTG) was
added to LB medium to a final concentration at 1mM to induce recombinant protein
expression. 4 hours later, bacteria were collected with centrifuging at 6,000 rpm at 4 °C
for 10 min. Bacteria pellet was washed with cold PBS twice and lysated in lysis buffer
containing 1mg/ml lysozome. The bateria lysate was sonicated for 1 min on ice and
centrifuged at 17,000 rpm for 20 min. The expression of recombinant PKM2 was
detected with SDS-PAGE gel. Most recombinant PKM2 protein was expressed in
inclusion bodies. The pellets were washed with washing buffer (0.5M Urea and 50mM
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phoshorylate buffer pH7.4) twice and lysated in a denature buffer (8 M Urea and 50 mM
phosphorylate buffer, pH7.4). The inclusion body was lysated at RT for 1 hour and
centrifuge at 16,000 rpm for 30 min. The supernatant was collected and diluted dropwise
with 50 mM phosphorylated buffer till 0.5 M Urea. Recombinant PKM2 protein was
purified with HiTrap column using Akta purifier 100 FPLC system. Recombinant PKM2
protein was gradient eluted with 0.5 M imidazole. The eluted protein was collected and
dialysis in buffer (50 mM Tris, pH 7.5, 0.1 M KCl, and 20% glycerol). 25mM DTT was
added into the buffer and dialysis into the refolding buffer (50 mM Tris, pH 8.0, 0.1 M
KCl, 20% glycerol, 0.1 M EDTA, 1 mM DTT)

6.3.2 Gel Filtration
Size filtration chromatograph was applied to separate tetrameric and dimeric PKM2
from the subcellular extracts. The separation process was performed in Superdex 200
10/300GL column with Akta purifier 100 FPLC system. Superdex 200 10/300GL column
can separate proteins molecular weight range from 10KD~600KD. Blue dextran, 2,000
KD, was applied to measure void volume (Vo) of the column. 100 ul of blue dextran was
loaded into the column with concentration at 1 mg/ml. The column was calibrated with
molecular weight standards, such as Aprotinin

6.5 KD, Ribonuclease A 13.7 KD,

Carbonic Anhydrase 29 KD, Ovalbumin 44 KD, Conalbumin 75 KD, Ferritin 440 KD,
Thyroglobulin 669 KD. These standards were dissolved in the same buffer as subcellular
extracts or recombinant proteins with salt concentration higher than 0.15M. The protein
standards concentration was 3 mg/ml or 4 mg/ml. UV280nm protein detector was applied
to monitor the chromatography. The flow rate was 0.4 ml/min. The standard curve was
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calculated by following the manufacture’s instruction. 100 ul cytosolic or nuclear extract
(500 ug) was loaded into Superdex 200 10/300GL column and eluted with elution buffer
(50 mM sodium phosphate buffer pH7.2, 0.15 M NaCl). The elution fraction was
collected in 300 ul aliquots. The molecular weight of each aliquot was calculated based
on the calibration curve made from standard proteins. 30 ul of each aliquot was analyzed
with 10 % SDS/PAGE gel followed by western blot procedure.

6.3.3 Protein Quantification
Protein concentration was determined with BioRad Protein Assay. The standard
curve was generated with a serial of diluted Bovine Serum Albumin (BSA) at the range
of 2.0-10.0 ug/ul. The standard curve was generated according to the absorption values of
BSA using Microsoft Excel. 1-2 ul of sample solution was diluted in 800 ul ddH2O
mixed with 200 ul BioRad dye solution. The optical density was examined with a
spectrophotometer at a wavelength of 595 nm. The protein concentration was calculated
according to the absorption values.

6.3.4 Sodium Dodecyl Sulfate Polyacryalmide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE gel was applied to separate protein complexes according to their
electrophoretic mobilities. The electrophoresis apparatus was assembled according to the
manufacturer’s instructions. Separating gel was prepared by following the recipes. The
solution was mixed in a 100 ml glass beaker and poured between the glass plates. 500 ul
isopropanol was poured on top of separating gel to remove air bubbles. Roughly, it took
45 min for separating gel to be polymerized. After the separating gel was polymerized,
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isopropanol was poured off and the top of the separating gel was rinsed with ddH2O
gently. The leftover of ddH2O was removed by a small piece of filter paper. Then, 4 %
stacking gel was prepared and poured on top of the separating gel. A comb was inserted
into the stacking gel to generate wells. The prepared SDS-PAGE gels were overlaid with
1X SDS-PAGE running buffer at 4 °C for a couple days. Protein samples were mixed
with 5X loading buffer and boiled at 95 °C for 8 min. Protein samples were loaded into
the wells with fine tips. The unused adjacent wells were loaded with 1X sample buffer.
SDS-PAGE running buffer was added into both the inner chamber and the outer
chamber. Run the gel at 60 V until the dye had reached the front of separating gel and
then switch to 120 V until the blue dye running out of the gel.
Separating gel buffer
375 mM Tris-HCl; pH 8.8
0.1% SDS
4% Stacking gel buffer
125 mM Tris-HCl; pH 6.8
0.1% SDS
SDS-PAGE running buffer
25 mM Tris; pH 8.3
250 mM Glycine
0.1% SDS
pH = 8.3
5X protein gel sample loading buffer
50 mM Tris-HCl; pH 6.8
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2% SDS
10% Glycerol
1% β-Mercaptoethanol
0.02 % Bromophenol Blue
12.5 mM EDTA

6.3.5 Coomassie Blue Staining
Proteins on SDS-PAGE gel can be detected with Coomassie blue stain. The gel was
washed with ddH2O for 2 min. Then, gel was stained with Coomassie blue solution for 30
min. The gel was destained with destaining buffer to remove extra coomssive blue dyes.
Coomssive blue solution
0.1 % Coomassive Brilliant Blue
20% Methanol
10% Acetic Acid
Destain buffer
40%Methanol
10% Acetic Acid

6.3.6 GelCode Staining
Small amount of proteins on SDS-PAGE Gels can be detected with GelCode
staining (Pierce). The gel was washed with ddH2O twice (5 min/each) at room
temperature. GelCode staining buffer without dilution was added into the staining tray
that would just cover the gel. The gel was stained for 2 hours at room temperature and
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destained with ddH2O for 2 hours. The protein bands were visualized with a UV
transilluminator with CCD camera.

6.3.7 Native Gel Preparation
Native gel was prepared and run by following the method of SDS-PAGE in the
absence of SDS.

6.3.8 Protein In-gel Digestion
Protein complexes were separated in SDS-PAGE gel or native gel. The presences of
interested protein bands were stained with Coomassie blue, SYPRO Rube dye, or
GelCode. The protein bands were carefully cut from the gel using a scalpel. The gel piece
were placed in a siliconized Eppendorf tube and destained with 200 ul of destaining
solution twice. The destaining process might be incubated in 37 ºC. The gel piece was
dried using a Speed Vac for 30 min. 20 ul (0.4ug of Trypsin) of Trypsin solution and 50
ul of the Trypsin reaction buffer were added into the tube and incubated with the gel
piece at 37 ºC overnight. The next day, the liquid was removed from the tube and
transferred into a new tube. 50 ul of peptide extraction solution was added to the gel
piece and incubated at 37 ºC for 30 min. The peptide extraction solution was removed
from the tube and combined with the liquid recovered from the previous step. Then, the
sample was ready for MALDI-MS analysis.
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6.3.9 Protein Identification by Peptide Mass Fingerprinting
The proteins complexes were separated in SDS-PAGE and digested with Trypsin.
The sample solution was concentrated with a Speed Vac to less than 10 ul. Then, the
sample was desalted with ZipTip (uC18) tips. 1.5 ul of neat formic acid was added into
the sample and mixed thoroughly. 8.5 ul of 0.1 % TFA was added into the tube and
mixed with the sample. The tip was wet with wetting solution (50 % ACN) twice and
equilibrated with 0.1 % TFA several times. The sample solution was aspirated and
dispensed with the tip 5 times. The bound sample was washed with 0.1 % TFA 10 times.
The sample was eluted from the ZipTip with 50 % ACN/0.1 % formic acid and spotted
directly onto a wax-coated MALDI-TOF plate. The matching of the experimental peptide
mass with database was examined with Peptident proteomic tools in ExPASy Molecular
Biology Server (http://www.expasy.ch/). The MALDI-TOF/TOF database was from
NCBInr.

6.3.10 Antibody Generation and Purification
Rabbits were immunized with KLH-conjugated peptides or recombinant proteins to
generate antibodies. KLH-conjugated peptides were synthesized in Global Peptide
Services Com.

Recombinant proteins were expressed in BL-21 and purified with

HiTrap columns in FPLC systems. For each rabbit, 5 ml pre-immune blood was
harvested from the auricular artery for test controls. The blood was allowed to clot at
room temperature and the serum was collected by centrifuging at 3,000 rpm for 15 min at
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4°C. 0.1 % NaN3 was added to the serum and the serum was stored at -80 °C. Antigens
(peptides or recombinant proteins) were emulsified by mixing with an equal volume of
complete Freund’s adjuvant. The emulsified antigen was injected into three subcutaneous
dorsal sites in each rabbit. 0.2 mg of peptides or 0.5 mg of proteins was used per
immunization. Two weeks later, 0.2 mg peptides or 0.5 mg of proteins were emulsified
with incomplete Freund’s adjuvant and injected into three subcutaneous dorsal sites of
the same rabbits. Four weeks later, 20 ml of production blood was bled from the rabbits.
The serum was collected by centrifuging at 3,000 rpm for 15 min at 4 °C and stored at 80 °C. Seven weeks later, 0.2 mg peptides was mixed with equal volume of incomplete
Freund’s adjuvant and injected into rabbits. Eight weeks later, the second bleeding was
carried out and 20 ml blood was harvested from the auricular artery. Nine weeks later,
the rabbits were immunized with 0.2 mg peptides mixed with equal volume of incomplete
Freund’s adjuvant. Ten weeks later, 50 ml production was bled.

6.3.11 Kinase Assay
SW620 cells were cultured in Leibovitz's L-15 Medium in flasks. SW620 cells were
seeded to 70% confluence in T150 flasks and infected with 200 ul adenoviruses lysate
(1X1013 pfu/ml) packed with PKM2 cDNA per flask. The infected cells were harvested
after 3 days and the nuclear extract were prepared. 100 ul of anti-HA antibody was
incubated with the nuclear extract from SW620 cells in NETs buffer supplemented with
protease inhibitors overnight. The next day 200 ul of agarose G beads were added and
incubated for 2 hours. The immunoprecipated complex was harvested with centrifuging
500 rpm at 4 ºC for 5 min. The beads were washed with NETs buffer 4 times and high
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salt solution (20mM Tris.HCl, 1M NaCl, pH7.5) for two times. Then the beads were
washed with kinase buffer twice. The kinase assay was performed in kinase solution
(100mM Tris.HCl, 100mM MgCl2, 2mM DTT, and 50 KCl). The recombinant protein
Stat3 was incubated with purified HA-PKM2 in agarose beads at 4 ºC for 1hours. The
reaction was stopped by adding 5XSDS-PAGE loading buffer and heating at 95 ºC for 8
min. The phosphorylation level of recombinant Stat3 was analyzed with phosphor-Tyr705-Stat3 antibody.

6.4 Mammalian Cell Techniques
6.4.1 Mammalian Cell Culture and Storage
LN686, M4C1, SW480, SW620, WM115, WM266, T98G, U87MG, H146 and
H460 cell lines were purchased from ATCC and cultured by following the vendor’s
instructions. To freeze cells, cells were cultured to 60-70 % confluence in a T75 flask and
trypsinized. Cell numbers were measured using hemocytometer. Cell pellets were
harvested with centrifuging at 1,000 rpm for 10 min. Then, cells were resuspended in
freezing medium (10% v/v DMSO, 10% FBS, 80%culture medium) and aliquoted into
freezing vials (5 x 106 cells/vial). The vials were stored in a freezing container at -80°C
overnight. The next day, freezing vials were transferred to a liquid nitrogen reservoir for
longer storage.

6.4.2 Transient Transfection Method
Mammalian cells applied in this project were transiently transfected with FugeneHD reagent (Roche) by following the manufacture’s instruction. Mammalian cells were
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cultured in normal medium in 6-well plates. The next day, cell density would reach 7090% confluence depending on cell types. The plasmids DNA-Fugene-HD mixture was
prepared in polystyrene transfection tubes. For each well, 2 ug of plasmid DNA was
added into 100 ul Opti-MEM medium and mixed thoroughly. Then, 5 ul of Fugen-HD
reagent was added into the tube and mixed with plasmid DNA thoroughly. The
transfection complex would be formed in 20 min at room temperature. The plates were
washed with fresh normal medium twice and fed back with 1ml normal medium. Then,
the transfection complex was added to each well dropwise. The transfected cells were
cultured in an incubator with/without 5 % CO2 at 37 °C for 48-72 hours before harvested.
For immuno-stain experiments, cells were cultured in chambers 24 hours after
transfection. Fluorescent microscope was applied to examine the fluorescent tagged
protein 48 hours after transfection.

6.4.3 RNA Interference
RNA interference technique was applied to knock down endogenous protein
expressions. Cells were seeded to 30-50 % confluence in 6-well plate in normal medium
one day before knockdown experiment performance. The next day, 2 ml Opti-MEM
medium was used to wash each well to remove FBS. siRNA duplex for PKM2, p68,
MEK5 or Stat3 were purchased from Dharmacon RNA Technologies. RNA duplex was
dissolved in DEPC-treated H2O to 40 pmol/ul. 200 pmol siRNA duplex was diluted in
250 ul Opti-MEM medium. 5 ul of transfection reagent, lipofectamine RNAiMAX
(invitrogen), was diluted into 250 ul Opti-MEM medium. The two solutions were
combined together and incubated for 30 min at room temperature. 0.75 ml of Opti-MEM
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medium was added into each well. Then, the mixture was added into each well dropwise.
Fresh medium might be added into each well next day. For re-expression wild type or
mutant proteins in knockdown cells, 24 hours later, knockdown cells were transfected
using FuGene HD by following the manufacturer’s instruction. 48 hours later, cells were
lifted by cell lifter and harvested by centrifuging at 1,000 rpm for 10 min at 4 °C.

6.4.4 Growth Factor Treatment of Cells
For growth factors stimulation, mammalian cells were starved for 6-12 hours with
Opti-MEM medium prior to treatment. Growth factors dissolved in either DMSO or
ddH2O were diluted in Opti-MEM medium. The starved cells were cultured in OptiMEM medium containing growth factor for a given amount of time. DMSO or ddH2O
was used as a control. The cells were harvested once the treatment was done and stored at
-80 °C immediately.

6.4.5 Whole Cell Lysate Preparation
Mammalian cells were washed with cold 1X PBS twice and collected by
centrifuging at 1,000 rpm for 10 min at 4ºC. Whole cell lysate was prepared with cold 1X
RIPA buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 0.25 % deoxycholic acid, 1 % NP40 and 1 mM EDTA) supplemented with Protease Inhibitors Cocktail (PIC) (Sigma) and
phosphatase inhibitors cocktail (Pierce). In general, 1X106 cells were resuspended in 1 ml
cold RIPA buffer and incubated for 1 hour on a rotary plate at 4 ºC. Then, cells were
centrifuged at 13,200 rpm for 10min at 4°C to get cell debris pellet. The supernatant was
removed carefully and stored at -80 ºC for later applications.
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6.4.6 Nuclear Extract and Cytoplasmic Extract Preparation
Nuclear extract and cytosolic proteins were made with a nuclear extraction kit from
Active Motif. Mammalian cells were washed with cold 1X PBS twice supplemented with
PIC to completely remove culture medium. The attached cells were harvested gently with
a cell lifter. The suspension cells were harvested with centrifuging at 1,500 rpm for 10
min at 4 ºC. In general, 1X106 cells were resuspended in 1 ml of 1X hydrophobic buffer
supplemented with PIC and incubated on ice for 15 min. Then, 50ul of detergent was
added into tube and the tube was vortexed at maximum speed for 30 seconds. The
supernatant was collected and stored at -80 ºC up to 2 months. The pellet, which was the
nucleus, was washed with cold 1XPBS twice to avoid cytoplasmic protein contamination.
Then, the nuclear pellet was resuspended in AM1 lysis buffer containing PIC and 1 mM
DTT and incubated at 4 ºC for 1hour. Next, the tube was centrifuged at 13,200 rpm for 10
min at 4 ºC. The supernatant was collected and stored at -80ºC for further applications.

6.4.7 Suspension Growth of HeLa S3 Cell
HeLa S3 cells were firstly cultured in MEM medium supplemented with 10 % FBS
on 2-3 plates. Medium was changed every 2 days until cell density reached 95 %
confluent. Then, cells were trypsinized and spinned down in a 15 ml conical tube. Cells
were resuspended in fresh medium and cell density was approximately 4X105 /ml. Cells
were transferred into a small spinner flask using 10 ml peptides from side arms. The
volume was around 100 ml in small spinner flask. The top lid and side arms was sealed
with parafilm tightly. The next day, cell density was carefully measured and cells were
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spinned down in 50 ml tubes. Then, cells were resuspended in fresh medium in a large
spinner flask to reach a density of 4X105 /ml. Cells were fed every day with flash
medium and cell density was maintained to 4~5x105 /ml. Finally, cells were cultured in a
one liter spinner flask and cell density might reach 6~7x105 /ml. Cells were collected
with centrifuging at 1,500 rpm for 10 min and were ready for later use.

6.4.8 Large Scale Nuclear Extract Preparation
To prepare large scale of nuclear extract for proteomic applications, we applied this
method to extract nuclear proteins from mammalian cells. Suspension cells were
harvested in 800 ml glass bottles spinning at 1,500 rpm for 10 min at 4°C. Cell pellets
were transferred in cold 1xPBS to 50 ml Falcon tubes. The tubes were spinned at 3,000
rpm for 5 min at 4 °C and the packed cell volume was noticed. The cell pellets were
resuspended in 5 times the packed cell volume of buffer A and quickly centrifuged at
3,000 rpm for 5 min at 4°C. A small sample was taken for microscope slide. The cell
pellets were resuspended in 2 times the packed cell volume of buffer A and allowed to
swell in buffer A for 10 min on ice. Then, the cells were homogenized in a large 40 ml
glass Dounce homogeniser with a B type pestle for 20 up and down strokes. The cell
lysate was examined under microscope. Additional strokes might be taken until cell lysis
was greater than 90%. The swollen nuclei were about the same size as unlysed cells. The
solution was transferred into a plastic tube and centrifuged at 4,000 rpm for 15 min at
4°C. The supernatant, the cytoplasmic fraction, was removed and the volume was
estimated. 0.11 volumes of buffer B was added to the supernatant and transferred to a
plastic tube. The mixture was centrifuged at 3,400 rpm for 1 hour at 4°C. The supernatant
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was dialyzed with the nuclear fraction later. The pellet volume was carefully estimated
and ½ volume of buffer C (low salt) was added to the nuclear fraction. The mixture was
then transferred to a small cold baked glass beaker at 4°C. ½ volume of buffer D was
added to the beaker dropwise. Stirring was continued for 30 min. The mixture was
transferred to plastic tubes and centrifuged at 8,000 rpm for 30 min at 4°C. The
supernatant was collected and dialyzed in buffer E. The supernatant was distributed in
eppendorf tubes and spinned for 20 min at 4°C. The supernatant was collected and stored
at -80°C.

Buffer A (hypotonic)
10mM Tris pH7.9
1.5mM MgCl2
10mM KCl
0.5mM DTT
0.2 mM PMSF
Buffer B
0.3 M Tris pH7.9
1.4M KCl
30mM MgCl2
0.5mM DTT
Buffer C (low salt)
20mM Tris pH7.9
25% Glycerol
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1.5mM MgCl2
20mM KCl
0.2mM PMSF
0.5Mm DTT
Buffer D (high salt)
20mM Tris pH7.9
25% Glycerol
1.5mM MgCl2
1.2M KCl
0.2mM PMSF
0.5Mm DTT
Buffer E
20Mm Tris Ph7.9
20% Glycerol
0.1M KCl
0.2mM EDTA
0.5mM DTT

6.4.9 Immunoprecipitation (IP) and Co-immunoprecipitation (Co-IP)
IP and Co-IP experiments were performed in 1X RIPA buffer supplemented with
1X PIC and phosphatase inhibitors (1mM SoV, 5mM NaF). 500ug of whole cell lysate or
subcellular extract were incubated with appropriate primary antibody in 1X RIPA buffer
overnight at 4°C. The next day, 50ul protein G agarose bead slurry was added into the
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reaction tube and incubated on a rotating platform for 2 hours at 4 °C. The beads were
washed with 600 µl 1XRIPA or NETS buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.5],
5 mM EDTA, 0.05 % NP-40) five times. The tubes were centrifuged at 1,000 rpm for 5
min at 4 °C. The immuno-complex samples were denatured with equal volume of
2XSDS-PAGE loading buffer by incubating at 95 °C for 8 min. The immuno-complexes
were separated in SDS-polyacrylamide gel electrophoresis (PAGE) and the presence of
interested protein bands were detected with western blot technique.

6.4.10 Western Blot
Certain amount of recombinant proteins, whole cell lysate, subcellular lysate or
immuno-complex was mixed with 5X SDS-PAGE loading buffer and denatured by
incubating at 95 ºC for 8 min. Proteins complex were separated in 8~10% SDS-PAGE
and transferred to nitrocellular membranes. Nitrocellular membranes, sponges and filter
papers were firstly soaked in transfer buffer (Tris-HCl, pH8.3, Glycine and 40 %
methanol) for 10 min. The transfer sandwich was assembled by following the
manufacturer’s instructions. The transferring was carried out at 100 mA for 1hour. After
transferring, the transfer sandwich was disassembled and the nitrocellular membranes
was stained with Pancrea S dye for 10 seconds and destained with ddH2O for 1 min to
remove extra dye. The protein bands would be visualized on the membranes. The
membranes were washed with TBST for 10 min to remove Panceau S dye completely.
The membranes were incubated with primary antibody with suitable dilutions in 2%BSATBST buffer at 4 °C for 2 hours to overnight. The next day, the membranes were washed
with TBST buffer three times totally for 15~20 min. Then, membranes were incubated
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with the secondary antibody (1:2,000 dilutions in TBST buffer) for 2 hours at room
temperature. The membranes were incubated with SuperSignal West Dura Extended
Duration Substrate (Pierce) for 2 min and the blotting signals were detected with a CCD
camera.

6.4.11 Cell Proliferation Assay
Cell proliferation rate was measured with BrdU cell proliferation assay by following
the manufacture’s instructions (Calbiochem). Briefly, cells were seeded into a 96 well
culture plate (1X104 cells/well). The next day, cells were transfected with adenovirus
containing expression plasmid vectors. Two days later, BrdU was diluted in a working
solution with fresh culture medium. 20 ul of working solution was added into each well
and incubated with cells in a cell culture incubator. 24 hours later, culture medium was
removed and cells were fixed with 50ul Fixative/Denaturing solution. Then, 20 ul of antiBrdU antibody was added into each well and incubated with cells for 1 hour at room
temperature. After extensive washing with washing buffer, secondary antibody
conjugated with HRP was added into wells and incubated with cells for 30 min at room
temperature. The plates were flooded with ddH2O and incubated with substrate solution
for 15 min. 50ul of stop solution was added into each well and absorbance was measured
using a spectrophotometric plate reader (Wallac 1420 multilabel counter) at wavelengths
of 450-540nm.

6.4.12 Recombinant Adenovirus Generation and Infection in Mammalian Cells
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PKM2 cDNA was purchased from OriGene Technologies. Recombinant
adenoviruses expressing PKM2 was constructed according to the method reported by Dr.
Tong-Chuan He (Luo J et al, Nature protocols, 2007, 2(5), 1236-1247). Briefly, PKM2
cDNA was cloned into a shuttle vector pAdEasy-1 with EcoRI and NotI restriction
endonuclease sites. The resultant plasmid was digested with Pme1 and transformed into
competent AdEasier cells containing the adenoviral backbone plasmid pAdEasy-1 by
electroporation method (BJ5183-AD-1, Stratagene). Recombinants were selected for
kanamycin resistance and further confirmed by restriction endonuclease analyses. The
confirmed plasmid with PKM2 cDNA was digested with PacI restriction endonuclease
and transformed into HEK-293 cells expressing adenovirus E1 (Stratagene). The
production of recombinant adenoviruses in HEK-293 cells was examined with GFP
expression under fluorescent microscope. The amplified virus was released from HEK293 cells by four freeze-thaw-vortex cycles. Cell debris was removed by centrifugation at
500 rpm at 4 °C for 15min. The recombinant adenoviruses were amplified three rounds in
HEK-293 cells to get higher titers. Titers were measured with GFP expression in HEK293 cells with a series of 10 folds dilutions of virus lysate. The titer in the initial lysate
was around 1.43X109 pfu/ml. After three rounds of amplification the titer reached
1.09X1013 pfu/ml. All viral lysates was stored in -80 °C for further appluications. To
infect cells, cells were seeded in 48-well plates to 70~80 % confluence one day before
infection. 50ul of viral lysate (1.09X1013 pfu/ml) was added to each well of a 48-well
plate and incubated with cells for 3-5 hours. For 24-well and 6-well plates, the scales
were increased according to the plate sizes. Fresh medium was changed 3~5 hours later.
The expression of HA-PKM2 was examined by Western blot 48 hours later.
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6.4.13 Metabolism Measurement
Pyruvate, lactate, and glucose assay kits are purchased from BioVision. Mammalian
cells overexpressing HA-PKM2 or control vectors were lysated in corresponding assay
buffers. The cell lysate were centrifuged at 13,000 rpm to precipitate insoluble material.
10 ul of the clear extracts was applied for assay test. The standard curves were generated
using probes supplied with the kits. Pyruvate, lactate, and glucose amounts were
measured by following the manufacture’s instruction.
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6.5 Materials
Table 2 Antibody List
Name
8E4
12CA5
124H6
27E8
β-actin
γ-tubulin
Anti-HA conjugated with
fluorescent dye
Anti-HA poly

Antigen
β-catenin
HA
Stat3
His
Actin
γ-tubulin
HA

Source
Mouse
Mouse
Mouse
Mouse
Rabbit
Rabbit
Mouse

Company
Upstate
Roche
Cell sigaling
Cell signaling
Cell Signaling
Abcam
Roche

HA

Rabbit

Beta-catenin poly
Biotin-labeled antibody for IHC
CRM1
D2E12
D3A7

Beta-catenin

Rabbit
Rabbit
Rabbit
Rabbit
Rabbit

Georgia State
University,
Animal center
facility
Cell Signaling
KPL
Abcam
Cell signaling
Cell signaling

DCS-291
Eg5
Fibrillarin
GAPDH
Histone 2A
KPNA2
Lamin A/C
Lamin B1
MAP2K5 antibody, clone 1B4,
MAP2K5(pSer311/Thr315)
NTF97/importin β
P68

CRM1
Jak2
p-Tyr-Stat3
(Tyr705)
Cdc14A
Eg5
Fibrillarin
GAPDH
Histone
KPNA2
Lamin A/C
Lamin B1
MAP2K5
MAP2K5
NTF97
P68 RNA helicase
C-terminal

Mouse
Rabbit
Rabbit
Mouse
Mouse
Rabbit
Rabbbit
Rabbit
Mouse
Rabbit
Mouse
Rabbit

P68-rgg

P68 RNA helicase

Mouse

Phosphor S10
PKM2

Hstone H3
PKM2 specific
sequences

Mouse
Rabbit

Abcam
Abcam
Abcam
Cell signaling
Cell Signaling
Abcam
Cell Signaling
Abcam
Abnova
AnaSpec
Abcam
Georgia State
University,
Animal center
facility
Auburn University
Hybridoma
Facility
Abcam
Georgia State
University,
Animal center
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PY20
p-Tyr-100
RNA polymerase II
Tyr1007/1008

Phosphor-Tyrosine
Phosphor-Tyrosine
RNA polymerase II
p-Jak2

Mouse
Mouse
Mouse
Rabbit

facility
Abcam
Cell signaling
Abcam
Cell signaling
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Table 3 Primers List
Construction
His-PKM2
HA-PKM2
NLS-PKM2

eGFP-PKM2

GST-PKM2

Primers

Vector

5’-GGGGAATTCTCGAAGCCCCATAGTGAAGC-3’
5’-GGGGCGGCCGCCGGCACAGGAACAACACGC-3’
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’
5’-GGGGCGGCCGCTTCGGCACAGGAACAACACGC3’
5’GGGGAATTCCCCTAAGAAGAAGCGCAAGGTGTCG
AAGCCCCATAGTGAAGC-3’
5’GGGGCGGCCGCTTCACCTTGCGCTTCTTCTTAGGC
GGCACAGGAACAACACGC-3’
5’-GGGGATATCAATCGAAGCCCCATAGTGAAGC-3’
5’GGGGCGGCCGCTTACGGCACAGGAACAACACGC3’
5’-GGGGGATCCTCGAAGCCCCATAGTGAAGC-3’
5’-GGGGAATTCGCTTACGGCACAGGAACAA-3’

pET30a
pHM6
pHM6

pcDNA3
.

K433E-PKM2

pGEX2
T
pHM6

R399E-PKM2

5'CAATTATTTGAGGAACTCGAGCGCCTGGCGCCCAT
TACC-3'
5'GGTAATGGGCGCCAGGCGCTCGAGTTCCTCAAAT
AATTG-3'
NLS-PKM2
5'-CATAATCGTCCTCACCGAGTCTGGCAGGTCTGC3'
5'GCAGACCTGCCAGACTCGGTGAGGACGATTATG-3'
PKM2- C5’-GGGGAATTCCATGTCGAAGCCCCATAGTGA-3’
terminal
5’deletion mutant GGGGCGGCCGCTTTCAGCTGGTAATGGGCGCCAG3’
L398A of
5’-GCAGCTGAGGAAGCCCGCCGCCTGGC-3’
PKM2
5’-GCCAGGCGGCGGGCTTCCTCAGCTGC-3’

pHM6

L401A of
PKM2

5’-GAAGCCCGCCGCGCGGCGCCCATTAC-3’
5’-GTAATGGGCGCCGCGCGGCGGGCTTC-3’

pHM6

P403A of
PKM2

5'-GCCGCGCGGCGGCCATTACCAGCG-3'
5'-CGCTGGTAATGGCCGCCGCGCGGC-3'

pHM6

pHM6

pHM6

pHM6
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I404A of
PKM2
K270M of
PKM2

1-432
truncating
mutant of
PKM2
1-515
truncating
mutant of
PKM2
1-269
truncating
mutant of
PKM2
270-432
truncating
mutant of
PKM2

5'-CGCGCGGCGGCCGCTACCAGCGACCC-3'
5'-GGGTCGCTGGTAGCGGCCGCCGCGCG-3'
5’AAGAACATCAAGATTATCAGCATGATCGAGAATC
ATGAGGGGGTTC-3'
5'GAACCCCCTCATGATTCTCGATCATGCTGATAATC
TTGATGTTCTT-3'
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’
5’GGGGCGGCCGCTAGGTGAGGACGATTATGGCCC3’
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’
5’-GGGGCGGCCGCTATCCGGTCAGCACAATGACC3’

pHM6

5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’
5’GGGGCGGCCGCTAGCTGATAATCTTGATGTTCTTT
C-3’
5’-GGGGAATTCCAAAATCGAGAATCATGAGGGG3’ 5’GGGGCGGCCGCTAGGTGAGGACGATTATGGCCC3’

pHM6

pHM6
pET30a
+

pHM6

pHM6

pHM6
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Table 4 Mammalian Cell Lines
Name
SW480

Company
ATCC

Origin
Human colorectal
adenocarcinoma
cells
Human colorectal
adenocarcinoma
cells derived from
metastatic site:
lymph node
Human skin
melanoma cells
Human skin
metastatic
melanoma cells
Human primary
lung
Human metastatic
lung
Human brain
glioblastoma cells

SW620

ATCC

WM115

ATCC

WM266

ATCC

H460

ATCC

H146

ATCC

T98G

ATCC

U-87 MG

ATCC

Human brain
astrocytoma cells

HeLa S3

ATCC

HEK293

ATCC

HEL 299

ATCC

NIH/3T3

ATCC

Human cervix
adenocarcinoma
cells
Human kidney
epithelial cells
immortalized by
adenovirus 5 DNA
Human lung normal
fibroblast cells
Mouse embryo
fibroblast cells

Culture medium
Leibovitz L-15 + 10
% FBS
Leibovitz L-15
Medium + 10% FBS

MEM + 10 % FBS
MEM + 10 % FBS
DMEM + 10 % FBS
DMEM + 10 % FBS
MEM + 10 %
FBS+1mM pyruvate
kinase+1mM nonessential amino acid
MEM +10 %
FBS+1mM pyruvate
kinase+1mM nonessential amino acid
F12K/DMEM + 10
% FBS
DMEM+ 10 %FBS

MEM + 10 % FBS
DMEM + 10 % FBS
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Table 5 Chemicals
Name of chemical
α-Cyano-4-hydroxycinnamic acid
[γ-32P] ATP
2-Mercaptoethanol
Acetic acid
Acetone
Acrylamide/bisacrylamide solutions
Agar
Agarose
Ammonium persulfate
Anhydrous acetonitrille
Bacto Yeast Extract
Bacto Tryptone
Bovine serum albumin
Bromophenol Blue
Coomassie blue
Deep purple total protein stain
Dithiothreitol
Ethanol
Ethidium bromide
Ethylenedinitro-tetraacetic acid (EDTA)
Fetal calf serum
Formaldehyde
Formic acid
FuGENE 6 Transfection Reagent
GelCode Blue Stain Reagent
Glycine
HiTrap affinity columns
Hydrochloric acid
Imidazole
Isopropyl-ß-D-thiogalactopyranosid
Isopropanol
Kanamycin solution
Lipofectamine 2000
Lipofectamin RNAiMAX
Lysozyme
Magnesium Chloride
Methanol
Molecular weight marker (DNA)
Molecular weight marker (protein)
N- (2-hydroxyethyl) piperazine-N`-(2-

Company
Agilent Tech, Santa Clara
PerkinElmer, Waltham
Sigma Aldrich, St. Louis
VWR International, West Chester
VWR International, West Chester
Fisher BioReagent, Fairlawn
Sigma-Aldrich, Saint Louis
MP Biomedicals, Aurora
Sigma-Aldrich, Saint Louis
Applied Biosystems, Foster City
BD Bioscience, Spark
BD Bioscience, Spark
Promega, Madison
EMD Biosciences, San Diego
Sigma-Aldrich, Saint Louis
Amersham Biosciences, Piscataway
Shelton Scientific, Shelton
AAPER Alcohol & Chemical,
Shelbyville
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
HyClone, Logan
Calbiochem, San Diego
EMD Biosciences, San Diego
Roche Applied Science, Indianapolis
Pierce, Rochford
MP Biomedicals, Aurora
Amersham Biosciences, Piscataway
VWR International, West Chester
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
VWR International, West Chester
Teknova, Hollister
Invitrogen, Carlsbad
Invitrogen, Carlsbad
Sigma-Aldrich, Saint Louis
Fisher Biotech, Fairlawn
VWR International, West Chester
MBI Fermentas, Hanover
MBI Fermentas, Hanover
Sigma-Aldrich, Saint Louis
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ethanesulfonic acid) (HEPES)
Nickel-nitrilotriacetic acid (Ni-NTA) agarose
Ni-TED™ Silica
N, N, N’, N’-Tetramethylethylenediamine
Nonidet P40
Normal goat serum (10%)
Phenol/Chloroform
Phenylmethylsulfonyl fluride
Phosphatase inhibitor cocktail
Poly-L-lysine solution
Ponceau S
Protease inhibitor cocktail tablets
Protein G agarose
Protein G sepharose 4 fast flow
Sephadex G-25
Superdex 200 HR 10/30
Sodium acetate
Sodium azide
Sodium bicarbonate
Sodium chloride
Sodium dodecyl sulfate
Sodium fluoride
Sodium hydroxide
Sodium orthovanadate
Sodium pyruvate
Triton X-100
Trypan Blue
Trypsin proteomics grade
Tween-20
Urea
X-tremeGene siRNA Transfection Reagent

Qiagen, Hilden
Active Motif, Carlsbad
Promega, Madison
Roche Applied Science, Indianapolis
KPL, Gaithersburg
Promega, Madison
Fluka, Switzerland
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
Roche, Germany
Upstate, Charlottesville
Amersham Biosciences, Piscataway
Amersham Biosciences, Piscataway
Amersham Biosciences, Piscataway
Promega, Madison
Fluka, Switzerland
Sigma-Aldrich, Saint Louis
Fisher BioReagent, Fairlawn
Fisher BioReagent, Fairlawn
Fluka, Switzerland
Fisher BioReagent, Fairlawn
EMD Biosciences, San Diego
Cellgro, Herndon
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
Sigma-Aldrich, Saint Louis
Fisher Biotech, Fairlawn
Roche, Germany
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Table 6 Experimental Kits
Name
AminoLink Plus Immobilization Kit
BrdU cell proliferation assay
ChIP-IT kit
DAB reagent set
EZ-link NHS-PEO solid phase
biotinylation kit
Glucose Assay Kit
Improm-II Reverse Transcription System
Lactate Assary Kit
MinElute PCR Purification Kit
Nuclear Extract Kit
ProteoSliver Plu Sliver Stain Kit
Pyruvate Assay Kit
RNeasy Plus Kit
Qiaprep Spin Mini-Prep
Qiaquick Gel Extraction Kit
QuickChange II XL site-directed
Mutagenesis Kit
Quick-ChIP
Trypsin Profile IGD kit for in-gel digests

Company
Pierce, Rockford
Calbiochem,
Active Motif, Carlsbad
KPL, Gaithersburg
Pierce, Rochford
BioVision, Mountain View
Promega, Madison
BioVision, Mountain View
Qiagen, Valencia
Active Motif, Carlsbad
Sigma-Aldrich, Saint Louis
BioVision, Mountain View
Qiagen, Valencia
Qiagen, Valencia
Qiagen, Valencia
Stratagene, La Jolla
Imgenex, San Diego
Sigma-Aldrich, Saint Louis
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CHAPTER 7: APPENDIX
7.1 Detection of Associated Nuclear Proteins to Phosphorylated p68 RNA Helicase
7.1.1 Abstract
P68 RNA helicase, a member of DEAD box family, is involved in pre-mRNA
splicing progress as well as many other important biogenesis processes. P68 RNA
helicase is phosphorylated at its tyrosine residues, which plays crucial roles in cancer
developments. Here we applied MALDI-TOF method to detect its phosphorylation sites
from HeLa cells. We also performed proteomic methods to examine the associated
nuclear proteins to p68 RNA helicase, which may be important for further study about
p68 biological functions in the nucleus.

7.1.2 Introduction
P68 is a member of the DEAD (Aspartic acid–Glutamic acid–Alanine–Aspartic
acid) box family proteins. DEAD box proteins have been shown to be involved in a wide
range of biological processes, such as pre-mRNA splicing, ribosome biogenesis and
translation (Liu 2002; Kahlina, Goren et al. 2004) . Protein phosphorylation is one of the
major post-translational modifications playing important roles in signal transduction
pathways. P68 RNA helicase is phosphorylated at its tyrosine residues in cancer cells
(Yang, Lin et al. 2005). Phosphorylation at Y593 tyrosine residue is required for colon
cancer cells proliferation and epithelial to mesenchymal transition (EMT) stimulated by
PDGF (Yang, Lin et al. 2007). Phosphorylation at Y593 residue of p68 promotes βcatenin translocate into the nucleus in colon cancer cells (Yang, Lin et al. 2006). To
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further illustrate the physiological functions of phosphorylated p68 in cancer cells, we
examined the nuclear associated proteins to phosphorylated p68 with proteomic methods.

7.1.3 Methods
7.1.3.1 Co-Immunoprecipitation and Peptide Pulldown
IP and Co-IP experiments were performed in NETS buffer (150 mM NaCl, 50 mM
tris-HCl[pH 7.5], 5 mM EDTA, 0.05% NP-40). SDS was added to a final concentration
of 1%. 30 ul of p68 mono-antibody was incubated with 500 ug of nuclear extract in 1 ml
NETS buffer for 3 hr at 4 °C. 100 ul of protein G agarose bead slurry was added into the
tube and incubated for 2 h. The beads were recovered by centrifuging at 1000 rpm for 10
min and washed with 600 µl of NETS five times. The proteins complexes were separated
in SDS-PAGE gel. For peptide pulldown experiment, 500 ug of nuclear extract was precleared with 50 ul of naked beads by incubating for 30 minutes at 4 °C. After
centrifuging, 100 ul of beads conjugated with phosphorylated or non-phosphorylated
peptides were incubated with the supernatant at 4 °C overnight. The tube was centrifuged
at 1,000 rpm for 10 min at 4 °C. The precipitated mixture was washed with 600 µl of
NETS five times and with 1% SDS twice.

7.1.3.2 Two-Dimensional SDS-PAGE Analysis
Protein samples were washed with 1 ml ddH2O twice. The protein samples were
then solubilized in re-hydration buffer (7 M Urea, 2 M thiourea, 2% CHAPS, 0.8%
ampholyte, 0.02% bromophenol blue, and 65 mM DTT). A dry strip was removed from -
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20 °C and was equilibrated in equilibration buffer [0.38 M Tris-base, pH 8.8, 6 M urea,
2% (w/v) SDS and 20% (v/v) glycerol] at room temparature for 15 min. The samples
were loaded into the rehydration tray. A paper wick was palaced at both ends of the
focusing try channel covered with 30 ul ddH2O. The tray was set into IEF cell and run
the following program: 250V for 20 min, 8000 V for 2.5 h and 8000 v for 20,000 VoltHours. The next day, IPG strip was taken out from IEF cell and set in a clean tray with
gel side up. 3.5 ml Equilibration buffer was added into IEF cell and incubated with the
strip for 10 min. The IPG strip was dipped in 1X SDS-PAGE gel running buffer. Then,
the strip was laid onto the top of the prepared SDS gel and sealed with 1% agarose in gel
box. The gel box was filled with 1X running buffer (25 mM Tris, 190 mM glycine and
0.1% SDS) and run at 60 volt for 20 min, then the volt was changed to 100 volt. After
electrophoresis, the gel was wash with ddH2O for 5 min. The gel was stained with Deep
Purple fluorescent dye or silver stain (Amersham Biosciences) according to the
manufactures instructions.

7.1.3.3 Protein Identification by Peptide Mass Fingerprinting
The proteins complexes were separated in 10% SDS-PAGE or 2-D gel. The
targeting proteins spots were picked up with Ettan spot picker. The samples were
digested with trypsin. After ZipTip purification, the digested peptide solution was eluted
from ZipTip with 50% ACN/0.1% formic acid and spotted directly onto a wax-coated
MALDI target plates. Nano LC MALDI TOF/TOF MS analysis was performed in
Applied Biosystems 4700 proteomics analyzer. The matching of the experimental
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sequences with tryptic peptide masses from database was performed with Peptident
proteomic tools in ExPASy Molecular Biology Server (http://www.expasy.ch/). The
MALDI-TOF/TOF database was from NCBInr.

7.1.4 Results and Discussions
7.1.4.1 Identification of Phosphorylated Residues of p68 RNA Helicase with
MALDI-TOF
Matrix-assisted laser desorption/ionization (MALDI)-time of flight (TOF) MS is a
well established tool for peptide or protein identification. The addition of a phosphate
monoanion to a hydroxyl group of tyrosine results in mass increases of the proteins or
peptides by 79.966 Da in monoisotopic mass. It is possible to estimate the number of
phosphates on a protein by comparing the mass shift between the modified and original
peptides. The strength of peptide signals in MALDI-TOF is important for detecting the
mass shift. In most cases, the protein staining method in SDS-PAGE gel may affect the
enrichment of peptide signals. To this purpose, we applied two protein staining methods
to detect p68 peptides digested by trypsin. The results showed that GelCode staining was
more sensitive for MALDI-TOF signal enrichment of the digested peptides than
Coomassive blue staining (Fig 7.1). Therefore, we applied Gelcode staining method in
the following experiments to detect the phosphorylated residues of p68. P68 RNA
helicase was immunoprecipated from the nuclear extract of HeLa cells. The presence of
p68 in the immunoprecipitated complex was confirmed by western-blot. P68 RNA
helicase was in-gel digested with trypsin and the presence of peptides was detected with
MALDI-TOF. Our results showed that the detected peptide signals were recovered
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around 70% by comparing with control (matrix only). The recovered peptides, including
1336.6 D, 1348.6 D, 1389.6 D, 1574.7 D, 2131.9 D, 2361.4 D, matched with theoretical
peptide masses (Fig 7.2). All the peptides above 1000 D were detected in MALDI-TOF
except one peptide, whose molecular weight was 5967.4D. Our result showed a peak
around 5571.8 D in the peptide complex. Whether this peak was due to the hydrolysis
effect or some other modifications was not known. The peptide, 2396.4 D, was found
163.4 D shift from 2133.04 D peptides whose compose was FVINYDYPNSSEDYIHR
including three tyrosine sites (Fig 7.2). According the prediction from Netphos 2.0, Y418
and Y425 sites had the high potential possibilities of phosphorylation. The shifted peak
may be the two phosphorylatd sites from Y418 and Y425. These phosphorylation sites
needs to be further confirmed with other biological methods, such as mutagenesis.

7.1.4.2 Detection of p68 Associated Nuclear Proteins Using 2-D Gel
P68 RNA helicase plays crucial roles in many biological process. To elucidate its
other functions in the nuclear, it is important to examine the associated proteins. To this
end,

Co-IP experiment was performed to precipitate these associated proteins with p68

antibody. Three antibodies generated from the C-terminal sequence and one from Nterminal sequence of p68 were applied to immunoprecipitate p68-associated proteins.
The precipitated protein complexes were separated in 2-D gel. The results showed that
some associated proteins specially precipated by the C-terminal antibody, which
indicated these proteins may be only associated with the C-terminal phosphorylated p68
RNA helicase (Fig 7.2). Some spots were picked up and will be identified with MALDITOF/TOF peptide fingerprinting method.
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7.1.4.3 Analysis of Nuclear Associated Proteins to Phosphorylated p68 using
Peptide-protein Interaction Screening Method
To specificly identify phosphorylated p68 RNA helicase associated proteins, we
synthesized two peptides according to its C-terminal sequences. One had double
phosphorylation sites at tyrosine residues, Y593 and Y595. The other was nonphosphorylated peptide with the same amino acid sequence. The synthesized peptides
were coupled to agarose beads. The associated proteins were pull down with agarose
beads conjugated with peptides. 2-D gel was performed to separate the protein
complexes. The results showed that three proteins spots specificly presented in the
complex precipitated with phosphorylated peptides, not with non-phosphorylated
peptides. Nine proteins spots specially presented in the protein complex pulled down
with non-phosphorylated peptides. These targeting proteins will be identified by MALDITOF/TOF (Fig 7.3).
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Fig 7.1.1 P68 Post-translation Modifications Analysis with MALDI-TOF.
(A) shows digested peptides of p68 by trypsin via GelCode staining. (B) shows digested
peptides from p68 by trypsin via Coomassive blue staining.
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Fig 7.1.2 2-D Gel Analyses of p68-associated Nuclear Proteins Immunoprecipitated with
p68 Antibodies
(A). 2-D gel analysis of p68 associated nuclear proteins immunoprecipitated by p68
antibody generated from the recombinant protein derived from C-terminal sequence of
p68. (B). 2-D gel analysis of p68 associated nuclear proteins immunoprecipitated by p68
antibody generated from the recombinant protein derived from N-terminal sequence of
p68. In (A) and (B), both gels were stained with silver staining.
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Fig 7.1.3 2-D Gel Analysis of p68-associated Nuclear Proteins Pulled Down with
Phophorylated Peptides Derived from p68
(A). 2-D gel analysis of p68 associated nuclear proteins pulled down using nonphosphorylated peptides derived from C-terminal sequence of p68. The cycled spots
showed the specific associated protein to non-phosphorylated peptides (B). 2-D gel
analysis of p68 associated nuclear proteins pulled down by phosphorylated peptide
derived from N-terminal sequence of p68. The cycled spots showed the specific
associated protein to phosphorylated peptides. In (A) and (B), both gels were stained with
silver staining.
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